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ABSTRACT 
This thesis describes the study of the 
neurochemistry of Huntington's disease using a large 
series of post mortem brain tissue taken from 
patients with Huntington's disease and from matching 
controls with no previous history of 
neuropsychiatric disorder. There were two main 
aims: firstly, to identify and characterise any 
altered parameters of neurotransmitter systems, 
especially in relation to the symptomatology of the 
disease; secondly, to understand the role of 
neurotoxins in the aetiology of the disease, 
particularly endogenous compounds that may have 
derived from aberrant metabolism. 
Concentrations of the amino acid transmitters, GABA 
and glutamate, were generally significantly 
decreased throughout the brain in Huntington's 
disease, including cortical and limbic regions. 
cortical deficits were not associated with the 
dementia of the disease, whereas caudate levels of 
GABA and glutamate showed a relationship with 
the dementia. In patients with severe chorea, the 
medial pallidum was found to have a relatively 
smaller GABA deficit than mildly choreic patients. 
Another novel finding was that 5HT and 5HIAA 
concentrations were significantly increased in most 
regions of the brain in Huntington's disease, 
perhaps reflecting abnormal . ~ r y p t o p h a n n metabolism. 
Such changes in the cortex provide evidence for a 
cortical involvement in the disease. Dopamine 
metabolism appeared to be reduced in Huntington's 
disease, reflected by the significantly decreased 
concentrations of its major metabolite, homovanillic 
acid, in most regions except for the cortex (where 
it was increased). 
Neuroactive compounds of the kynurenine pathway of 
tryptophan metabolism were measured in Huntington's 
disease. Quinolinic acid concentrations were not 
significantly altered, however 3-hydroxykynurenine 
concentrations were significantly increased in the 
striatum and cortex. This provides the first 
evidence for increased concentrations of an 
endogenous neurotoxic compound in the brain in 
Huntington's disease. 
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Chapter 1 
Introduction 
1.1 General background information 
In 1872 George Huntington, from New York, published 
the first medical description of the disorder, 
Huntington's disease (HD): 'On Chorea' (Huntington, 
1872).HD is found throughout the world, but there 
is evidence suggesting early transmitters of the HD 
gene emigrated from Bures, East Anglia to the USA in 
1630. 
HD is a progressive autosomal dominant disorder of 
unknown aetiology with 100% penetrance. DNA markers 
linked to the gene have been localised to the short 
arm of chromosome 4 (Gusella et al., 1983), but as 
yet the locus of the gene itself remains unknown. 
Recombinant DNA technology and linkage analysis have 
enabled predictive and prenatal testing to be 
developed, now available for those at risk of 
inheriting the disease, but currently the accuracy 
is only about 95% (Wexler et al., 1991). New 
mutations are thought to be unlikely (Martin, 1984) 
and there are no proven cases. The prevalence of HD 
varies between areas, but 7.5 per 100,000 is an 
average figure for England (Hayden, 1981). The 
onset of the disease is usually in the 3rd-4th 
decade with an average durat;on of 15-20 years. 
However, onset can occur at any age, although the 
character of the disease may be different. Juvenile 
HD (onset < 20 years) often displays a more severe 
and rapid progression whereas, when the onset is 
late in life (onset> 60 years), the progression is 
milder and slower. A further notable effect is 
'anticipation'. Patients inheriting the HD gene 
from the father have been shown to have onset 10 
15 
years earlier than their parent (Bird, 1974). 
Furthermore, studies of juvenile HOdemonstrate that 
they are four times as likely to have inherited the 
disease from the father, than from the mother 
(Barbeau, 1970). Thus, a sex-associated modifying 
gene may be influencing the HO gene. Homozygotes 
have been reported to be phenotypically similar to 
heterozygotes (Wexler et al., 1987). 
1.2 Clinical profile 
Clinically, the disease is h e t e r o g e ~ s , ,
characterised by the progressive movement disorder, 
psychiatric symptoms and dementia. Chorea (an 
involuntary, jerky, random hyperkinesia) is usually 
present in about 90% of patients, beginning slightly 
and becoming more pronounced as the disease 
progresses, but with increasingly more rigidity and 
akinesia in the latter stages. Some cases, such as 
the Westphal variant, have no chorea at all and only 
show rigidity; this is particularly common in 
juvenile HO. Other neurological symptoms include 
myoclonus, spasticity, bradykinesia,.tremor, 
athetosis, dysarthria, dysphagia, olfactory 
dysfunction, oculomotor dysfunction (e.g. saccades) 
and latterly, epilepsy (Hayden, 1981). B e h a v ~ v r a l l
changes may precede or appear concurrently with the 
early motor abnormalities. Symptoms such as 
unipolar depression, aggression, apathy, 
schizophreniform psychosis, ~ n x i e t y y and mania have 
been reported. Peyser and Folstein (1990) made a 
study using HO as a model for mood disorders. They 
described affective'disorder as the most common 
psychiatric symptom (38%) in HO, preceding chorea in 
over 50% of the cases. Ten per cent also had 
episodes of mania, 6% schizophreniform psychosis, 
31% showed severe irritability, and aggressive 
symptoms (59%) have been reported in a further study 
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by Burns et ale (1990). cognitive impairment is a 
further common feature in HO, occurring in 84% of 
cases (Pflanz et al., 1991), but the precise nature 
of the dementia is controversial. Many believe it 
is subcortical in origin, resembling dementia in 
Parkinson's disease (PO) and qualitatively different 
to that seen in Alzheimer's disease (AD), where 
there is aphasia and agnosia (Chui, 1989). 
Cognitive symptoms in HO include forgetfulness, 
apathy, slowness of thought (McHugh and Folstein, 
1975). Other clinical signs include excessive 
sweating, increased appetite and weight loss, not 
clearly due to increased energy demands of chorea or 
rigidity (Sanberg and Fibiger, 1979; Morales et al., 
1989). Thyroid function has· been reported to be 
normal (Bird and Coyle, 1986) and a possible link 
with diabetes mellitus (Podolsky et al., 1972) has 
been strongly disputed (Kremer et al., 1989). 
However, growth hormone regulation is reported to be 
disturbed and prolactin release decreased (Kremer et 
al., 1989; Hayden et al., 1977). Juvenile HO (6%) 
has a different clinical profile with increased 
rigidity, epilepsy, cerebellar signs and rapid 
progression; symptoms which may be compared with 
late-stage HO (Hayden, 1981). 
1.3 Neuropathology 
1.3.1 Macroscopic. studies 
Gross pathological assessment of the brain in HO 
show it to be "generally shrunken (with a 20-30% loss 
in brain weight) (Bird and Spokes, 1982; Lange, 
1981; De La Monte et al., 1988). There is a 
widening of the sulci and a reduction of the gyri 
and the meninges are often thickened (Hayden, 1981). 
Coronal sections show dilated lateral ventricles, 
partly as a consequence of shrinkage of the caudate 
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and putamen. The extent of observed tissue losses 
is not uniform throughout the brain, with the basal 
ganglia appearing to have the greatest atrophy. 
Lange et a1. made extensive quantitative 
investigations of the HO brain (1976, 1981). They 
described volume reductions in the caudate (55% 
loss), putamen (57% loss), lateral pa11idum (57% 
loss), medial pa11idum (50% loss), subthalamic 
nucleus (24% loss) and cortex (20% loss). These 
values are consistent with results from a study by 
De La Monte et a1. (1988) that also reported 20-30% 
loss of hippocampus, nucleus accumbens, white 
matter, amygdala and thalamus. Furthermore, they 
suggested that the 200% increase in ventricular 
volume was disproportionate to the shrinkage of 
structures around it and thus was a primary finding 
of hydrocephalus in HO. other regions of known 
pathology in HO are sUbstantia nigra (s.nigra) pars 
compacta and pars reticu1ata, hypothalamic nuclei 
(supraoptic, venteromedia1, lateral tubera1, 
paraventricu1ar and tuberomami11ary), cerebellum, 
corpus callosum, pons, medulla oblongata, claustrum, 
tegmentum, dentate nuclei and superior olivary, 
vagal and hypoglossal nuclei, as well as pallor in 
the, spinal cord (anterolateral tract) (Oyangi et 
a1., 1989: Kremer et a1., 1990: Bruyn et a1., 1979: 
Lange et a1., 1976: Vonsatte1 et a1., 1985: Hayden, 
1981). No patho1Qgy was reported in the basal 
nucleus of Meynert, dorsal raphe or locus coeru1eus 
(Mann, 1989). The neuropatho,logica1 involvement of 
the cortex in HO has provoked much discussion. 
Vonsatte1 et a1. (1985), Ha11ervorden (1957) and 
Za1neraitis et a1. (1981) all produced studies 
refuting any cortical abnormalities in HO, however, 
recent evidence presents a strong case for global 
cortical losses (20%), not correlated with striatal 
changes (Cudkowicz and Kowall, 1990; De La Monte et 
a1., 1988: Bruyn et a1., 1979). There is evidence 
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suggesting a gradient of atrophy throughout the 
basal ganglia in HO, which varies according to the 
progression of the disease. Thus Reiner et ale 
(1988) noted that the lateral pallidum showed 
atrophy much earlier than the medial pallidum, and 
likewise with the s.nigra (pars reticulata) compared 
with s.nigra (pars compacta). Furthermore, dorsal 
and medial parts of the caudate and putamen were 
found to be affected earlier than the anterior 
parts, parallelled by the' relatively less atrophy in 
the nucleus accumbens until la-ber stages of the 
disease process (McCaughey, 1961; Bird, 1980; 
Vonsatte1 et al., 1985). A comprehensive 
investigation was made by Vonsattel et ale (1985) to 
try to grade severity of the disease with atrophy of 
the caudate and putamen (by macroscopic and 
microscopic neuropathological criteria). The grades 
(0-4) were shown to correlate strongly with clinical 
rating. Thus, grade 1 required changes in the 
paraventricular caudate, tail of the caudate and 
dorsal putamen. These changes were demonstrated to 
progress laterally and basally throughout the 
grades, until grade 4 which displayed severe 
degeneration throughout the striatum. The nucleus 
accumbens was only found to be damaged in grade 4 
cases and always relatively less affected. The 
pallidum was described as only shrunken in grades 3 
and 4. In 3% of 9ases there were no 
neuropathological differences (grade 0), although 
clinical symptoms were d i s p l ~ y e d , , together with a 
positive family history. This was suggested to be an 
illustration of 'anatomy lagging behind clinical 
m a n i f e s t a t i o n ~ ' . . However, there have been reports 
of the converse situation, in particular a case 
which displayed severe atrophy of the caudate and 
putamen, but was presymtomatic (Carrasco and 
Mukherji, 1986). A further case of interest showed 
grade 0 neuropathology, but exhibited selective 
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intermediate glutamatergic deficits (Albin et al., 
1990b). Juvenile HD cases show faster atrophy and 
more severe pathology than adult cases (Reiner et 
al., 1988). 
1.3.2 Neuronal losses 
It is important to understand the actual cell types 
lost in HD and many studies have been made. It is 
evident that there are no' uniform losses but, 
instead, specific neuronal deficits in s p ~ i f i c c
regions of the brain. It has been demonstrated that 
within the striatum in HD, spiny projecting and 
interneurones are lost, whilst medium aspiny 
interneurones are spared. There is also an increase 
in the ratio of large:small neurones (Graveland et 
al., 1985; Ferrante et al., 1987b; Reiner et al., 
1988; Lange et al., 1976). One such population of 
striatal interneurones that are spared have been 
demonstrated to contain somatostatin (55), 
neuropeptide Y (NPY) and NADPH-diaphorase (NADPH-d) 
(Ferrante and Kowall, 1987; Dawbarn et al., 1985). 
This selectivity is also evident in the lateral 
pallidum, but not in the medial pallidum (Dawbarn, 
1985). Normally, the striatum is defined by a 
pattern of patch or matrix zones (Graybiel and 
Ragsdale, 1978, 1984). The patches are believed to 
contain relatively reduced activity of 
acetylcholinesterase (ACE), tyrosine hydroxylase, as 
well as increased levels of e,nkephalin, VIP, CCK, 
substance P, dynorphin and opiate receptors. In 
contrast, the,matrix is rich in ACE, tyrosine 
hydroxylase, calbindin, calcineurin,. synaptophysin, 
55, NPY and NADPH-d (Ferrante et al., 1987b). 
Ferrante et al. (1987b) demonstrated that the 
patches are relatively unaltered in HD striatum, but 
the matrix shows sUbstantial deficits. Thus, in HD 
losses of calbindin, calcineurin and synaptophysin 
20 
occur from the medium, spiny cells of the matrix 
(Seto Oshima et al., 1988; Ferranteet al., 1988: 
Goto and Hirano, 1990). Tyrosine hydroxylase 
immunoreactivity remained not significantly changed 
despite being located in the matrix (Ferrante and 
Kowall, 1987); also ACE-containing large aspiny 
interneurones were found to be relatively spared in 
the matrix, as were the somatostatin/NPY/NAOPH-d 
neurones. Furthermore, as choline acetyl transferase 
(CAT) activity may co-localise with ACE activity 
(Levey et al., 1983), it was hypothesized by 
Ferrante et-al. (1987a) that the CAT-containing 
axons and terminals may be lost, whilst the same 
ACE-containing cell bodies survive. Whether the 
spines or the size or the contents of the neurones 
are the vital characteristic for neurodegeneration 
to occur remains unclear. It was previously 
suggested that SS/NPY/NAOPH-d neurones were spared 
because NAOPH-d had some protective detoxifying 
role, but this is unlikely to be the case for ACE 
neurones (Ferrante et al., 1987b). There was 
evidence that the main cortical input 
(glutamatergic) usually terminates on spiny cells in 
the matrix; these are the same neurones which are 
lost in HO (Ferrante et al., 1987a) and it is known 
that an intact corticostriatal projection is a 
prerequisite for neurotoxicity (Schwarcz et al., 
1984b). A further hypothesis was that SS/NPY/NAOPH-
d neurones (and possibly ACE neurones) were 
resistant because they l a c k e ~ ~ NMOA receptors. (Koh et. 
al., 1986). Finally, areas rich in SS/NPY/NAOPH-d 
neurones are those that are relatively unaffected in 
HO, t h e r e f o r ~ ~ m a y y be offering some kind of 
resistance. 
In the striatum, dopamine (OA), vasopressin, 5-
h y d r o x y t ~ p t a m i n e e (5HT) and noradrenaline (NA) 
afferents show no significant losses in HO. 
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striatal projection neurones are differentially lost 
in HD. Reiner et ale (1988) described subgroups of 
GABAergic neurones which were co-localised with 
neuropeptides. Thus, the striatal projections to 
the s.nigra (pars reticulata and pars compacta) and 
to the medial pallidum contained substance P and the 
striatal projections to the lateral pallidum 
contained enkephalin. Reiner et ale also described 
early losses from the lateral pallidum and the 
s.nigra (pars reticulata) pathways in HD, compared 
with the medial pallidum and s.nigra (pars compacta) 
pathways. However, as the disease progresses there 
is further degeneration until all the pathways are 
equally affected. 
A gliosis in HD has been described often (Kowall et 
al., 1987; stevens et al., 1988; Martin, 1984) and 
Bruyn et ale (1979) has even suggested that HD could 
be caused by failure of glial function. However, 
Lange et ale (1976) reported that there is no 
absolute increase in numbers of glia, but in fact a 
decrease, and that the gliosis was relative to 
atrophy of the striatum. Vacca-Galloway and Nelson 
(1984) provided a further hypothesis: that 
astrogliosis may precede or contribute to the 
disease. The study cites evidence that abnormal 
astrocyte proliferation occurs in some areas such as 
the striatum, but not in the pallidum and therefore 
is not merely reflecting neuronal atrophy. 
Cellular losses within the cortex are documented as 
occurring in layers 3, 5 and 6 (Bird and Coyle, 
1986) and the atrophy appears to be general 
throughout the cortical regions, and unrelated to 
the severity grades of HD (De La Monte et al., 
1988). A recent study (Cudkowicz and Kowall, 1990) 
identified a degeneration of frontal cortex 
pyramidal projection neurones in HD, which are 
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likely to be glutamatergic and to innervate the 
striatum (Oka, 1980). Cudkowicz and Kowall also 
found a relative sparing of NPY neurones, but there 
was no correlation between the cortical losses and 
striatal losses or grade of disease severity. 
However, Sotrel and Myers (1990) reported the same 
loss of pyramidal cells in the prefrontal cortex, 
but showed an association with severity of disease 
and no significant increase in glial cells. 
Hippocampal changes specifically appear to involve 
neuronal losses in the pyramidal band, H5 field and 
subiculum (Bird and coyle, 1986). In the s.nigra it 
has previously been reported that the pars 
reticulata was more atrophied than the pars compacta 
and thus appeared darker due to a relative increase 
in melanin and tyrosine hydroxylase containing cells 
(Bird and Coyle, 1986; Richardson, 1990). A 
morphometric study by Ferrante et al.(1989) produced 
data to support previous reports: the compacta 
showed 18% loss and the reticu1ata showed 68% loss. 
Neuronal counts showed no overall loss of pigmented 
neurones, but 65% loss of non-pigmented neurones. 
This is also consistent with observations of waters 
et al. (1988) that there was no significant loss of 
pigmented cells in the s.nigra in HO. However, 
there is a contrary report (Oyanagi et al., 1989) 
suggesting equal l,osses (40%) of both pigmented and 
non-pigmented cells, with a relative sparing of the 
central part of the s.nigra ip HO. Studies into the 
cerebellar changes in HO describe a degeneration of 
Purkinje cells (Jeste et al., 1984) and neuronal 
depletion in the dentate nucleus (Rodda, 1981). 
At the ultrastructural level in HO, investigations 
have revealed deposits of cerebrosides and fatty 
acids, increased lipofuscin in neurones, dysfunction 
of the smooth endoplasmic reticulum and Golgi 
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vesicles and mitochondria, loss of presynaptic 
endings, axonal losses,dysfunction'and lipofuscin 
accumulation in astrocytes (Tellez-Nagel et al., 
1973; Goebel et al., 1978; Roisin et al., 1976). 
There is also evidence suggesting membrane changes 
in HO, including alterations to fibroblasts, 
lymphocyte capping and red blood cells (Butterfield 
and Markesbery, 1981; Pettegrew et ale" 1987). 
1.4 Transmitter neurochemistry 
1.4.1 GABAergic neurones 
~ - a m i n o b u t y r i c c acid (GABA) is a major inhibitory 
neurotransmitter and is widely distributed thoughout 
the brain, together with its biosynthetic enzyme, 
glutamic acid decarboxylase (GAD). Perry et ale 
(1973) made the first observation of reduced GABA 
concentrations in the brain in HO. They reported 
losses in the putamen/pa1lidum (62% loss), caudate 
(40% loss), s.nigra (60% loss) and temporal and 
occipital cortex (32% loss), but with no significant 
changes in the frontal cortex or the cerebellum. 
Subsequent studies have confirmed these losses 
( u r q u h ~ t t et al., 1975; Bird and Iversen, 1974; 
Spokes et al., 1979; Gramsbergen et al., 1986) and 
extended them to include the nucleus accumbens (47% 
loss), lateral pallidum (38% loss), subthalamic 
nucleus (19% loss), venterolateral thalamic nucleus 
(24% loss), s.nigra (25% loss) and frontal cortex 
(5% loss), although the hippocampus, amygdala, 
dentate nucleus, premotor cortex and cerebellum were 
described as showing-no change (Spokes et al., 
1980). More recently, Ellison et ale (1987) made an 
extensive study of reductions of GAB A concentrations 
in the brain in HO, to search for an association 
with the grades of severity of the disease. They 
concluded that GABA deficits correlated positively 
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with the severity grade. They also identified some 
regional gradients of GABA deficits; thus, (caudate 
> putamen> nucleus accumbens) and (s.nigra pars 
reticu1ata> s.nigra pars compacta). However, they 
reported that cortical GABA concentrations were not 
significantly changed in HO, as were levels in the 
hippocampus, claustrum, subthalamic nucleus, 
ventero1atera1 and dorsomedia1 thalamic nuclei. Of 
note was a 50% increase in GABA concentrations in 
the anterior thalamic nucieus. Kish et a1.(1983) 
and Bea1 et a1. (1988d) both found no significant 
deficit in GABA concentrations in the cerebellum in 
HD. 
Changes in GAD activity have also been well 
documented in HD, but unfortunately some studies did 
not control adequately for agonal state of the 
patient, which has been shown to influence the 
activity of GAD (Spokes et a1., 1979). Thus, only 
recent investigations are properly controlled. 
Spokes et a1. (1979, 1980) described a 54% reduction 
of GAD activity in the putamen, as well as the 
c ~ u d a t e e (50% loss) and the lateral pa11idum (45% 
loss). All other areas examined showed no 
significaAt reductions (medial pa11idum, s.nigra 
pars reticu1ata, s.nigra pars compacta, nucleus 
accumbens, cerebellum, dentate nucleus, red nucleus, 
olivary nucleus, motor cortex and hippocampus). 
However, Yates et a1. (1990) reported a reduction in 
the frontal cortex. ActivitY,of GABA transaminase 
(GABA-T), the metabolic enzyme for GABA, has been 
little studied in the HD brain. urquNrt et a1. 
(1975) reported no change in the striatum, but with 
only two cases this is merely an observation. 
Carter (1984) showed a 40-50% reduction in the 
activity of GABA-T in the putamen in HD. 
Lloyd et a1. (1980) reviewed the literature and 
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challenged the early report of Enna et al.(1976a) 
that found no significant changes in GABA receptor 
binding in the brain in HO. Lloyd provided data 
suggesting that there was decreased GABA binding in 
the caudate (80% loss) and the putamen (50-75% 
loss), whilst cerebellar binding was 100% increased 
and the s.nigra and cortex remained not 
significantly changed (Lloyd et al., 1977; Olsen et 
al., 1979; Reisine et al., 1979; Iversen et al., 
1979). Further reports described a reduction of 
binding in the putamen (55% loss), venterolateral 
thalamus but with no significant change in the 
cortex (Penney and Young, 1982; Young et al., 1988). 
L'oyd noted that although there was no significant 
change in the frontal cortex, this was due to 
increased affinity together with decreased Bmax. In 
addition, the Kd in the cerebellum in HO was three 
times lower than that in the controls. Furthermore, 
they suggested that there may be phospholipid 
regulation of GABA and the receptor, which could be 
abnormal in HO. Cross and Waddington (1981) 
described a difference in the s.nigra in HO, 
contrary to previous reports. They found 200% 
increase in the density of high-affinity sites and a 
small increase in the density of low-affinity sites. 
The benzodiazepine site is ~ n e e subunit of a 
macromolecular complex consisting of a GABA A 
receptor recognition site, chloride ionophore, 
benzodiazepine site and barbiturate-picrotoxin 
receptor (Olsen, 1981; R o t h s t ~ : d n n et al., 1989). 
Benzodiazepines are thought to be positive 
allosteric modulators of GABA function and may act 
by displacing an endogenous inhibitor of GABA 
binding and potentiate GABA action (Rothstein et 
al., 1989). Several groups have measured 
benzodiazepine binding in the brain in HO (Reisine 
et al., 1978; 'Young et al., 1988; Kish et al., 
1983). Reisine et al.(1978) found a 35% reduction 
in the number of sites together with reduced 
affinity in the putamen in HO, which could be 
normalised by adding GABA. They also reported a 25% 
increase in binding in the frontal cortex and 
cerebellum, consistent with another study by 
Trifeletti et ale (1987), as well as an increase in 
the s.nigra (but with no change in affinity). Kish 
et ale (1983) produced contrary results showing no 
significant change in binding in the cerebellum, and 
Young stale (1988) demonstrated a 55% loss of 
binding in the putamen, but no change in the cortex. 
R e i s m e ~ ~ s u g g e s t e d d that GABA losses in the putamen 
may be responsible for the reduced affinity of 
benzodiazepine receptors, however this did not seem 
to occur in the cortex, where there are also GABA 
losses in HO. An associated parameter is diazepam-
binding inhibitor (which may be the endogenous 
ligand for the benzodiazepine receptor). Ball et 
al.(1988) determined diazepam-binding inhibitor in 
the brain in HO, finding increases (50-90%) in the 
caudate, putamen, pallidum and nucleus accumbens, 
but no significant difference in the cortex, 
hippocampus or hypothalamus. GABA uptake sites 
(using binding of radio-labelled nipecotic acid) 
have identified an actual decrease of neurone 
terminals in HO in the caudate (52% loss) and 
putamen (67% loss), but not in the temporal cortex 
(Simpson et al., 1987). Here, the caudate deficit 
appears less than their 74% loss of GABA 
concentrations.· However, Czuc;iek and Reynolds (1990) 
reported 58% loss of uptake binding in the putamen, 
compared with 62% loss of GABA levels, thus showing 
no difference between the alternative measures in 
HO. Furthermore, they suggested that the 
methodology of simpson et al. (1987) under-estimated 
the number of uptake sites, but unfortunately, the 
cases in the Czudek study are too small for S + ~ + \ . s " H c . o . \ \
analysis. 
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Thus, the evidence appears to reflect the selective 
loss of GABAergic neurones (particularly 
striatonigral and intrinsic pathways) ,which is 
described in HD. consequently there is decreased 
inhibition of the dopaminergic nigrostriatal pathway 
which has been suggested to be involved in the 
production of chorea. Furthermore, differential 
losses of the GABAergic striatopallidal pathways 
result in the alteration o'f the medial/lateral 
balance. There is also an association of GABA' 
changes with affective disorder, particularly 
depression (Peyser and Folstein, 1990) which is a 
common feature of HD (see section 8.1). 
1.4.2 Dopaminergic neurones 
The nigrostriatal dopaminergic pathway was initially 
thought to be overactive in HD, but evidence does 
not support this theory. There have been many 
inconsistent reports regarding the concentrations of 
DA in the striatum in HD. Studies have been made 
reporting a significant increase in the putamen 
(Melamed et al., 1982), caudate (Bernheimer and 
Hornykiewicz, 1973), both areas (Spokes, 1980) or 
neither areas (Bird and Iversen, 1974; Reynolds and 
Garrett, 1986). Kish et al.(1987) described a 
gradient of losses,of DA concentrations in both 
areas, reaching significance in the caudal caudate. 
The variability in these r e s u ~ t s s has been suggested 
to reflect an increased range of DA concentrations 
in the striatum in HD (Reynolds and Garrett, 1986), 
or differences between the studies in the control of 
postmortem delay (Kish et al., 1987), or perhaps a 
drug effect (see section 3.4). Increased 
concentrations of DA have been reported in other 
nonstriatal regions including the lateral pallidum 
(by 71%), medial pallidum (by 79%), nucleus 
accumbens (by 87%), s.nigra pars compacta (by 34%) 
whereas there are no reported" significant 
differences in the s.nigra pars reticulata, red 
nucleus, anterior perforated substance or septal 
nucleus (Spokes, 1980). However, Kish et al.(1987) 
found no significant change in the nucleus accumbens 
or the s.nigra. 
concentrations of homovanillic acid (HVA, the major 
metabolite of DA) have been previously used to 
reflect the turnover of the DA system. In HD, 
concentrations of HvA appear to be greatly reduced 
in the caudate (48% loss) and putamen (50% loss) 
(Reynolds and Garrett, 1986), consistent with 
reports by Kish et al.(1987) and Walsh et ale 
(1982), whereas, Melamed,et al.(1982) found no 
significant difference. A trend towards reduced HVA 
concentrations has also been demonstrated in the 
nucleus accumbens and s.nigra pars reticulata (Walsh 
et al., 1982; Kish at al., 1987). 
The determination of tyrosine hydroxylase activity 
(the rate-limiting enzyme in the formation of DA) 
has demonstrated no changes in the caudate, putamen, 
nucleus accumbens, s.nigra, lateral and medial 
pallidum or hippocampus in HD (McGeer and McGeer, 
1976b). However, Bird and Coyle (1986) made a 
similar study s h o w ~ n g g a 30% increase in the caudate 
and a 300% increase in the s.nigra. 
A study of the activities of the enzymes monoamine 
oxidase A and B (MAO A,B) was made in HD; DA is 
m e t a b o ~ i s e d d mainly by MAO B in the human brain. 
Mann et ale (1986) found the kinetics of MAO A to be 
not significantly changed in the caudate and the 
frontal cortex. However, MAO B activity was 
increased in the frontal cortex (by 26%) and 
significantly in the caudate (by 260%). 
Two types of DA receptors have been investigated in 
HD: D1 and D2. A deficit in the binding to D1 
receptors has been reported to occur in the striatum 
(80-90% loss) with a relative sparing of the nucleus 
accumbens (50% loss) (Joyce et al., 1988; Cross and 
Rossor, 1983). A 70% loss has also been described 
in the s.nigra in HD, that correlates with an 
adenylate cyclase deficit (Filloux et al., 1990). 
Recently, DeKeyser et ale (1989a) identified two 
subtypes of D1 receptors : GTP sensitive (GS) and 
GTP insensitive (GI). In the brain in HD they 
demonstrated a 58% loss of binding in the putamen 
(50% increase of GI and 100% loss of GS), 20% loss 
in the pallidum and no significant change in the 
amygdala (100% loss of GS and 100% increase of GI) 
and the cortex (no changes). They suggested that 
there may be abnormal coupling of GS-D1 receptors 
with a G-protein in HD. In the brain in HD, D2 
binding losses of 50% have been reported in the 
caudate and putamen (Seeman et al., 1987; Reisine et 
al., 1977; Cross and Rossor, 1983; Joyce et al., 
1988). Here too, De Keyser et ale (1989b) 
subdivided D2 receptors into two categories: GS and 
GI •. They demonstrated a 28% loss in the putamen 
(100% loss of GI and no loss of GS) and 100% loss in 
the pallidum (100% loss of GI). These findings were 
challenged by Reyn?lds et ale (1990b) who reported 
no significant change in D2 receptor binding in the 
lateral pallidum in HD, which contradicts the above 
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report. A further study by Seeman et ale (1989) 
suggested that the link between D1 and D2 receptors 
was reduced in HD (and schizophrenia). D1-D2 
interactions, perhaps mediated by a G-protein, were 
reported to be missing in over half the HD cases 
analysed. There is evidence from one study that DA 
uptake sites are increased by 65% in the putamen and 
caudate in HD (Oldroyd et al., 1990). 
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Thus, the overall evidence would seem to reflect an 
intact nigrostriatal pathway, but with down-
regulation resulting in reduced activity. 
Therefore, the initial view of an overactive system 
in HD may only be relative, reflecting a lack of 
inhibition by GABA and acetylcholine. As glutamate 
affects DA release (Roberts and Andersen, 1979) and 
DA has been suggested possibly to affect 
corticostriatal glutamatergic transmission 
(Kornhuber and Kornhuber, 1986) the glutamate 
dysfunction in HD may be associated with 
dopaminergic changes. Furthermore, dopaminergic 
alterations in limbic regions in HD may have some 
connection with symptoms such as schizophreniform 
psychosis (Reynolds, 1983). 
1.4.3 Cholinergic neurones 
In the striatum the cholinergic system appears to be 
made up of interneurones. Acetylcholine itself 
shows strong postmortem losses, thus, markers for 
the system have often been measured. These include 
the activity of the biosynthetic enzyme, 
cholineacetyltransferase (CAT) and 
acetylcholinesterase (ACE). ACE is not always 
localised in cholinergic neurones, therefore changes 
of its activity may not identify cholinergic 
deficits. Slight increases or no significant 
changes were observed of ACE ~ c t i v i t y y in HD in both 
cortical and subcortical regions (Hammond and 
Brimijoin, 1988; McGeer and McGeer, 1976b; Stahl and 
Swanson, 1974). Many studies have investigated CAT 
activity in the brain in HD. Bird and Iversen 
(1974) described 'patchy' losses in HD in the 
caudate (50% loss) and putamen (50% loss) and 
subdivided the groups to select a 'normal' activity 
group, as compared with 85% losses in the remainder. 
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No significant changes were found in the frontal 
cortex. The results of McGeer and McGeer (1976b), 
Spokes (1980) and Cross (1986b) confirm these 
findings as well as identifying deficits in the 
locus coeruleus, hippocampus and septal nucleus in 
HO. Neither group found a significant deficit in 
the nucleus accumbens (and Spokes reports a slight 
increase). The pallidum (lateral and medial), 
cerebellum, cortex, s.nigra (pars compacta and pars 
reticulata) and red nucleus were all not 
significantly changed. Aquiloniu$ et al. (1975) 
made an investigation of the subdivided striatum in 
HO (but only using two brains). They reported a 
patchy gradient of deficits across the neostriatum 
with a maximum loss of 90% in the paraventricular 
caudate and rostral caudate. Other nonstriatal 
regions were found to have no significant changes, 
except for an increase in the cingulate gyrus. 
Muscarinic cholinergic receptors have been 
investigated in binding studies in the brain in HO. 
Enna et al.(1976a) identified a 50% loss of binding 
in the putamen and the pallidum., This confirmed the 
findings of Hiley and Bird (1974) and Young et 
al.(1988), although no significant changes were 
reported in the cortex. Wastek et al.(1976, 1978) 
extended the negative findings to include 24 other 
brain regions. 
These changes sugg,est that the,re appears to be 
deficits in the cholinergic system, resulting in 
reduced antagonism of the dopaminergic nigrostriatal 
pathway. A possible 'cholinergic association with 
dementia may be evident in HO, as cortical deficits 
are reported to occur with dementia in PO and AD 
(Perry et al., 1983; Rossor et al., 1984). 
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1.4.4 Noradrenergic neurones 
A pathway of noradrenergic neurones originates 
from the locus coeruleus, but as there are only 
small concentrations of NA in the basal ganglia, it 
has been little studied in HO. One investigation 
(Spokes, 1980) identified increases in NA 
concentrations in HO in the caudate (by 63%), 
lateral pallidum (by 38%), nucleus accumbens (by 
46%) and s.nigra pars reticulata (by 40%). The 
putamen, medial pallidum, s.nigra compacta/red 
nucleus, septal nucleus and anterior perforated 
substance showed no significant changes. 3-Methoxy-
4-hydroxyphenylethylene glycol, a metabolite of NA, 
was not significantly altered in the CSF of HO 
patients (Chase, 1973). Enna et ale (1976a,b) 
described results indicating that there was no 
significant difference in the density of B-
adrenergic receptors in the caudate or the putamen 
in HO, but there was a deficit in the pallidum. 
It is possible that NA and DA may act 
synergistically (Spokes, 1980), therefore, any 
changes may influence thenigrostriatal DA system. 
The effects of NA in other brain regions (eg. 
cortex) are more likely to be linked with 
psychiatric symptoms or dementia or affective 
disorder (Peyser and Folstein, 1990), than with 
dyskinesia. 
1.4.5 Serotonergic neurones 
A major striatal serdtonergic pathway, derives from 
the r ~ p h e e nucleus. There are only a few studies 
reporting the serotonin (5HT) system in the brain in 
HO. Bernheimer and Hornykiewicz (1973) described 
normal concent'rations of 5HT in the brain in HO, 
with a slight increase in the putamen, but only 
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reported from four cases. Recently, Kish et 
ale (1987) made a study of SHT concentrations 
throughout the striatum, nucleus accumbens and 
s.nigra (rostral) in HD. They identified a general 
increase throughout the HD'striatum, reaching 
significance in the rostral caudate and intermediate 
putamen, but with no significant change in the 
nucleus accumbens or the s.nigra. Furthermore, they 
measured concentrations of the major metabolite of 
SHT, S-hydroxyindoleacetic acid (SHlAA), and found a 
similar pattern (except for the head of the caudate 
which was not significantly altered). 
Binding studies provide evidence that suggests that 
SHT2 receptors are not significantly altered in the 
HD brain in the putamen, frontal cortex and temporal 
cortex (Cross et al., 1986b). However, Cross et 
al.(1986b) also reported deficits of SHT1 receptors 
in the putamen (SO% loss) and hippocampus (36% loss) 
but not significantly altered in the frontal or 
temporal cortex in HD. These findings were 
consistent with the results of Enna et ale (1976b) 
and Waeber and Palacios (1989) that extended the 
deficit to include the caudate, nucleus accumbens, 
pallidum (medial and lateral) and s.nigra (pars 
compacta and pars reticulata), but found no 
significant effect in the hippocampus or the cortex. 
SHT uptake sites showed a 64% increase in the 
putamen, but no significant change in the caudate in 
the brain in HD (Cross et al." 1986c). 
SHT has a possible effect in the production of 
myoclonus and hyperactivity and chorea (Gerson and 
Baldessarini, 1980; Ringel et al., 1973). Decreased 
SHT activity has also been associated with 
depression, aggression and dementia (Peyser and 
Folstein, 1990; Bowen et al., 1983). Tryptophan 
concentrations have also been measured in the brain 
in HD: Perry et al. (1973) found no significant 
change, as did Beal et al. (1990). Total t ~ p t o p h a n n
in the plasma in HD was not significantly altered, 
whereas, free tryptophan was abnormally reduced 
after fasting or hypoglycaemia (Phillipson and Bird, 
1977). 
1.4.6 Glutamatergic neurones 
A major input into the stri'atum is the excitatory 
corticostriatal pathway, which is known to be 
glutamatergic (Fonnum et al., 1981). There is also 
a glutamatergic projection from the subthalamic 
nucleus to the medial and lateral pallidum 
(Robertson et al., 1989). However, glutamate is 
also an important intermediate of metabolism and 
thus altered concentrations do not necessarily 
reflect neuronal losses. Diminished concentrations 
of glutamate in the brain in HD have been described 
in the caudate and the putamen (30% loss), but 
frontal cortex, cerebellum and s.nigra remained not 
significantly changed (Perry et al., 1973, 1982; 
Gramsbergen et al., 1986; Beal et al., 1988d). 
Ellison et al. (1987) made a comprehensive 
investigation of the regional distribution of 
glutamate concentrations in the brain in HD. They 
found deficits in severe grades of the disease, in 
the caudate (39% loss), putamen (27% loss), nucleus 
accumbens (19% loss) and in frontal (BA 9),premotor 
(BA 6), postcentral (BA 3-1-2) ,and occipital (BA 17) 
cortex (16-20% losses). The s.nigra pars compacta 
showed an increase, but all other regions measured 
showed no significant" changes (s.nigra pars 
reticulata, medial and lateral pallidum, 
hippocampus, claustrum, subthalamic nucleus, 
thalamus and other cortical regions). cortical 
losses in HD are also consistent with Kremzner et 
ale (1979). 
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A possible marker for the glutamatergic system is 
the enzyme, ornithine aminotransferase, which has 
been suggested t & ~ o n c e n t r a t e d i n n glutamatergic 
terminals (Wong et al.·, 1982). They demonstrated 
reduced activity of ornithine aminotransferase in 
the caudate, putamen, parietal and frontal cortex 
(34-49% losses) in HD. 
High-affinity uptake sites were also reported (Cross 
et a1., 1986c) to be diminished in the caudate (70% 
loss) '. putamen (60% loss) and hippocampus (30% 
loss), whereas the temporal cortex remained not 
significantly changed in HD. Greenamyre et al. 
(1985) and Young et al. (1988) measured glutamate 
receptor binding sites in the HD brain. They 
identified a loss of total glutamate and 
quisqualate-sensitive binding in the caudate and 
putamen (67% loss), whereas' there was no significant 
change in the cortex, claustrum and basal nucleus. 
However, in the putamen, N-methyl-D-aspartate 
(NMDA)-sensitive binding showed a 93% deficit, 
although in the cortex (insular) " there was no 
~ i g n i f i c a n t t reduction. The phencyclidine receptor 
(associated with the NMDA receptor complex) showed 
67% loss in the putamen in HD, with no significant 
change in the cortex. Beaumont et al. (1979) 
determined the density of kainate binding in HD 
brain. They reported a deficit in the caudate (55% 
loss) and putamen ( ~ 3 % % loss), with no significant 
change in the pallidum, frontal cortex or 
cerebellum. 
These changes reflect the loss of the 
corticostriata1 pathway and cell losses from the 
striatum (matrix), which receives the major cortical 
input (Seto-Ohshima et ai., 1988a). other evidence 
supporting the theory of glutamatergic losses, is 
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the atrophy of layer 5 of the cortex, the origin of 
the corticostriatal fibres (Bruyn et al., 1979). 
Lesions of the subthalamic-pallidal pathway has been 
shown to be important in the balance between medial 
and lateral pallidum (Crossman et al., 1988). Thus, 
if there is a deficit, there may be dyskinetic 
consequences (see section 4.1). The changes in the 
glutamatergic system are potentially of relevance to 
the 'excitotoxic hypothesis' regarding the aetiology 
of the disease, which is thought to be mediated by 
glutamate r e c e p ~ o r s s (especially NMDA) (Bruyn and 
stoof, 1990). Furthermore, cortical losses of amino 
acids have been demonstrated to occur in other 
dementing disorders, suggesting a common feature 
(Rossor et al., 1984; Reynolds and Warner, 1988). 
Glutamate and DA may also moduiate the release of 
each other (as discussed in section 3.2) (Roberts 
and Andersen, 1979; Kornhuber and Kornhuber, 1986). 
1.4.6 Other amino acids 
Aspartate is also a p ~ i b l e e neurotransmitter in the 
corticostriatal tract and in cerebellar climbing 
fibres (Fonnum, 1984; wiklund et al., 1982). 
Ellison et al. (1987) and Perry et al. ( ~ 9 7 3 ) ) found 
no significant difference in aspartate 
concentrations in the HD brain, but Beal et al. 
(1988d) found a 21%' increase in the cerebellum and 
Gramsbergen et al. (1986) reported a slight increase 
in the s.nigra. The meaning of such increases is 
unclear, but it may reflect increased aspartate 
system or a selective sparing in a region of 
atrophy. 
Taurine is also a putative neurotransmitter (Baskin 
et al., 1976) which is derived from cysteine 
metabolism (Perry et al., 1975). Gramsbergen et 
al.(1986) reported a slight increase in taurine 
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concentrations in the putamen in HO, but Ellison et 
ale (1987) and Perry et ale (1973) found no 
significant changes. Beal et ale (1990a) reported 
increased cysteine concentrations in the putamen in 
HO. 
Glycine is thought to have a major role at the NMOA 
receptor complex, potentiating responses (Foster and 
Kemp, 1989). It also has an inhibitory role in the 
central n e r v o u ~ ~ system. Thus any changes in HO may 
have relevance to the 'excitotoxic hypothesis' of 
the disease (see section 6.3). Perry et ale (1973) 
reported no significant changes in glycine 
throughout the brain in HO. 
1.5 Neuropeptides and enzymes 
1.5.1 Neuropeptides 
Many of the neuropeptides have been suggested to be 
neuromodulatory to, as well as reacting to 
dopaminergic changes. Changes in immunocytochemical 
activity or concentrations have been well 
established in HO, thus identifying losses of 
subpopulations of neurones. Substance P is known to 
be present in a subpopulation of medium spiny 
GABAergic neurones projecting from the striatum to 
the medial pallidum and s:'nigra (pars compacta and 
pars reticulata) (Reiner et al., 1988). Extensive 
losses of 80-90% of substance P have been described 
in the lateral and medial pallidum, s.nigra (pars 
compacta and pars reticulata) and' caudate and 
putamen (Emson, 1986; Arai et al., 1987; Gale et 
al., 1978; Kanazawa et al., 1977; waters et al., 
1988), but no significant changes in the amygdala, 
hippocampus or frontal and temporal cortex. Beal et 
ale (1988a) attempted to correlate substance P 
deficits with gradings of severity of pathology. 
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They found sUbstantial losses of substance P 
throughout the basal ganglia (including the nucleus 
accumbens), that strongly correlated with striatal 
neuronal losses. Furthermore, they described losses 
in non-striatal regions including the subthalamic 
nucleus and stria terminalis, but no significant 
changes in the thalamus, claustrum, hippocampus, 
locus coeruleus, lateral geniculate and red nucleus. 
Of 24 cortical regions studied, only premotor, 
frontal eye field and frontal areas (BA 6,8,9) 
showed 20-30% increase. The relevance of these 
changes must be understood in terms of co-
localisation described above. These GABAergic spiny 
neurones are lost in HO, thus pallidal, nigral and 
striatal regions show deficits of substance P. The 
deficit in the subthalamic nucleus was described by 
Beal et ale (1988a) as reflecting a possible loss of 
substance P - c o n t a i ~ i n g g pallidal-subthalamic 
afferents, but this is only speculative. substance 
P has been reported to co-localise with NPY or SS in 
some cortical neurones, thus cortical increases 
would identify selective sparing (Jones and Hendry, 
1986). The role of substance P is thought to be 
excitatory and modulatory for OA (Beal et al., 
1988a). Related to substance P, are neurokinin A, 
neurokinin Band neuropeptide K (all of which derive 
from the same two precursors). In HO, neurokinin A 
showed losses in all areas except for the cortex; 
neurokinin B was reduced in the s.nigra and medial 
pallidum and neuropeptide K was reduced in the 
s.nigra and frontal cortex (Arai et al., 1987). The 
normal function of these peptides and their possible 
relevance to HO is unknown. 
Somatostatin (SS) has been described to be increased 
in HO in the caudate. (by 100%) and nucleus accumbens 
(by 300%), with no significant change in the 
amygdala, hypothalamus or cortex (Nemeroff et al., 
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1983). Increases were also reported in the putamen-
and pallidum (medial and lateral), but no 
significant changes in the s.nigra (pars compacta 
and pars reticulata), hippocampus or hypothalamus 
(Emson, 1986; Aronin et al., 1983). SS-related 
peptides were also reported to be increased (by 55%) 
in the putamen in HO (Sperk et al., 1987). Beal et 
-
ale (1988c) again tried to correlate changes with 
severity of striatal neuronal degeneration. They 
confirmed the increases (by 300%) of SS in the basal 
ganglia (except the medial pallidum) and extended 
the regions with increases to include the red 
nucleus, locus coeruleus and several cortical areas. 
No association was evident with pathological grading 
of severity. There is strong evidence that SS co-
localises with NPY and NAOPH-d in striatal and in 
cO,l-tical (GABAergic) medium aspiny neurones 
(Ferrante et al., 1987b). Studies of NPY in the 
brain in HO reveal similar patterns of increases (by 
250%) throughout the basal ganglia (except the 
medial pallidum) (Emson, 1986; Beal et al., 1988c) 
and also in the subthalamic nucleus, s.nigra pars 
compacta, claustrum, thalamus, stria terminal is and 
locus coeruleus. Increases were also found in many 
regions of 'the cortex. Here too, there was no 
correlation with pathological severity. The pattern 
of increase for SS and NPY, reflects the selective 
sparing of this subpopulation of aspiny medium 
neurones in HOi thus, within the cortex identifies 
GABAergic neurones that are not lost. It was noted 
that the medial pallidum showed no significant 
increases in SS or NPY (Oawbarn et al., 1985). Kish 
et ale (1987) made a suggestion that 'preservation 
of 5HT2 receptor-containing neurones corresponds 
with sparing of ss-containing neurones in HO', but 
there is no strong evidence for this. SS is thought 
to be associated with increased production and 
release of OA (Aronin et al., 1983). 
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Met-enkephalin has been measured in HD brain by 
Emson (1986) who reported losses (50%) in the 
pallidum (lateral and medial) and s.nigra (pars 
compacta and pars reticulata), but no significant 
changes in the caudate or putamen. Met-enkephalin 
co-localises with the GABAergic striatal projection 
to the lateral pallidum, which is lost in HD (Reiner 
et al., 1988). Thus, a met-enkephalin deficit would 
be expected. Met-enkephalin may modulate DA 
turnover (Diamond and Borison, 1978). A further 
opioid peptide is dynorphin, which is lost from the 
pallidum and s.nigra and striatum in HD (Waters et 
al., 1988; Seizinger et al., 1986; Dawbarn et al., 
1986). 
The neuropeptides, cholecystokinin (CCK) and 
vasoactive intestinal peptide (VIP) were also 
determined in the brain in HD (Emson, 1986). VIP w ~ ~
described as not significantly changed throughout 
the brain, whereas CCK showed losses (50%) in the 
pallidum and the s.nigra, but was not s i g n i f i c a n t \ ~ ~
altered in the striatum. Furthermore, 'there was 
reduced CCK binding in the basal ganglia (70% loss) 
and the cortex (43% loss) (Hays et al., 1981). CCK 
defines a subpopulation of GABAergic cortical 
neurones, which appear to be lost in HD; whereas 
subcortically, CCK is thought to co-localise with DA 
in the ventero-tegmental and nucleus accumbens 
neurones, having an antagonistic effect (Hokfelt et 
al., 1980 ). 
Nemeroff et al. (1983) and Emson (1986) 'measured 
neurotensin in the HD brain, finding a 50% increase 
in the caudate and medial pallidum, but no 
significant change in the nucleus accumbens, 
amygdala, hypothalamus, putamen, lateral pallidum or 
s.nigra. Neurotensin is also thought to co-localise 
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with DA (Hokfelt et al., 1984). 
1.5.2 Peptides of the hypothalamus 
Thyrotropin-releasing hormone (TRH) showed increases 
in the caudate and amygdala and putamen (300%) in 
HD, but no significant change in the hippocampus or 
the nucleus accumbens (Nemeroff et al., 1983; Emson, 
1986; Spindel et al., 1980). A sUbstantial increase 
(by 400%) of gonadotropin-releasing factor in the 
median eminence in HD was described by Bird et al. 
(1976). Angiotensin-converting enzyme (ACEZ) has 
been reported to be decreased in the caudate, 
p u t ~ m e n , , pallidum, s.nigra and nucleus accumbens, 
but not significantly altered in the cortex in HD 
(Arregui et al., 1978; Butterworth, 1986). 
Angiotensin is reportedly neuroactive and ACEZ is 
described to be localised in the striatonigral 
pathway (Arregui et al., 1978). One HD case report 
has been published describing 'dramatic 
deterioration of clinical state' whilst taking ACEZ 
inhibitor, with vast improvement on withdrawal of 
the drug (Goldblatt and Bryer, 1987). 
1.5.3 Pituitary hOrmones 
DA has been shown to inhibit prolactin secretion, 
whereas GABA increases it (Hayden, 1981). Hayden 
reviewed reports of prolactin in HD: 4 studies 
suggested that basal levels were nou' significantly 
changed, two reported an increase and two a 
decrease. However, responses to various stimuli 
(TRH, L-Dopa, bromOcryptine) suggested an impaired 
system. Hayden also reviewed the literature on 
growth hormone regulation in HD. Growth hormone 
release is thought ~ o o be stimulated by DA. There is 
a general consensus that basal levels of growth 
hormone are normal in HD (in 6/7 studies). stimuli 
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(eg. insulin, L-Dopa, bromocryptine) appeared to 
have increased growth hormone responses in HD 
patients. 
1 5.4 Enzyme changes in HD 
Butterworth (1986) made an extensive study of many 
enzyme markers for neurones, glia and endothelial 
cells in the caudate in HD. There were losses of 
all neuronal marker enzymes (ACEZ, thermolysin-like 
metanoendopeptidase, alanine aminopeptidase, 
glutamate-oxaloacetate transaminase). Glial marker 
enzymes showed varying changes (glutamine synthetase 
was reduced, B-glucuronidase was increased and 
pyruvate carboxylase was variable). Glutamine 
synthetase was reported to be reduced in the 
putamen, cortex (frontal and temporal) and 
cerebellum (Carter, 1981). The endothelial enzymes 
(alkaline phosphatase and plasminogen activator) 
were not significantly changed in HD. Butterworth 
et ale (1985) also measured the activity of 4 other 
enzymes throughout the HD brain. Phosphate-
activated glutaminase, succinic dehydrogenase and 
pyruvate dehydrogenase were reduced in the caudate, 
however, 1-glutamyl transpeptidase was increased. 
This is consistent with other reports (Zhu et al., 
1990; Cross et al., 1986a), which suggested an 
increased 1-glutamyl transpeptidase activity may be 
a glial marker. Cross et ale (1986a) determined 
activities of many enzymes in the putamen in HD, 
using markers of subcellular organelles and acid 
hydrolases. A plasma membrane associated enzyme 
(5'nucleotidase) was not significantly changed, 
whereas l-glutamyltransferase (described above) was 
increased (but not in the cortex and cerebellum). 
2',3'-cyclic nucleotide p h o s ~ ~ d r o l a s e , , a myelin 
marker, was increased which is consistent with the 
demonstration of increased cholesterol and 
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sphingomyelin (Borri et al., 1967) reflecting 
relative axonal sparing. DNA concentrations were 
increased, as was one of the lysosomal markers ( ~ ~
glucuronidase) however, the other one (acid 
phosphatase) was not significantly altered. 
Catalase (a peroxisome marker) and fumarase (a 
marker for mitochondria) were not significantly 
changed, but neutral a-glucosidase (a marker for 
endoplasmic reticulum) was reduce,d (but not 
significantly altered in the cortex and cerebellum). 
Glycoside hydrolases were variable: N-acetyl-B-
glucosaminidase, B-glucosidase and a-fucosidase were 
all reduced, whereas a-galactosidase was increased. 
All the other enzymes in this group (B-xylosidase, 
a-mannosidase, B-galactosidase) were not 
significantly changed, . 
Cross concluded that B-glucufunidase activity was a 
marker for neuronal degeneration and that a-
glucosidase differences may reflect dysfunction of 
glycoconjugate processing, which may explain the 
specific degeneration of neurones in HD. Yates et 
ale (1990) reported reduced activity of pyruvate 
dehydrogenase in the caudate in HD and suggested 
that this also was a measure of neuronal losses. 
Furthermore, they stressed the importance of pH and 
lactate in the interpretation of neurochemical 
measurements, highlighting the need for controls of 
similar agonal state ( s e ~ ~ section 1.4). Bird and 
Coyle (1986) described further determinations of the 
enzymes involved in glucose metabolism (Bird et al., 
1977). They reported specific losses, in the 
putamen and caudate, of phosphofructokinase and 
ouabain-insensitive ATPase,' whereas in the pallidum, 
glutamate dehydrogenase was increased. There were 
no significant changes of hexokinase, glucose-6-
phosphate dehydrogenase or lactic acid 
dehydrogenase; the cortex, hippocampus and 
cerebellum showed no significant changes. A further 
enzyme (NAOH: ubiquinone oxidoreductase (complex 1) 
measured in the platelets from patients with HO, was 
shown to be reduced. Other measures of 
mitochondrial function (succinate: cytochrome c 
oxidoreductase and cytochrome oxidase) were not 
significantly altered (parker et al., 1990). They 
suggested that HO could be a genetic mutation of the 
nuclear coded subunits for this enzmye. A similar 
deficit has been noticed in PO, suggesting a common 
complex I defect (Shapira et al., 1989). 
Furthermore, Shapira (Mann et al., 1990) measured 
mitochondrial function in the putamen, caudate and 
cortex in HO finding decreases in complexes II and 
III, but not in I or IV. Thus, their hypothesis 
contrasted HO with PO (where only complex I is 
abnormal) • 
1.5.5 Calcium-associated proteins 
Calbindin-containing neurones are localised in the 
striatal matrix, in medium spiny neurones, thus 
there are losses of these neurones in HO (Seto-
Oshima et al., 1988b). Calcineurin . has 
been described as providing a marker for striatal 
efferents,'as it is found only in the striatum and 
striatal projections (Goto et al., 1989). They 
reported striatal losses and also in the pallidum 
(the dorsal part being less affected) in HO (but 
only one case). They measured synaptophysin in the 
same brain, as a vesicular marker for pallidal 
afferents. Synaptophysin also shows losses in the 
pallidum (also with the dorsal part less affected). 
These losses were not as great as the calcineurin 
deficit and were not marking the same p ~ a t i o n n of 
neurones. 
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1.6 Neuropharmacology 
At present there is no cure and no effective 
treatment to stop the disease progressing. However, 
individual symptoms can be addressed with some 
success. Hayden (1981) reviewed some aspects of 
drug therapy in HD. 
The most common drugs used in HD are those which 
interact with the DA system. In the UK, 
tetrabenazine is the drug of choice (Jankovic, 1982) 
for the alleviation of chorea, although its use is 
banned in other countries. Like reserpine it 
depletes monoamine storage and thus reduces 
DA activity. However, it also acts on other 
monoamines, such as 5HT and NA, which are more 
likely to mediate the serious side effects 
associated with its use (drowsiness, depression and 
suicide) (Lane et al., 1976). Neuroleptics are also 
used; they act as postsynaptic DA antagonists. 
These drugs include butyrophenones such as 
haloperidol and phenothiazines ego perphenazine, the 
USA drug of choice for reducing chorea' (Fahn, 1979). 
Common side effects of DA antagonists include 
p a r k i n s o n i ~ m , , akathesia, dystonia and tardive 
dyskinesia which may limit their use. L-Dopa 
predictively a g g r ~ v a t e s s chorea, but some DA agonists 
(eg. apomorphine, bromocryptine) at low doses 
unexpectedly reduced choreiform movements. At 
higher doses, the chorea was worsen$d and these 
actions were postulated to be mediated via 
presynaptic dopaminergic autoreceptors (Frattiola et 
al., 1977; Carlsson, 1976). Substituted benzamides 
(e.g. sulpiride) were described to be more specific 
with less side effects (Zanglein et al., 1978). 
Combination therapy.of a D2 receptor blocker and a 
DA storage blocker has been described as a better 
therapy for the alleviation of chorea. This was 
longer lasting (after an initial deterioration 
period) and free from the usual psychiatric side 
effects (Fog and Pakkenberg, 1970). The psychosis 
of HD responds to neuroleptics, but with higher 
doses than are needed to reduce chorea (Hayden, 
1981). Clozapine has also been used to treat HD 
(Dose, 1991; Sajatovic et al., 1991) with limited 
success in some patients that had problems 
associated with other traditional neuroleptics. 
One obvious form of therapy in HD appeared to be the 
restoration of GABA levels, by replacement therapy 
or by reducing its breakdown. However, the drugs 
which influence the GABA system seem in general not 
to be effective in the reduction of chorea, and side 
effects are possible from the nonspecific effects of 
GABA in other regions of the brain. Receptor 
agonists have been tried (muscimol, baclofen) 
(Shoulson et al., 1978, 1989) as have GABA-T 
inhibitors (isoniazid, aminooxyacetate) (McLean, 
1982; Perry et al., 1980), none of which have proven 
consistently effective in the amelioration of. 
chorea. Associated with GABAergic transmission, 
benzodiazepines have been used in the treatment of 
HD, usually as sedatives, and reports suggest some 
success in the reduction of chorea (Peiris et al., 
1976). However, tolerance may occur which limits 
their use. 
A further obvious line of therapy has been 
influencing the cholinergic system. This can be 
achieved in several ways; by providing choline 
(Aquilonius and Eckernas, 1977) or deanol, which is 
converted to acetylcholine (Reibling et al., 1975), 
or by using anticholinesterases (physostigmine) 
(Tarsy et al., 1974). None of these approaches were 
successful in the reduction of chorea, however, 
anticholinergics (benzotropine) have been reported 
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to increase movements (Klawans and Rubovits, 1972). 
Drugs affecting the noradrenergic system have also 
been used in HD, but with little effect. 
Antagonists (thymoxamine and propanolol) were tried, 
with the latter ameliorating chorea slightly and 
also used in the treatment of aggression in HD (Nutt 
et al., 1979) •. 
Influencing the serotonergic system is a further 
approach to pharmacological therapy, but findings 
have been inconsistent. Tryptophan administration 
has been reported to have no effect on chorea 
(McLeod and Horne, 1972), whereas 5-
hydroxy tryptophan has been described as increasing 
choreiform movement (Lee, 1968). However, 5HT 
antagonists (methysergide) and agents which reduce 
5HT synthesis (parachlorophenylalanine) both have no 
ameliorative effects on chorea (Ringel et al., 
1973). 
Tricyclics and lithium have also been used with some 
success in the treatment of psychiatric symptoms of 
the disease, but not with the chorea (Vestergaard et 
al., 1977; 'Chiu, 1979). corticosteroids have also 
had no consistent success (Brown et al., 1979). A 
drug that depletes SS levels (cysteamine) was tried 
in one study, but with no beneficial results (Shults 
et al., 1986). Another observation comes from a 
single case report, suggesting that.that clinical 
symptoms of HD were a g g r ~ v a t e d d by treatment with 
ACEZ inhibitor, and improved on withdrawal of the 
drug (see section 1.5) (Arregui et al., 1978). 
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1.7 Imaging techniques 
Imaging techniques can provide a useful tool in the 
study of HD. structural and metabolic changes can 
be investigated, although specific diagnosis cannot 
be made solely ~ m p l o y i n g g these measures. There have 
been many attempts to correlate early changes that 
may predict the disease; however, clinically, they 
are used as part of a battery of ,testing of 
presymptomatic patients, rather than as individual 
tests. The results of such studies have been 
inconclusive, especially as the longitudinal 
evidence will take many years to collect. 
1.7.1 Computed tomography lCT) imaging 
CT measures of striatal atrophy in HD (e.g. 
bicaudate ratio) have been reported that correlated 
with the progression of the disease symptoms, 
although it has been suggested that cortical cell 
losses would need more sensitive methods for 
accurate assessment (Bamford et al., 1989). 
Cognitive and oculomotor impairment was suggested to 
be associated with measures of caudate atrophy in 
this and other studies (Bamford et al., 1989; 
Starkstein et al., 1988, 1989), but not with 
cortical changes (Starkstein et al., 1988,1989). 
They determined both sub-cortical measures 
(bicaudate ratio, bifrontal ratio and third 
ventricular ratio) and cortical measures (frontal 
fissure ratio and cortical sulci ratio) in HD. Sub-
cortical measures were associated with duration of 
disease, whereas cortical measures were linked with 
age, however, these measures were independent of 
each other. The bicaudate ratio was described as a 
useful diagnostic parameter (even in early HD). 
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1.7.2 Magnetic resonance imaging (MRI) 
Lebrun-Grandie et ale (1988) reported focal atrophy 
in caudate that was less pronounced in the putamen, 
and associated with diffuse cortical atrophy. Reid 
et ale (1988) and Simmons et al. (1986) also 
reported similar changes using MRI to study HO. 
1.7.3 Single photon emission computed tomography 
(SPECT) imaging 
Reid et ale (1988) made a study in HO using SPECT 
and identified a reduction in blood flow in the 
caudate in HO. This was confirmed by comparison 
with MRI (and neuropathological findings, in one 
case). 
1.7.4 Positron eQ)ission tomography (PET) imaging 
Many PET studies have been made in HO (using mainly 
18 f1uorodeoxyglucose, FOG) (Young et al., 1986; 
Kuhl et al., 1984; Mazziota et al., 1987; Weinberger 
et al., 1988; Kuwert et al., 1990). Hypometabolism 
in the caudate and putamen was common to all 
studies, h ~ w e v e r , , cortical hypometabolism was only 
described by Kuwert et al. (1989, 1990). Changes in 
some cortical regions were related to cognitive 
symptoms, but caudate measures showed a stronger 
correlation (Kuwert et al., 1990; w e i ~ b e r g e r r et al., 
1988). Further associations were de$cribed by Young 
et al. (1986): putamen indices with motor function; 
thalamic metabolism with dystonia and caudate with 
bradykinesia and functional capacity. 
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1.7.5 Presymptomatic studies 
People at risk to HO have been examined in many 
studies to try to get early diagnosis, or prediction 
of the disease, using four main approaches: 
neurological, metabolic, structural and genetic (all 
studied concurrently by Grafton et al., 1990). Many 
PET or CT investigations have been made, comparing 
changes with those found in HO itself. PET was 
suggested to reveal much earlier changes (especially 
in the caudate), as compared to CT (Kuhl et al., 
1984; Mazziota et al., 1987) and thus, was a more 
useful tool in the prediction of HO. The study of 
Mazziota provided evidence that reduced caudate 
glucose metabolism was obvious in the statistically-
predicted number of at risk subjects, although 
genetic linkage and clinical follow up was 
imperative to prove the hypothesis. Grafton et ale 
(1990) produced evidence that altered PET measures 
precede clinical or structural abnormalities, using 
DNA marker-tested at risk subjects. This effect was 
especially obvious in the putamen, caudate, pallidum 
and precentral gyrus. Young et ale (1986) 
previously produced an investigation showing that 
'soft n e u r ~ l o g i c a l s i g n s ' c o u l d d be used to predict 
HO, but the study of Grafton did not concur with 
these findings. 'Soft signs' include saccadic eye 
movement, optokinetic movement, co-ordination of 
finger to nose, finger tapping, rapid alternating of 
movements. 
1.8 Aims of this project 
The main aims of this project were to study the 
neurochemistry of HO using a large series of post 
mortem brain tissue ,taken from patients with HO and 
from matched controls with no previous history of 
neuropsychiatric disorder. There were two main 
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aims: firstly, to identify and characterise any 
altered parameters of neurotransmitter systems, 
especially in relation to the s y m p t o ~ o ~ y y of the 
disease. Secondly, to understand the role of 
neurotoxins in the aetiology of the disease, 
particularly endogenous compounds that may have 
aberrant mechanisms (see section 6.3). 
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Chapter 2 
Materials and methods 
2.1 General details regarding cases studied 
Brain tissue, provided by the Cambridge Brain Bank, 
was prepared and stored as described previously 
( S p o ~ e s , , 1979). This was obtained post mortem from 
patients neuropathologically confirmed as having 
Huntington's disease (HD) and from controls with no 
previous history of neuropsychiatric disease. These 
groups (Table 2.1) were matched for age and post 
mortem delay, however the control group contained 
fewer females,' reflecting the low death rate of 
females of this age range. Furthermore the cause of 
death in HD is usually bronchopneumonia, whereas 
there are more acute deaths in the control group, 
thus agonal state is another potentially artefactual 
factor that must be considered. 
The HD cases were clinically assessed 
retrospectively by a neurologist (Dr. Kenneth 
Heathfield) in order to determine the s y m p t o n t t ! . o ~ y . .
This 'global impression' was based on all 
information in the medical and nursing case notes. 
Thus drug history, age at onset and duration of the 
disease, the degree of chorea (mild, moderate and 
severe), and of dementia (absence, mild, moderate 
and severe), or the presence or absence of 
schizophreniform, depressive, aggressive and rigid 
features were assessed. Consequently it was 
possible to investigate any 'neurochemical correlates 
of these features, by sub-dividing from the major 
group. 
53 
Table 2.1 
Details of subiects providing brain tissue post mortem 
Values are means. Ranges in parentheses. 
Age Sex Post Duration 
(Years) mortem (Years) 
(Hours) 
Controls 57 24M 3F 31 
c.n (21-82 ) (3-79) 
,£10. 
Huntington's 
disease· 56 23M 23F 43 12 
(30-83) (3-153) (3-24) 
Neurochemical measurement was carried out using 
specific regions of the brain. The areas of 
particular interest were the basal ganglia (caudate, 
putamen, medial and lateral pallidum), the 
sUbstantia nigra (s.nigra) pars compacta, as well as 
limbic (amygdala and hippocampus) and cortical areas 
(frontal and temporal). 
2.2 Limitations of human post mortem brain studies 
of neurotransmitters 
It is often difficult to acquire post mortem brain 
tissue, especially in the case of rare disorders. 
Thus the numbers of cases in a series may well be 
limited, making statistical analysis inappropriate. 
Post mortem delay from time of death until the 
freezing of the tissue is highly variable (e.g. 
ranging from 3-153 hours). Many neurochemical 
changes occur in the initial few hours following 
death, but are then stable in the long-term (e.g. 
increased ¥-aminobutyric acid (GABA) 
concentrations). Thus although absolute values may 
not be accurate, they have been shown to correlate 
strongly with pre-mortem values. 
Age, sex and agonal state inevitably vary and 
differences may have effects on specific compounds 
(e.g glutamic acid decarboxylase (GAD) activity is 
strongly affected by agonal state) ... 
Differences associated with prior drug treatment 
provide a further variable that is unavoidable, 
particularly when dealing with neuropsychiatric 
disorders. 
For all the above limitations, there is no ideal 
solution, but a compromise must be reached. Of 
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primary importance is the use of 'matched' controls 
which are treated in an identical fashion to the 
samples involved in the investigation. Thus any 
inherent methodological errors will be negated. If 
it is impossible to match individuals completely, 
then a statistically similar mean and range of 
values from group to group would be acceptable. 
However, parameters such as drug treatment will 
never be matched in these studies,. so appropriate 
statistical tests must be used to rule out the 
effects of such factors on any reported changes. 
2.3 Measurement of concentrations of monoamines and 
their metabolites 
Concentrations of noradrenaline (NA), dopamine (DA) 
and its major metabolite homovanillic acid (HVA) and 
S-hydroxytryptamine (SHT) and its metabolite S-
hydroxyindoleacetic acid (SHIAA) were measured using 
an adaptation of an established high-performance 
liquid chromatography (HPLC) technique (Reynolds, 
1983). For most brain areas a simple 'direct' 
method (which did not use any extraction techniques) 
was used, but for hippocampus, amygdala and cortex, 
an extraction process was necessary in order to 
determine the very much smaller concentrations of NA 
and DA in these regions. These methods allowed the 
concurrent measurement of ' amino acids from the same 
homogenate, on a different HPLC system. 
2.3.1 'Direct' method 
Tissue (approx. so mg) was homogenised in 0.5 ml 0.1 
M perchloric acid (PCA) using a glass/glass 
homogeniser. All solutions contained 0.1 aM 
ascorbate (an anti-oxidant) and 0.1 aM EDTA (a 
chelating agent). The homogenate was centrifuged at 
12000 g for 3 minutes and the supernatant was 
diluted if necessary with 0.1 M hydrochloric acid 
(HCI). stock solutions (2 mg/ml in 0.1 M HCI) of 
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standards were diluted to 50 ng/ml with 0.1 M HCI. 
20 ~ l l were injected onto the HPLC system, whilst 100 
~ l l was diluted 1+4 vols 0.1 M disodiumtetraborate 
buffer (pH 9.5) and stored at -20°C for later 
analysis of amino acids. 
2.3.2 Extraction method 
An extraction process is necessary to 
the small amounts of DA and NA in the 
amygdala and especially the cortex. 
concentrate 
hippocampus, 
The other 
compounds (5HT, HVA and 5HIAA) can be determined 
using the same 'direct' method as described above. 
A large volume of supernatant is added to the 
alumina at high pH and under these conditions the 
catecholamines such as DA, NA and 
dihydroxybenzylamine (DHBA) adhere to the alumina, 
whereas other compounds are washed away. Rapidly 
decreasing the pH results in the elution of the 
catecholamines into a small volume: also there is 
improved chromatography due to the removal of many 
contaminants. 
This method was used for the hippocampus and 
amygdala (for the cortex the concentrations of the 
standards and solutions were 10 fold smaller). 
Tissue (approx. 150 mg) was homogenised in 1.0 ml 
0.1 M PCA containing 10 ng/ml DHBA as an internal 
standard, which was demonstrated not to co-elute 
with any sample peaks. The homogenate was 
centrifuged at 12000 g for 3 minutes and aliquots 
were injected, or diluted and frozen as described 
previously. The remaining supernatant (approx. 700 
~ l ) ) was added to 25 mg alumina and 0.5 ml Tris 
(hydroxymethyl) methylamine (TRIS) buffer (0.1 M pH 
8.6) for extraction at 4°C. The tube was gently 
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shaken for 10 minutes then allowed to settle. The 
supernatant was sucked off and washed rapidly with 
two successive 1 ml water washes. The remaining 
liquid was removed and 100 ~ l l 0.4 M PCA was added to 
the alumina and gently agitated for 10 minutes, to 
elute the catecholamines. The eluate was removed 
and 50 ~ l l were injected into the HPLC system. 
Standards solutions containing equivalent amounts 
(e.g. 10 ng) of NA, DA and DHBA were extracted onto 
the alumina in the same way. 
2.3.3 HPLC characteristics 
This isocratic reverse phase system used a 
Spherisorb ODS-2 5 ~ m m (25 cm x 4.6 mm) column at 
40°C, together with a 0.1 M phosphate/acetate buffer 
at pH 3.6 containing 2.5 roM octylsulphonate, 0.05 roM 
EDTA and 15% methanol. Quantification was achieved 
using an electrochemical (ED) detector (BAS) 
containing a glassy carbon electrode set at +0.75 V 
(vs. Ag/AgCI). 
The retention time of peaks in samples were compared 
to the co-elution of authentic standards, and their 
identity further confirmed by the recovery of added 
standards to samples. Thus NA, DHBA, 5HlAA, DA, HVA 
and 5HT all produced single peaks. There was 
linearity of response to varying concentrations for 
all compounds, as well as good reproducibility from 
repeat injections. other compounds Gould also be 
measured using this particular HPLC system (e.g. 
tryptophan, tyrosine, 3-hydroxykynurenine, 3-
hydroxyanthranilic acid, DOPAC, xanthurenic acid, 5-
h y d r o x y t ~ p t o p h a n , , DOPA, adrenal ine etc.). These 
could be optimally separated by manipulation of the 
mobile phase characteristics (e.g. % methanol or pH 
change) or by altering the potential of the detector 
or by omitting the octylsulphonate (which acts as an 
ion-pairing agent to increase the retention of some 
compounds, in particular, fast-eluting species). 
2.3.4 Calculation of concentrations (ng/g tissue): 
'Direct' method 
Ratios of sample peak height to standard peak height 
were adjusted to allow for the concentration of 
standard used, dilution factor and weight of tissue. 
Example calculation: 
HVA in sample 
HVA in standard 
X 50 ng/ml X 4 X 0.5 (+ weight) ml 
weight (g) 
= ng/g tissue 
Extraction method 
Extracted ratios of compound in sample to internal 
standard in sample were compared to similar ratios 
in standards, and corrected to allow for the weight 
of tissue used. 
Example calculation: 
DA in sample/DHBA in sample X 10 X --1 
DA in standard/DHBA in standard weight 
= ng/g tissue 
2.4 Determination of choline acetyltransferase (CAT) 
activity 
CAT activity in post .mortem brain in HD and controls 
(frontal and temporal cortex, hippocampus and 
caudate) was determined using our modification of 
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the radioenzymatic method of Fonnum (1975). This 
involved the measurement of tritium-labelled· 
acetylcholine (ACH) production from the enzymatic 
(CAT) conversion of tritiated acetyl CoA and 
choline. 
CAT 
Acetyl CoA* + choline => acetylcholine* + CoA 
(* = radiolabel) 
Eserine was present during the incubation to inhibit 
the cholinesterase activity. Tetraphenylboron (TPB) 
was used for the extraction of acetylcholine* into a 
toluene-based scintillant, resulting in a two phase 
solution which could have the r a d i o a c t i v ~ y y measured 
using a liquid scintillation counter. 
The method was as follows: 
Tissue (approx. 50 mg) was homogenised on ice using 
a glass/glass homogeniser in 0.25 ml 0.1 M 
phosphate-buffered saline (PBS, pH 7.5) containing 
0.4% vol/vol Triton X-100, 1 roM EDTA and 428 roM 
sodium chloride. The homogenate was transferred and 
a further 250 ~ l l PBS used to wash the tube. The 
pooled PBS homogenate was centrifuged for 10 minutes 
at 50000 g at 4°C. At regular timed intervals, 50 
~ l l supernatant was mixed and incubated at 37°C with 
50 ~ l l ·prewarmed "hot" working buffer-containing 8 
roM choline, 0.1 roM eserine 0.2 roM labelled acetyl 
CoA (hot/cold) in PBS. This was done in triplicate 
for each sample in a scintillation vial insert. 
After a timed period (5 or 15 minutes) the reaction 
was stopped by adding and mixing ice-cold phosphate 
buffer (PB) (0.01 M pH 7.4) and removal from the 
water bath, onto ice. Freshly made (1 ml) TPB (2 
gIl in acetonitrile) was added with 3 ml toluene 
based scintillation fluid and mixed. The 
radioactivity/tube was measured using liquid 
scintillation counting. Blanks were made using PBS 
in the place of the tissue supernatant. Activities 
were compared with specific activity standards 
prepared by adding 50 JJI "hot" working buffer to 3 
ml aqueous based scintillation fluid, in the 
presence of 300 JJI water to aid mixing. Two time 
points (5 and 15 minutes) were measured for each 
sample, because investigation of the time course of 
the reaction showed a greatly increased surge during 
the first two minutes, resulting in a lack of 
linearity. To avoid this factor, 10 minute activity 
was determined by subtracting the 5 minute value 
from the 15 minute value, and corrected to produce a 
value/hour. 
2.4.1 Example calculation: 
(sample - blank)15 - (sample-blank)5 X ACH X time 
specific activity standard weight 
= JJmole ACH produced/hour/g tissue 
Good linearity was demonstrated from a curve 
produced from diluting homogenate samples. There 
was good stability of samples except for caudate, 
which needed further dilution (1+9), which made it 
more susceptible to degradation during assays. Thus 
assays of shorter duration were used··for caudate. 
The small volume in a large scintillation vial 
insert was thought to be introducing variability, as 
the liquid drop was difficult to mix, therefore a 
microassay was tried resulting in better 
reproducibility. Plastic microtubes (1.2 ml) were 
used to incubate the assay. After stopping the 
reaction, the contents were poured into a 
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scintillation vial insert and the TPB was used to 
wash out the microtube into the scintillation vial 
insert, which was then counted as usual. 
2.5 Determination of concentrations of amino acids 
Recent HPLC methods for the measurement of amino 
acids involve pre-column derivatisation followed by 
isocratic separation and ED. Two modified methods 
were used here to determine concentrations of GABA, 
glutamate and aspartate in human post mortem brain 
tissue (Pearson et al., 1991). 
2.5.1 Method Al 
The first method (Allison et al., 1984) used tert-
butylthiol and o-phthalaldehyde (OPA) as a reagent 
to produce relatively stable consistent derivatives. 
The method (modified by Czudek, personal 
communication) was used to measure concentrations of 
GABA and glutamate. 
Brain tissue (50-100 mg) was homogenised in 0.5 ml 
0.1 M PCA containing 100 ~ M M ascorbate. The 
homogenate was centrifuged at 12000 g for 3 minutes. 
An aliquot of supernatant was derivatised and a 
further aliquot was used for the concurrent 
measurement of monoamines and their metabolites in a 
separate HPLC system. Reagent was prepared by 
dissolving 54 mg OPA in 1 ml ethanol and adding 80 
~ l l t-butylthiol and 8.9 ml ~ B B (0.1 M pH 9.5). 
Refrigerated stock solutions of amino acids (2 
mg/ml) were diluted daily to 100 ~ g / m l l using 
methanol/water (50/50 vol/vol). 20 ~ l l standard 
solution or sample supernatant was reacted with 200 
~ l l reagent for 4 minutes at room temperature. This 
was shown to produce a maximal reaction producing 
derivatives which were stable for at least 30 
minutes. A 40 ~ l l aliquot of derivative was diluted 
with a 25-fold excess of mobile phase and then 
injected into the HPLC system. This involved the 
isocratic separation of amino acid derivatives at 
40°C using a reverse phase HPLC-ED. The system 
comprised of a 25 cm X 4.6 mm Spherisorb ODS 5 ~ m m
column with a BAS detector containing a glassy 
carbon electrode set at +0.7 V (vs. Ag/AgCI) for 
quantification. The mobile phase consisted of PB 
(0.1 M pH 5.8) containing 0.05 roM EDTA and 52% 
methanol. Concentrations were determined using 
sample peak height compared with standard peak 
height, and correcting for dilution and weight. 
2.5.2 Example calculation: 
glutamate (sample) X 100 ~ g / m l l X CO.5 + weight) 
glutamate (standard) weight 
= ~ g / g g tissue 
This method was used successfully for about 1 year 
(providing much of the data in this thesis), but 
proved to have some limitations. Careful timing of 
derivatisation was necessary and derivatives 
decomposed n o t i ~ ~ l y y after approximately 30 minutes. 
Moreover the use of t-butylthiol was banned in the 
institution, due to a noxious smell, together with a 
high volatility. Therefore an alternative approach 
had to be found. 
2.5.3 Method B) 
The second method used was modified by us from 
Jacobs (1987) which used inorganic sulphite instead 
of thiol, to produce.stable OPA derivatives of 
primary amines suitable for ED. our new method 
replaced the 80 ~ l l t-butylthiol in the previously 
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described reagent with 1 ml 1 M sodium sulphite. 
This has now been routinely used for several years 
in this laboratory, simply producing clean, stable, 
odourless and reproducible derivatives (Pearson et 
al., 1991). 
Tissue was prepared as described for the previous 
method. If required, dilution with 4 volumes 0.1 M 
disodiumtetraborate buffer (pH 9.5) permitted 
storage frozen at -20°C, for later analysis. B-
aminobutyric acid (BABA, 2 mg/ml) was used as an 
internal standard as this was similar in structure 
to GABA, although it was shown not to co-elute with 
any sample peaks. Refrigerated stock solutions (2 
mg/ml) were dissolved using water (with a few drops 
of sodium hydroxide where necessary), and diluted 
weekly to 100 ~ g / m l l with 0.1 M PCA. BABA (20 ~ l ) )
was added to 800 ~ l l standard or sample supernatant 
and 100 ~ l l of this mixture was reacted with 160 ~ l l
reagent for 20 minutes. The reagent was made by 
dissolving 54 mg OPA in 1 ml ethanol and adding 1 ml 
1 M sodium sulphite and 18 ml 0.1 M borate buffer 
(pH 9.5). This reagent was stable at room 
temperature for several weeks. The derivative (40 
~ l ) ) was diluted 20-fold with water and 50 ~ l l was 
injected into the HPLC system. This was a similar 
system to that described earlier, except an ODS-2 5 
~ m m column was used with mobile phase at pH 5.6 and 
containing 5% m e t h a n o l ~ ~ Here the detector was set 
at +0.85 V for optimal response. 
Amino acid concentrations were determined by the 
calculation of ratio of peak height to internal 
standard in samples, compared to the equivalent 
ratio in standards. This was corrected for sample 
dilution and weight to give a concentration ( ~ g / g g
tissue). 
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2.5.4 Example calculation: 
glutamate (sample) 
BABA 
glutamate (standard) 
BABA 
= ~ g / g g tissue 
X 100 (0.5 + weight) 
weight 
The chromatogram (Fig. 2.1) shows a typical standard 
and a typical sample. Single peaks (retention times 
in minutes) were demonstrated for aspartate (1.4), 
glutamate (2.2), glycine (3.8), GABA (21.0) and B A ~ A A
(26.7). The peaks in the samples were assigned after 
comparison of retention times with those from 
standard solutions, and by confirmation of their 
identical co-elution by observing the expected 
summation of peak heights of standards added to 
samples. Percentage recoveries from added standards 
were aspartate: 99 ± 6, glutamate: 98 ± 4, GABA: 100 
± 5 (mean ± SD n = 5). Reproducibility was tested 
using eight samples from two brain tissue 
homogenates which yielded coefficients of variation 
of 3% for aspartate, 6% for glutamate and 7% for 
GABA. Linear standard curves for concentration (0-
150 ~ g / m l ) ) versus response were demonstrated for all 
the amino acid derivatives. 
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Figure 2.1 
HPLC chromatogram of amino acid derivatives 
A shows a typical brain sample; B shows a typical 
~ t a n d a r d d (100 ~ g / m l ) . . Peaks are in order: 
aspartate, glutamate, glycine, GABA and BABA (full 
scale deflection = 500nA). 
A B 
2 
3 
3 1 
5 4 
5 
4 ,... .' 
lJL II ~ ~ Lv J U 
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Minutes 
The derivatives were shown to be stable for more 
than five hours when kept on ice. Borate-diluted 
samples were found to be stable on storage at -20°C; 
this was demonstrated in samples frozen for several 
weeks that yielded for glutamate: 98.8± 8%; 
aspartate: 100 ± 11%; GABA: 97 ± 10% (mean ± SO n = 
6) of the values obtained from freshly prepared 
homogenates of the same tissue. These results also 
demonstrate the low variability b e ~ w e e n n different 
preparations from the same sample of dissected 
tissue. Values of frozen samples kept for several 
months were shown to be within their expected range. 
The optimal time of derivatisation was tested using 
4 minute increments; 20 minutes derivatisation was 
shown to produce a maximal response. Brain amino 
acids were typically in the range of 100-1000 ~ g / g g
tissue, although much greater sensitivity could be 
achieved by eliminating the dilution stages of the 
method. Here the limit of detection for GABA was 
0.5 pmol on the column, although this sensitivity 
was not possible for aspartate and glutamate due to 
their proximity to the solvent front. If GABA 
determination was not required, the resolution of 
glutamate a ~ d d aspartate could be improved by 
increasing the retention time by reducing the 
methanol content/adjusting the pH of the mobile 
phase; this would decrease sample throughput. 
Similarly if GABA alone were required, its retention 
time could be diminished. This would make the 
method more applicable to the determination of GABA 
in dialysates from the recently-developed in vivo 
brain dialysis techniques (Ungerstedt, 1984). 
other amino acids also giving single peaks (not 
shown) were asparagine, threonine, glutamine and 
arginine. Three amino acids produced a co-eluting 
peak: histidine, taurine and alanine. Using these 
conditions no peaks were identified for tyrosine, 
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lysine, tryptophan, methionine, phenylalanine, 
cystine, valine, isoleucine, cysteine, leucine or 
homocysteine within a 30 minute run time (Mercer, 
personal communication 1988). However the three 
aromatic acids of neurochemical importance as 
neurotransmitter precursors could be measured using 
a modified buffer to increase the elution rate. 
Thus for optimal separation of tryptophan, 
phenylalanine and tyrosine, a mobile phase of pH 5.7 
and containing 22% methanol was used yielding 
retention times (relative to BABA:100) of 664, 555 
and 127 respectively. 
The sulphite method described is the final protocol 
used, where many factors have been o p t i m \ s ~ d . .
Most problems were solved although some (e.g. the 
"lump" in the solvent front) could not be eliminated 
from method. A time course for derivatisation, 
showed a maximal response at 20 minutes (at room 
temperature), producing derivatives that were stable 
for up to 4 hours if kept at 4°C. If not kept cold, 
the stability was reduced to 1 hour, particularly 
for derivatives of GABA. originally mobile phase 
was used for the final dilution of the derivatives, 
however, water was demonstrated to increase both the 
response and the stability. Alkaline conditions for 
the reaction were described by Jacobs (1987) as 
optimal so pH 9.5 borate buffer was used, whereas 
Jacobs suggested that the mobile phase needed a pH 
greater than 5-6. We used a mobile phase of pH 5.6 
which was a compromise between maximal response and 
separation, particularly of the fast-eluting 
aspartate and glutamate w h i ~ h h Jacobs preEl:icted would 
be difficult to determine without an ion-pairing 
agent. We tried usingdodecyltetramethylammonium 
bromide, but this resulted in a high interfering 
solvent front. 
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Many parameters were changed in an effort to reduce 
or remove the "lump" in the solvent front, that was 
even present in blanks and standards and thus was 
inherent in the derivatisation reaction. We tried 
varying reagent:sample ratio, OPA concentration and 
sulphite concentration; using fresh reagents, 
different column, HPLC grade water for all 
solutions, different temperature for the HPLC 
system, testing for the presence o,f ammonia, altered 
pump speed of the HPLC system, different containers 
for the reaction and diluting the derivative more 
after the reaction. Reducing the OPA concentration, 
diluting the reagent more and increased dilution 
post-derivatisation were the only parameters which 
had a decreasing effect and these were incorporated 
into the method. However further reducing the OPA 
concentration compromised the linearity of response 
and thus could not be continued. 
2.6 statistics and validation 
statistical comparisons were generally made by using 
the Student's t-test of data, logarithmically 
transformed to achieve a normal distribution. Where 
there were only very small groups, the non-
parametric Mann whitney u-test was employed. 
Pearson correlation coefficents were used. 
All the methods used were validated by comparison 
with authentic standard solutions, and in some cases 
an internal standard. Also, standards added to 
samples were determined to assess recovery and 
losses attribut6ble to the method. The precision 
and linearity of response to varying concentrations 
were verified, by the determination of replicate 
samples and standard$. 
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Chapter 3 
Neurotransmitter results and discussion 
3.1 Results 
Our results from the major study of 
neurotransmitters and their metabolites in 
Huntington's disease (HD) and controls can be seen 
in Tables 3.1 - 3.8 (Reynolds and Pearson, 1987a). 
3.1.1 t-aminobutyric acid 
From Table 3.1 it can be seen that there is a 
significant decrease in t-aminobutyric acid (GABA) 
concentrations throughout the whole brain in HD, 
including areas of the basal ganglia, s.nigra, 
limbic system and cortex. The caudate, putamen, and 
lateral pallidum show the greatest deficits (about 
65% loss), whereas the medial pallidum is slightly 
less affected (59% loss). Even in the cortex there 
are GABA losses ranging from 29-37%. There was no 
overlap, at all, of HD and control ranges in the 
basal ganglia. Interestingly, there was no 
significant correlation between striatal GABA 
concentrations and duration of disease (results not 
shown). 
3.1.2 Glutamate 
Table 3.2 shows significant deficits of glutamate in 
the HD brain in the caudate, putamen, hippocampus, 
frontal and temporal cortex;' however, in the· 
pallidum and s.nigra concentrations are 
significantly increased above control values. The 
greatest losses of glutamate can be seen to occur in 
the caudate and putamen (losses of 32% and 24% 
respectively). 
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Table 3.1 
GABA concentrations in the brain in Huntington's disease 
Values are means ± s.d. in ~ g / g g tissue. Ranges in 
parentheses. *p < 0.05, **p < 0.01 ***,p < 0.001 
Region 
Caudate 
Putamen 
Medial pallidum 
Lateral pallidum 
SUbstantia nigra 
(compacta) 
Hippocampus 
Amygdala 
Frontal cortex 
(BA 10) 
Temporal cortex 
(BA 21) 
controls 
·314 ± 89.8 
(232 - 563) 
461 ± 61.7 
(366 - 571) 
783 ± 66.7 
(638 - 924) 
744 ± 112 
(522 - 994) 
405 ± 177 
(207 - 797) 
196 ± 55.0 
(124 - 334) 
224 ± 37.8 
(156 - 288) 
196 ± 37.1 
(119 267) 
203 ± 27.9 
(147 - 250) 
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Huntington's 
disease 
100 ± 40.3*** 
(40 - 195) 
165 ± 52.1*** 
(70 - 352) 
318 ± 105*** 
(127 - 545) 
241 ± 92.7*** 
(116 - 452) 
209 ± 138*** 
(70 - 736) 
139 ± 43.0*** 
(68 - 247) 
193 ± 57.6** 
(68 - 381) 
140 ± 36.8*** 
(65 - 223) 
128 ± 32.4*** 
(36 - 194) 
Table 3.2 
Glutamate concentrations in the brain in Huntington's 
disease 
Values are means ± s.d. in ~ g / g g tissue. Ranges in 
parentheses. *p < 0.05, **p < 0.01, ***p < 0.001 
Region Controls Huntington's 
disease 
Caudate 1694 ± 219 1137 ± 384*** 
(1327 - 2344) (444 - 2058) 
Putamen 2160 ± 272 1638 ± 397*** 
(1631 - 2848) (702 - 2570) 
Medial pallidum 749 ± 139 1114 ± 541** 
(383 - 1104) (468 - 3442) 
Lateral pallidum 885 ± 179 1009 ± 218* 
(554 -.1191) (581 - 1473) 
Substantia nigra 1001 ± 146 1275 ± 319*** (compacta) (788 - 1294) (682 - 1884) 
Hippocampus 1232 ± 166 .1082 ± 298** 
(692 - 1556) (406 - 1698) 
Amygdala 1616 ± 172 1586 ± 402 
(1314 - 2089) (707 - 2426) 
Frontal cortex 1507 ± 272 1366 ± 407* 
(BA 10) (1041 - 2128) (628 - 2281) 
Temporal cortex 1252 ± 139 1048 ± 286*** 
(BA 21) (993 - 1522) (475 - 1645) 
., 
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3.1.3 Dopamine 
Dopamine (DA) concentrations in the HD brain (Table 
3.3) are seen to be significantly increased in the 
putamen (48% increase), lateral pa11idum (198% 
increase) and medial pa11idum (471% increase), 
compared with control values. Significant losses 
were identified in the s.nigra and. hippocampus and 
values in the amygdala and cortex were not 
significantly changed from normal. 
3.1.4 Homovani11ic acid 
Significant losses of homovani11ic acid (HVA) were 
evident (Table 3.4) in the HD brain throughout the 
basal ganglia, with the caudate showing the greatest 
deficit of 48% and the medial pa11idum being 
relatively less affected (loss of 24%). However, in 
both regions of the cortex, HVA concentrations were 
significantly increased (by 72-151% compared with 
control values). 
3.1.5 5-Hydroxytryptamine 
Table 3.5 demonstrates the increased concentrations 
of 5 - h y d r o x y t ~ t a m i n e e (5HT) observed throughout the 
HD brain (except for the hippocampus, which was not 
significantly changed). significance is achieved in 
the basal ganglia, amygdala and temporal cortex, 
with the lateral pa11idum showing the greatest 
effect (increase of 129%) and the amygdala the least 
effect (increase of 24%). 
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Table 3.3 
Dopamine concentrations in the brain in Huntington's 
disease 
Values are means ± s.d.in ng/g tissue. Ranges are in 
parentheses. *p < 0.05, **p < 0.01, ***p < 0.001 
Region Controls 
Caudate 2667 ± 694 
(1410 - 4571) 
Putamen 4125 ± 1176 
(466 - 6899) 
Medial pallidum 96.6 ± 76.1 
(21 - 299) 
Lateral pallidum 976 ± 662 
(55 - 2908) 
Substantia nigra 649 ± 267 
(compacta) (369 - 1617) 
Hippocampus 21.6 ± 18.6 
(7 - 80) 
Amygdala 48.5 ± 35.8 
(6 133) 
Frontal cortex 2.0 ± 1.4 
(BA 10) (0.4 - 5) 
Temporal cortex 5.9 ±o4.7 
(BA 21) (1.2 - 22) 
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Huntington's 
disease 
2645 ± 2300* 
(108 - 12133) 
6093 ± 2844* 
(1488 - 13048) 
554 ± 531*** 
(22 - 2143) 
2918 ± 2171*** 
(137 - 6166) 
574 ± 357* 
(18 - 1517) 
14.9 ± 13.0* 
(2 - 67) 
75.0 ± 77.2 
(3 - 297) 
2.0 ± 1.4 
(1 7) 
10 ± 9.5 
(1 - 41. 9) 
Table 3.4 
Homovanillic acid concentrations in the brain in 
Huntington's disease 
Values are means ± s.d. in ng/g tissue. Ranges in 
parentheses. *p < 0.05, **p < 0.01, ***p < 0.001 
Region 
Caudate 
Putamen 
Medial pallidum 
Lateral pallidum 
Substantia nigra 
(compacta) 
Hippocampus 
Amygdala 
Frontal cortex 
(BA 10) 
Temporal cortex 
(BA 21) 
Controls 
4401 ± 1194 
(2332 - 7130) 
9538 ± 2600 
(4658 - 17638) 
3855 ± 1343 
(2103 - 7864) 
6110 ± 1674 
(3580 - 10928) 
5217 ± 1092 
(3313 - 7409) 
333 ± 111 
(128 - 607) 
865 ± 200 
(569 1354) 
61.4 ± 19.9 
(34 - 118) 
124 ± 33.6 
(64 202) 
Huntington's 
disease 
2306 ± 1101*** 
(810 - 5262) 
6176 ± 2158*** 
(2855 - 11895) 
2937 ± 896** 
(1513 - 5941) 
4440 ± 1450*** 
(1583 - 8063) 
3920 ± 1080*** 
(1641 - 5424) 
310 ± 160 
(122 - 925) 
818 ± 352 
(308 - 1853) 
154 ± 78.8*** 
(41 - 289) 
213 ± 102*** 
(72 - 465) 
Table 3.5 
5-Hydroxytryptamine concentrations in the brain in 
Huntington's disease . 
Values are means ± s.d in ng/g tissue. Ranges in 
parentheses. 
*p < 0.05, **p < 0.01, ***p < 0.001 
Region Controls 
Caudate 219 ± 60.7 
(97 - 339) 
Putamen 320 ± 75.7 
(147 - 435) 
Medial pallidum 245 ± 80.8 
(117 - 492) 
Lateral pallidum 224 ± 53.9 
(147 - 350) 
Substantia nigra 671 ± 170 
(compacta) (399 1210) . 
Hippocampus 117 ± 82.8 
(36 - 471) 
.-
Amygdala 233 ± 57.5 
(138 - 366) 
Frontal cortex 11.8 ± 5.2 
(BA 10) (6 - 28) 
Temporal cortex 13.8 ± 6.9 
(BA 21) (8 - 35) 
76 
Huntington's 
disease 
328 ± 221* 
(81 - 1017) 
632 ± 216*** 
(151 - 1094) 
458 ± 179*** 
(145 - 928) 
514 ± 219*** 
(141 - 1141) 
813 ± 322 
(288,- 1566) 
95.1 ± 48.7 
(14 - 225) 
290 ± 112* 
( 46 - 569) 
20.3 ± 18.1** 
(5 - 98) 
18.1 ± ~ . 6 6
(4 - 36) 
3.1.6 5-Hydroxyindoleacetic acid 
Changes in concentrations of 5-hydroxyindoleacetic 
acid (5HlAA) in the HD brain can be seen in Table 
3.6. A significant increase is obvious throughout 
the brain (except again the hippocampus, which was 
not significantly changed). Here, the putamen shows 
the greatest increase (by 135%) and the s.nigra and 
amygdala the smallest increase (by 30%). 
3.1.7 Noradrenaline 
Noradrenaline (NA) concentrations (Table 3.7) in the 
HD brain were significantly increased in pallidal 
regions (by 115 and 257%), whereas in limbic regions 
and the temporal cortex there were significant 
decreases (20% losses) compared with control values. 
3.1.8 Choline acetyltransferase 
Table 3.8 demonstrates the significant deficits 
observed in choline acetyltransferase (CAT) activity 
in the HD brain. The caudate showed a decrease of 
60% and the hippocampus and frontal cortex showed 
losses of 31% and 12% respectively. 
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Table 3.6 
5-Hydroxyindoleacetic acid concentrations in the brain in 
Huntington's disease 
Values are means ± s.d in ng/g tissue. Ranges in 
parentheses. 
*p < 0.05, **p < 0.01, ***p < 0.001 
Region 
Caudate 
Putamen 
Medial pallidum 
Lateral pallidum 
Substantia nigra 
(compacta) 
Hippocampus 
Amygdala 
Frontal cortex 
(BA 10) 
Temporal cortex 
(BA 21) 
Controls 
441 ± 139 
(189 - 813) 
794 ± 227 
(352 - 1151) 
1195 ± 261 
(905 - 1767) 
995 ± 132 
(692 - 1214) 
2241 ± 672 
(1348 - 3876) 
331 ± 99.7 
(98 - 569) 
566 ± 102 
(385 - 750) 
64.7 ± 17.8 
(42 - 102) 
89.9 ± 21.3 
(58 - 142) 
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Huntington's 
disease 
762 ± 367*** 
(217 - 2182) 
1864 ± 724*** 
(803 - 3596) 
2021 ± 789*** 
(870 - 4608) 
2015 ± 748*** 
(937 - 3848) 
2857 ± 1080** 
(1332 - 5839) 
362 ± 176 
(132 - 1027) 
742 ± 295** 
(346 - 1756) 
117 ± 45.8*** 
(45 - 219) 
153 ± 59.6*** 
(42 - 291) 
Table 3.7 
Noradrenaline concentrations in the brain in Huntington's 
disease 
Values are means ± s.d. in ng/g tissue. Ranges in 
parentheses. *p < 0.05, **p < 0.01, ***p < 0.001 
Region 
Caudate 
Putamen 
Medial pallidum 
Lateral pallidum 
Substantia nigra 
(compacta) 
. Hippocampus 
Amygdala 
Frontal cortex 
(BA 10) 
Temporal cortex 
(BA 21) 
Controls 
36.0 ± 20.9 
(14 - 102) 
31.9 ± 36.1 
(2 134) 
33.4 ± 16.6 
(13 - 87) 
95.5 ± 51. 3 
(31 - 141) 
6.3 ± 3.1 
(1 - 13) 
7.0 ± 3.2 
(2.2 - 13) 
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Huntington's 
disease 
77.4 ± 52.1*** 
(14 - 223) 
114 ± 96.8*** 
(4 - 446) 
25.6 ± 27.8*** 
(4 - 94) 
.' 71.3 ± 52.0** 
(7 - 205) 
5.5 ± 2.6 
(2 - 13) 
5.8 ± 3.3* 
(0.1 - 15.5) 
Table 3.8 
Choline acetyltransferase activity in the brain in 
Huntington's disease 
Values are means ± s.d. in ~ m o l / h / g g tissue. Ranges in 
parentheses. *p < 0.05, **p < 0.01, ***p < 0.001 
Region Controls 
Caudate 5.5 ± 2.0 
(0.5 - 8.4) 
Hippocampus 1.04 ± 0.42 
(0.59 - 2.42) 
Frontal cortex 0.34 ± 0.06 
(BA 10) (0.22 0.60) 
Temporal cortex 0.38 ± 0.06 
(BA 38) (0.22 - 0 . ~ 6 ) )
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Huntington's 
disease 
2.2 ± 1. 8*** 
(0.01 - 6.2) 
0.72 ± 0.42*** 
(0.14 - 1. 65) 
0.30 ± 0.10* 
(0.14 - 0.47) 
0.34 ± 0.11 
(0.14 - 0.57) 
., 
3.2 Discussion 
3.2.1 GABA 
Our results are consistent with and confirm the 
well-established (Perry et al., 1973; Spokes et al., 
1980; Urquhart et al., 1975) losses of GABA in the 
basal ganglia in HD, and indicate that these 
deficits extend to all nigral, limbic and· cortical 
areas measured. While pallidal regions both show a 
loss, there is a differential effect with the medial 
part exhibiting a smaller loss than the lateral. 
This is consistent with an observation by Spokes 
(1980) that there is a loss of of glutamic acid 
decarboxylase activity in the lateral, but no 
significant change in the medial part of the HD 
pallidum. Further evidence comes from work by 
Reiner et al, (1988) suggesting that in HD the 
inhibitory GABAergic striatal-pallidal pathways are 
lost, but that relatively more degeneration occurs 
to the lateral than to the medial. As the disease 
advances, further losses of the medial pathway occur 
altering the medial/lateral balance, thought to 
, 
result in the initial choreiform movements being 
replaced by more rigid symptoms. 
The identified losses of GABA can be further 
understood in association with previously reported 
-losses of neuropeptides in HD (Emson, 1986; Beal et 
al., 1988b), including substance P, met-enkephalin 
and dynorphin. Albin et al, (1990a,b) has suggested 
that in HD, the striatal (enkephalin-containing) 
projections to the lateral pallidum and those 
projecting to the s.nigra (containing substance P) 
are relatively lost compared to the striatal-medial 
pallidum pathway (containing substance P). This is 
again consistent with our observation of 
differential pallidal losses. Furthermore, 
c o ~ c e n t r a t i o n s s of met-enkephalin are reduced in the 
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whole pallidum and s.nigra and there are losses of 
sUbstance P, again in the whole pallidum and s.nigra 
(Emson, 1986).-
Another report (Ellison et al., 1987) suggested that 
there are gradients of GABA deficits (caudate > 
putamen) and (external> internal pallidum), with 
which our findings are consistent, although in their 
study the hippocampus and frontal cortex (BA 10) did 
not exhibit significant losses. Pathological 
changes, with gradients of losses, have been 
reported to parallel these neurochemical changes 
(Vonsattel et al., 1985), in particular the losses 
of striatal spiny neurones. 
Spokes et al. (1980) and Ellison et al. (1987) did 
not find the significant cortical or hippocampal 
losses that we identified, however Urquhart et al. 
(1975) reported general cortical losses which 
reached significance in the occipital cortex. 
Similarly, Perry et al. (1973) reported losses in 
occipital and temporal cortex, as did Gramsbergen et 
al. (1986), who also reported losses evident in the 
s.nigra. These cortical losses in HD are very 
similar to those identified in another 
neurodegenerative disorder, 'Alzheimer's disease, and 
there has been speculation as to whether these 
., 
cortical GABA deficits are related to cognitive 
changes seen in HD patients (see section 5.3). 
Deficits in GABA concentrations maybe a reflection 
degenerating GABAergic neurones, or perhaps a change 
in GABA regulation and turnover. However, 
indications from the measurement of GABA uptake 
sites in HD (defined by radio-labelled nipecotic 
acid binding) may provide relevant evidence,. as GABA 
terminals can be identified which are unlikely to be 
altered by changes in metabolism. The determination 
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of GABA uptake sites in the putamen in a small 
subgroup of the HD series (Czudek and Reynolds, 
19Qo) revealed a deficit which was parallelled by 
the losses of GABA concentrations. This was also 
reported by another study (Simpson et al., 1988). 
These findings suggest actual GABAergic 
neurodegeneration is occurring in "HD. This view is 
also consistent with other measures of GABAergic 
terminals, including reduced GAD activity and 
immunohistochemical neuropathological markers of 
GABAergic neuronal losses (Spokes et al., 1979, 
1980; Reiner et al., 1988). Further evidence 
supporting a GABAergic deficit are reports of 
reduced GABA binding in HD (Lloyd et al., 1980). 
It is unlikely that external factors can explain the 
deficits of GABA concentrations identified in HD. 
Differences between the groups were minimised and 
GABA is reportedly unaffected by postmortem delay, 
apart from an initial increase (Spokes et al., 
1979). Also GABA concentrations are unaffected by 
agonal state, unlike previous measures of GABAergic 
activity such as GAD activity ,(Spokes, 1979), so the 
unavoidable difference in cause of death between the 
groups (HD patients generally die of 
bronchopneumonia, whereas most of the controls died 
suddenly) is not a causative factor here. Another 
.' 
difference is the male/female ratio, as the control 
group is predominantly male (reflecting the low 
incidence of sudden death in females of this age 
range). There was no effect of sex difference on 
GABA concentrations in the HD group. It is always 
important to consider drug effects, especially as 
almost all of the HD patients were taking 
neuroleptics or tetrabenazine. However, we have 
found that such treatment has no effect on GABA 
concentrations in HD brain (see section 3.4); 
certainly concentrations of GABA in striatal and 
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pallidal regions are reportedly not significantly 
changed from control values in neuroleptic-treated 
schizophrenic patients (Toru et al., 1988). 
3.2.2 Glutamate 
The significant losses of glutamate in the HD 
striatum, hippocampus and cortex (frontal and 
temporal) have largely been unreported previously, 
except for in the striatum (Perry et al., 19821 
Gramsbergen et al., 1986), but neither group found 
cortical losses. However, the recent results of 
Ellison et ale (1987) are consistent with our 
findings. They found reduced striatal glutamate 
concentrations and cortical losses, significant in 
four areas: frontal (BA 9), premotor (BA 6), 
postcentral (BA 1,2,3) and occipital (BA 17). The 
losses in BA 10 and BA 21 appeared to be not 
significant and the hippocampus was not 
significantly changed, in contrast to our findings. 
Also, Kremzner et ale (1979) found a glutamate 
deficit in the frontal cortex. A notable effect was 
obvious in the pallidum and s.nigra, where we found 
a significant increase in concentrations of 
glutamate, the effect being the strongest in the 
medial pallidum. Here too, the results of Ellison 
et ale (1987) match ours: they also demonstrated 
" 
increased concentrations in the pallidum (medial > 
lateral) and reaching significance in the s.nigra 
(pars compacta). 
In this case too, the interpretation of any changes 
in glutamate concentrations is complex, as glutamate 
is not solely a neurotransmitter and plays a vital 
role in metabolism in the brain. Thus any changes 
may be due to metabolic differences, or could be 
reflecting glutamatergic neuronal losses. 
Alternatively, losses of GABAergic neurones may 
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consequently produce changes in turnover of 
glutamate. Evidence regarding the nature of the 
losses comes from work by Fonnum (1984). He 
suggested that lesioning glutamate pathways produces 
losses of glutamate concentrations (20-45%), whereas 
lesioning GABA pathways, such as the striatonigral, 
has no effect on glutamate concentrations in the 
s.nigra. Thus our results show regions with 
increases or decreases of glutamate concentrations, 
together with deficits in GABA, suggesting that they 
are not directly related. Other evidence regarding 
the nature of the changes in glutamate 
concentrations comes from studies of glutamate 
uptake sites (defined by D-aspartate binding) in the 
HD brain (Cross et al., 1986c). They demonstrated 
losses of glutamate uptake sites in the caudate (72% 
loss), putamen (60% loss) and hippocampus (32% 
loss), but no significant change in the one area of 
cortex examined (temporal). This suggests an actual 
loss of glutamatergic neurones in these areas. 
Another putative (but unproven) marker for glutamate 
terminals is the presence of ornithine 
decarboxylase, thought to be found predominantly in 
glutamate terminals (Wong et al., 1982). Their 
study showed significant losses of this enzyme in 
the HD striatum and losses in the cortex 
(significant only in frontal and parietal). Further 
evidence for a reduced glutamatergic system comes 
from receptor studies showing a deficit in the 
binding to NMDA, kainate and quisqualate receptors 
in HD (Greenamyre et al., 1985; Young et al., 1988; 
Beaumont et al., 1979). 
There is evidence that glutamate is a 
neurotransmitter in the corticostriatal tract 
(Fonnum et al., 1981), and also that glutamate 
uptake predominantly occurs in the glutamatergic 
corticostriatal tract (Henn and Hamberger, 1971). 
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Thus, the deficits of striatal glutamate that we 
have identified are consistent with degeneration of 
the corticostriatal tract. Furthermore, there is 
evidence suggesting that layer V of the cortex is 
atrophied, and this is the origin of the 
corbCostriatal fibres (Bruyn et al., 1979). Ellison 
et ale (1987) showed that striatal lesioning causes 
secondary degeneration of the glutamatergic 
corticostriatal pathway, however, there was no 
deficit of glutamate concentrations. Therefore, 
they suggested that in HD there must be a primary 
degeneration of glutamatergic neurones, reflected by 
the reduced glutamate concentrations in the cortex. 
The increases found in the pallidum and s.nigra are 
less expected. There is evidence to suggest a 
glutamatergic pathway from the subthalamic nucleus 
to the pallidum (Robertson et al., 1989) which is 
important in the balance between the medial and 
lateral pallidum. Thus, any differential increase 
may result in the medial part becoming relatively 
less active producing choreiform movements (Crossman 
et al., 1989)'. Increases in concentrations of 
glutamate may just be reflecting general tissue 
atrophy, producing a relative increase, as the 
pallidum shrinks by as much'as the striatum (Lange 
et al., 1976). 
cortical losses of amino acids have been described 
in other dementing disorders (Rossor et a l ~ , , 1984; 
Sasaki et al., 1986; Reynolds and Warner, 1988) 
suggesting a possible common feature, however, we 
have shown no association between these cortical 
deficits of amino acids and the dementia of HD 
(Reynolds et al., 1990a) (see section 5.3). 
Here too, as with the GABA data, it is important to 
eliminate any potential factors or group difference, 
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which may have contributed to the changes observed. 
There is no effect of agonal state (Perry et al., 
1982), post mortem delay (Perry et al., 1981) or 
prior drug treatment (see section 3.4). There was a 
small sex effect (males glutamate concentration = 
1750 ~ g / g g / females = 1522 ~ g / g ) , , which may be 
related to the longer average duration of disease 
(males = 11.0 years/ females = 13.7 years) producing 
greater deficits. However, these slight differences 
are unlikely to be responsible for the sUbstantial 
deficits identified. 
Glutamate has also been suggested to be a neurotoxin 
and was of potential interest in the aetiology of HD 
(McGeer and MCGeer, 1976a) (see section 6.2). 
However, our findings in HD do not support the 
hypothesis suggesting an increased glutamatergic 
system. 
3.2.3 5HT and 5HIAA 
In the HD brain, our results demonstrate a 
sUbstantial increase of 5HT and the metabolite 
5HIAA, in all examined regions other than the 
hippocampus, in which there was no significant 
change. One previous report (Bernheimer and 
Hornykiewicz, 1973) showed striatal 5HT not to be 
significantly changed, but this study only used 3 or 
4 cases. Otherwise this system was little studied 
in HD until a recent report by Kish et al •. (1987). 
Their group found generally elevated concentrations 
of 5HT throughout the putamen (81% increase) and 
caudate (30-40% increase) which is consistent with 
our results (increases of 98% and 50% respectively). 
Furthermore, these changes were parallelled by 
increased 5HIAA concentrations in both stUdies. 
Kish also found no significant effect in the nucleus 
accumbens, no significant effect in the s.nigra and 
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did not examine the cortex. 
5HT uptake sites (defined by radio-labelled 
paroxetine binding) were shown by Cross et ale 
(1986c) to be increased in the striatum 
(significantly in the putamen). Thus, the increases 
we have shown are consistent with ·an increase in 
striatal serotonergic terminals. Whether this 
increase is absolute or relative remains unclear, as 
it may solely reflect tissue atrophy. Kish reported 
that the lack of significant effect in the nucleus 
accumbens and s.nigra was evidence for the latter, 
as these regions undergo little atrophy in HO, 
however, in our hands the s.nigra shows a 20% 
increase in concentrations of both 5HT and 5HIAA. 
In the temporal cortex, at least there appears to be 
a greater increase of 5HIAA compared with 5HT, 
suggesting that here there is an increase in 
turnover. One hypothesis is that this may be 
reflecting a difference in tryptophan metabolism, as 
tryptophan concentrations are increased in the HO 
cortex (see kynurenine chapter). Other recent 
evidence (Kalen et al., 1989) suggests that GABA may 
have a tonic inhibitory effect on serotonergic raphe 
neurones via its influence on the lateral habenula-
dorsal raphe pathway. T h u s ' ~ ~ GABA losses such as 
those we have identified in HO, may increase 5HT 
., 
turnover and release. It has been suggested that 
most serotonergic cortical axons innervate GABAergic 
neurones (Tork et al., 1988) and thus our data. are 
consistent with possible altered regulation of these 
systems in HO. Furthermore, subcortical receptor 
losses (5HT 1) have been reported in HO (cross et 
al., 1986b; Waeber et al., 1989), but they found no 
significant cortical losses. 
The consequences of such serotonergic increases are 
not clear. 5HT has been reported to have a possible 
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role in the production of myoclonus and 
hyperactivity (Gerson and Baldesserini, 1980). 
Furthermore, 5HT or 5HIAA have been implicated in 
depression, aggression and dementia, but usually 
associated with decreased serotonergic activity 
(Palmer et al., 1988; KurIan et al., 1988; Peyser 
and Folstein, 1990). 
As with the other measures, any group differences 
must be considered. There was no effect of sex 
difference or post mortem delay. However, agonal 
state has been shown to affect 5HT and 5HIAA 
concentrations (Gottfries et al., 1974). As 
terminal hypoxia correlates with reduced 
concentrations, this is unlikely to be a causative 
factor because the HO group (with more hypoxic 
death) has the higher 5HT and 5HIAA values. There 
was no effect of neuroleptics, but prior treatment 
with tetrabenazine is known to deplete monoamines 
(Pearson and Reynolds, 1988) (see section 3.4), 
including 5HT which argues against it causing the 
increases found in HO. 
3.2.4 OA and HVA 
In the past the nigrostriatal pathway was thought to 
be relatively spared in HO, and responsible for the 
hyperkinetic movement disorder, but p r ~ v i o u s s reports 
of OA concentrations in the HO brain have been 
inconsistent, thus providing no real evidence., 
Suggestions have included an increase in the putamen 
(Melamed et al., 1982), caudate (Bernheimer and 
Hornykiewicz, 1973), both (Spokes, 1980) or neither 
(Reynolds and Garrett, 1986; Bird and Iversen, 
1974). Also, increased concentrations have been 
described in the s.nigra.and the nucleus accumbens 
(Spokes, 1980). Thus our results from this study 
are predictably consistent with one of the reports. 
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In our hands, DA was increased (by 48%) in the 
putamen but with no significant increase in the 
caudate or the s.nigra. Kish et ale (1987) recently 
reported reduced concentrations of DA in both the 
putamen and the caudate, and postulated that the 
discrepencies between the various studies were due 
to differences in post mortem delay. In particular 
they suggested that the study by Spokes (1980) had a 
control group which was artefactually low, because 
they had a mean post mortem delay 10 hours longer 
than their HD group. The converse would be 
predicted for our series, as the controls were 12 
hours shorter than the HD group. The Kish groups 
were closer matched. However, Reynolds and Garrett 
(1986) demonstrated that there was much greater 
variability of DA concentrations in the HD group, 
which they suggested had contributed to the 
inconsistencies reported: individual values were 
described as falling well below and well above the 
control range. Our own results concurred with this, 
thus, in the caudate although the means were 
identical, the HD range (108-12133 ng/g) was 
obviously not 'similar to the controls (1410-4571 
ng/g). The identified increase of DA concentrations 
in both parts of the pallidum is consistent with the 
results of Spokes (1980). Areas, other than the 
basal ganglia (such as the cortex) have not been 
determined in these studies. One factor that may 
explain some of the variability, is prior drug 
treatment. Neuroleptics have been reported not to 
affect DA concentrations in the striatum (Shannak 
and Hornykiewicz, 1980: Crow et al., 1979), whereas, 
tetrabenazine has been shown to deplete monoamines 
(Pearson and Reynolds, 1988) (see section 3.4), 
especially striatal DA (loss of 2/3). Thus the HD 
group appears to predictibly have a sub-group with 
low striatal DA concentrations. 
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The functional activity of the DA system must be 
considered to understand the changes observed" 
therefore HVA concentrations were determined. We 
found significant losses throughout, except for the 
hippocampus and amygdala and in fact in the cortex 
there were significant increases. These findings 
are consistent with results from Reynolds and 
Garrett (1986) and Kish et al. (1987), although 
Melamed et al. (1982) found no change in their 
study. Tyrosine hydroxylase (the rate-limiting 
enzyme in the formation of DA) activity is 
reportedly unchanged in the HD striatum (McGeer and 
McGeer, 1976b) and D1 and D2 receptors are decreased 
in the striatum (Seeman et al., 1989; Joyce et al., 
1988; Cross et al., 1983), athough the reported 
deficit in the pallidum (De Keyser et al. 1989a,b) 
has been challenged and in our hands there was no 
significant change (Reynolds et al., 1990b). 
Therefore, evidence would appear to support the 
suggestion that there is a down-regulation of the 
nigrostriatal dopaminergic system in HD, which still 
remains intact. 
HVA concentrations are unaffected by post mortem 
delay and neuroleptics (Crow et al., 1979) and only 
slightly reduced by tetrabenazine (see section 3.4), 
indicating that these factors are not responsible 
for the SUbstantial deficits seen in the HD brain. 
There was no effect of age, sex and agonal state on 
the measurements of either DA or HVA concentrations. 
What these chqnges mean in the disease profile is 
unclear. Within the basal ganglia, dyskinesia may 
be predicted from such changes, although there is 
evidence implicating GABAergic losses in the 
pallidum in the production of choreiform movements 
(Pearson et al., 1990). An altered DA system in 
areas of the brain other than the basal ganglia, may 
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be producing psychiatric symptoms. It is reported 
that there are limbic dopaminergic and GABAergic 
changes occurring in schizophrenia (Reynolds, 1989). 
3.2.5 Acetylcholine 
We observed the well established loss of CAT 
activity in the striatum in HO (Bird and Iversen, 
1974; Aquilonius et al., 1975; McGeer and McGeer, 
1976b; Spokes, 1980). Our results showed a 
significant 60% decrease in caudate and 30% loss in 
the hippocampus, which is consistent with Spokes 
(1980) who demonstrated significant losses in the 
caudate, putamen, hippocampus and to a lesser extent 
in the nucleus accumbens. However, he did not find 
any significant pallidal or cortical changes, 
whereas we found a significant decrease in the 
frontal cortex only. McGeer and McGeer (1976b) 
reported "low but variable CAT activity in some 
areas of the cortex and patchy losses in the basal 
ganglia". Bird and Iversen (1974) described "a 
subgroup of normal CAT activity range" in the 
striatum within the HO group, as well as a group 
severely affected with significant CAT activity 
deficits, the loss being unrelated to clinical 
symptoms. Here too they supported the "patchy loss" 
description, but as the caudate appeared to 
correlate with the putamen a "low activity tissue 
patch" was thought to be unlikely. These CAT 
activity deficits are consistent with a significant 
loss of cholinergic receptors in the putamen in HO, 
although there was no significant change in the 
cortex. These changes of neurochemical cholinergic 
markers may reflect a down regulation of the 
cholinergic system resulting in reduced antagonism 
of the nigrostriatal dopaminergic pathway. The 
cortical deficit appears to be be unassociated with 
the severity of dementia, as was the striatal 
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deficit (see section 5.3). These findings are 
contrary to those seen in Alzheimer's disease and 
Parkinson's disease (Rossor et al., 1984: Perryet 
al., 1983). It would seem that in HD cortical 
cholinergic projections are not lost to the same 
extent as in these other disorders. 
3.2.6 NA 
The increased pallidal concentrations of NA 
concentrations in HD that we observed are consistent 
with the study of Spokes (1980), whereas the 
deficits in limbic and temporal cortex are novel 
findings. Pallidal noradrenergic receptors were 
also decreased in HD (Enna et al., 1976a,b) which is 
also consistent. However, the effects of these 
pallidal changes are difficult to predict, although 
NA and DA may have synergistic influences. The 
limbic and cortical deficit in HD would be expected 
to be associated with psychiatric symptoms (e.g. 
dementia or affective disorder). However, in HD 
there was no such relationship between these 
clinical symptoms and NA concentrations (see section 
5.3) • 
3 ~ 3 3 Cortical changes in HD 
There has been a long-running debate regarding the 
involvement of the cortex in HD (Reynolds and 
Pearson, 1987b). The question remains as to whether 
there are cortical neuronal losses and if so, which 
specific neurone populations are affected. There is 
a view that cortical changes are not particularly 
obvious when compared at a gross neuropathological 
level (Richardson, 1990; Vonsattel et al., 1985; 
Hallervorden, 1957). However, there is now strong 
evidence supporting the concept of global cortical 
losses (of 20%) independent of striatal changes or 
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severity of grade of HD (Bruyn et al., 1979; 
Cudkowicz and Kowall, 1990; de la Monte et al., 
1988; Lange, 1981). Particular layers (3,5 and 6) 
apppear to be affected and frontal (and prefrontal) 
pyramidal projection neurone populations have been 
reported to show degeneration which may, or may not 
be associated with severity of the .. disease (Bird and 
Coyle, 1986; Cudkowicz and Kowall, 1990; sotrel and 
Myers, 1990). Evidence of cortical atrophy has also 
been described using imaging techniques in HD. The 
study of Starkstein et al. (1988, 1989) used 
computed tomography (CT) in HD and reported cortical 
atrophy that correlated with age, but not with 
measures of subcortical atrophy. Positron emission 
tomography (PET) studies have also revealed cortical 
hypometabolism in HD (Kuwert et al., 1990; 
Weinberger et al., 1989). At the moment, single 
photon emission computed tomography and magnetic 
resonance imaging investigations have not reported 
measures of the cortex (Reid et al., 1988; Simmons 
et al., 1986). 
The aim of our study was to determine any 
neurochemical cortical changes, in order to identify 
and understand the specific profile of neuronal 
losses. We examined samples from frontal (BA 10) 
and temporal (BA 21) cortex, as part of our 
comprehensive regional distribution i n v ~ s t i g a t i o n n in 
the brain in HD. 
We found (see section 3.2) significant losses of 
GABA and glutamate concentrations, together with 
significantly increased concentrations of HVA, 5HT, 
5HlAA and 3-hydroxykynurenine in the cortex in HD. 
Tryptophan concentrations were significantly 
increased in the t e m p o r a ~ ~ cortex and CAT activity 
was decreased in the- frontal cortex, whereas, 
concentrations of quinolinic acid (QA) (see section 
94 
6.7), DA and NA were not significantly changed. In 
a blind test of the data it was easily possible to 
differentiate the HD cases from the controls, using 
decreased cortical GABA and glutamate concentrations 
as the criteria. Our finding of decreased levels of 
cortical GABA was consistent with the studies of 
Perry et ale (1973), Gramsbergen et ale (1986) and 
Urquhart et ale (1975), but contrary to Spokes et 
ale (1980) and Ellison et ale (1987) that reported 
no significant cortical changes. Substance P has 
been shown to be increased in cortical regions, as 
have neuropeptide Y (NPY), somatostatin (SS) and 
NADPH-diaphorase in some areas. As substance P co-
localises with NPY or SS in some cortical GABAergic 
neuronal populations, this provides evidence for 
selective sparing. However, cholecystokinin has 
been shown to be decreased in the cortex, defining 
an alternative subpopulation of GABAergic neurones; 
those which are lost in HD (Hays et al., 1981). 
This would be consistent with the cortical GABA 
deficit that we have identified. As described 
earlier, a further subpopulation of GABAergic 
neurones are innervated by serotonergic axons (Tork 
et al., 1988), and the absence of cortical 5HT 
receptor losses suggests that these may also be 
spared in HD. 
The cortical glutamate deficit that we identified in 
HD was also reported by Ellison et ale (1987) and 
Kremzner et ale (1979), but not found in t h ~ ~ studies 
of Perry et ale (1973) or Gramsbergen et ale (1986) 
and glutamate uptake sites were found to be not 
significantly changed (Cross et al., 1986c). The 
deficit is consistent with the described losses of 
frontal cortex pyramidal projection neurones, which 
are likely to be glutamatergic. However, in the 
temporal cortex the glutamate deficit may be 
reflecting intrinsic glutamate losses, not solely 
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projection neurones showing retrograde losses, as 
postulated by Sotrel and Myers (1990). Further 
evidence in support of glutamatergic losses is the 
atrophy of cortical layer 5 in HO (thought to be the 
origin of the corticostriatal glutamatergic 
pathway). 
Our results show, for the first time, increased 
concentrations of 5HT and 5HlAA in the cortex in HO. 
This may merely be a reflection of cortical atrophy 
resulting in a relative increase, but in the 
temporal cortex at least there appears to be 
increased turnover of 5HT. As discussed earlier 
(see section 3.2), most cortical serotonergic axons 
innervate GABAergic neurones, therefore it is 
possible that there is altered regulation of these 
transmitters. The increased tryptophan and 3HK 
concentrations (see section 7.8) are consistent with 
dysfunction of tryptophan metabolism generally, even 
in the cortex, although QA concentrations were not 
significantly altered (see section 6.7). 
The CAT activity deficit in one cortical region was 
examined to identify any association with the 
dementia occurring in HO, similar to the changes 
seen in dementia of Alzheimer's or Parkinson's 
diseases. However, we showed cortical neurochemical 
parameters (including monoamines and amino acids) to 
be unassociated with dementia in HO (see section 
5.3) •. Moreover, the only correlates with the 
dementia were caudate glutamate and GABA 
concentrations. These findings are consistent with 
PET and CT studies showing caudate (and not 
cortical) measures to be related to the dementia in 
HO (see section 5.3). Further studies of 
psychiatric symptoms h a v ~ ~ correlated depression in 
HO with greater cortical atrophy and hypometabolism 
in the prefrontal cortex, whereas apathy in HO was 
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linked with hypometabolism of the cingulate gyrus 
(Peyser and Folstein, 1990). In Alzheimer's 
disease, aggression has been reported to correlate 
with reduced 5HT concentrations in the orbital gyrus 
(Palmer et al., 1988) and in schizophrenics, there 
are reports of increased cortical glutamatergic 
markers and turnover of dopamine (Reynolds, 1989; 
Oeakin et al., 1989). 
The increased HVA concentrations in the cortex in HO 
are a novel finding. Further examination of the 
data suggests a bimodal distribution in HO, with a 
'normal HVA' group within control range, and a 'high 
HVA' group. Furthermore, high HVA is found to be 
associated with increased glutamate concentrations, 
and normal HVA with decreased concentrations of 
glutamate (p < 0.001 in BA 21). There was no 
correlation in the control group, and no association 
with GABA concentrations, neuroleptics or 
tetrabenazine treatment. One possible explanation 
for this abnormal distribution may be that in HO the 
striatal degeneration results in increased cortical 
HVA. However, with glutamatergic losses, this HVA 
increase may not occur. One consequence of 
treatment with long-term neuroleptics is increased 
HVA concentrations in the frontal cortex (Bowers 
and Hoffman, 1986) (due to a mesocortical feedback 
mechanism, that could be GABAergic or 
glutamatergic). In HO, we found no association of 
cortical HVA and prior neuroleptic treatment, thus 
it would seem that the controlling influence is lost 
in HO. Furthermore, another result of long-term 
neuroleptics is an initial increase followed by a 
chronic decrease of striatal HVA concentrations 
(perhaps mediated by long-loop GABA feedback). As 
there is also no relationship between striatal HVA 
and neuroleptics in HO, this feedback loop also 
seems to be lost in HO. Thus, the usual peripheral 
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effects (increased HVA in the CSF and plasma) with 
neuroleptic treatment, would be predicted not to 
occur in HO. Indeed, studies by Caraceni et ale 
(1977) or Mattson and Persson (1973) indicated no 
changes of CSF HVA concentrations in HO, after 
neuroleptic treatment. 
3.4 The effects of prior treatment with 
tetrabenazine 
At present there is no drug treatment that can 
prevent the overall progressive decline of HO, 
however, individual symptoms can be ameliorated to 
some extent. The hyperkinetic movementscanbereduced 
by the use of drugs that block OA receptors (e.g. 
phenothiazines, butyrophenones) or drugs that 
deplete the storage of OA (tetrabenazine, 
reserpine). Tetrabenazine and reserpine have a 
similar action as monoamine-depleting agents. 
Tetrabenazine causes reversible depletion of storage 
granules, is relatively fast-acting and of short 
duration, compared with reserpine which causes 
longer-term depletion of storage granules (Jankovic, 
1982). Both drugs can produce side effects such as 
drowsiness, anxiety and depression, which are more 
severe with reserpine. This would suggest that it 
is not solely the nigrostriatal OA system which is 
" affected. Thus, tetrabenazine is the drug of choice 
for the suppression of chorea (Jankovic, 1982). 
Previous animal studies have shown that 
tetrabenazine depletes the three monoamine 
neurotransmitters OA, NA and 5HT (Lane et al., 
1976). Post-mortem studies provide a unique 
opportunity to assess the neurochemical effects of 
tetrabenazine in man, as its actions have so far 
only been studied clinically or in the experimental 
animal. 
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Here we discuss such an investigation using results 
from sub-groups of the large series of patients with 
HD and from control subjects (described in section 
2.1). Two groups were obtained after assessment of 
drug histories: those known to have been taking 
tetrabenazine at death and those known never to have 
taken tetrabenazine. Several different regions were 
studied (caudate, putamen, medial and lateral 
pallidum, amygdala, hippocampus, s.nigra pars 
compacta, temporal and frontal cortex). 
Concentrations of DA, NA, 5HT, 5HlAA, HVA, glutamate 
and GABA and activities of CAT were analysed 
statistically using the Student's t-test of 
logarithmically transformed data. Details of the 
two groups can be seen in Table 3.9. 
The results (Pearson and Reynolds, 1988) in Table 
3.10 show that the mean concentrations of monoamine 
neurotransmitters were less in almost all regions of 
the brain studied in the tetrabenazine-treated 
group, except for the medial pallidum and DA in the 
frontal cortex. This depletion reached 
significance. 'for DA (in the striatum, hippocampus 
and s.nigra), NA (in the limbic regions) and 5HT (in 
the s.nigra and frontal cortex). HVA concentrations 
were also reduced in all areas, but not 
significantly (results not shown). 5HlAA, glutamate 
and GABA concentrations were unchanged, "with no 
trend to lower levels apparent (Table 3.11). The 
activity of CAT was also simila! in both groups 
(results not shown). There were no significant 
group differences in age, sex, post-mortem delay, 
neuroleptic treatment or duration of disease. 
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Table 3.9 
Details of subjects providing brain tissue post mortem 
: tetrabenazine 
Values are means ± s.d. 
Age Sex Post Duration 
(Years) mortem (Years) 
(Hours) 
Tetrabenazine-treated 59 ± 9 5M 6F 40 ± 26 12 ± 4 
Tetrabenazine-free 51 ± 15 3M 4F 41 ± 23 8 ± 4 
" 
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Table 3.10 
Monoamine neurotransmitters in the brain in Huntington's 
disease following tetrabenazine (TBZ) treatment 
Values are means ± s.d. in ng/g tissue. *p < 0.05, **p < 
0.01 
Noradrenaline Dopamine Serotonin 
Caudate 
TBZ-treated 1113 ± 993** 213 ± 128 
TBZ-free 3281 ± 2089 340 ± 261 
Putamen 
TBZ-treated 4019 ± 3013* 550 ± 208 
TBZ-free 7358 ± 2101 644 ± 278 
Lateral pallidum 
TBZ-treated 88.5 ± 105 1797 ± 1697 426 ± 182 
TBZ-free 101 ± 81.8 3456 ± 1867 604 ± 323 
Medial pallidum 
TBZ-treated 55.5 ± 41.2 457 ± 536 425 ± 133 
TBZ-free 55.7 ± 45.0 379 ± 408 401 ± 198 
Amygdala 
TBZ-treated 47.1 ± 40.2* 59.4 ± 95.7 222 ± 100 
TBZ-free 105 ± 77.3 73.0 ± 6 2 ~ 3 3 306 ± 162 
Hippocampus 
TBZ-treated. 14.1 ± 10.2* 9.6 ± 7.2* 78.9 ± 48.7 
TBZ-free 47.4 ± 54.5 22.2 ± 14.4 93.8 ± 43.6 
Nigra (compacta) 
TBZ-treated 324 ± 220* 631 ± 300* 
TBZ-free 610 ± 186 954 ± 225 
Frontal cortex 
TBZ-treated 5.2 ± 2.4 2.4 ± 
., 
1.8 13.0 ± 6.6* 
TBZ-free 6.6 ± 2.2 2.2 ± 1.4 39.7 ± 37.6 
Temporal cortex 
TBZ-treated 5.5 ± 4.8 6.4 ± 4.2 15'.9 ± 10.7 
TBZ-free 6.2 ± 1.8 8.1 ± 7.0 20.4 ± 8.5 
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Table 3.11 
Amino acid neurotransmitters in the b r ~ i n n in Huntington's 
disease following tetrabenazine (TBZ) treatment 
Values are means ± s.d. in ug/g tissue. 
GABA "Glutamate 
Caudate 
TBZ-treated 90 ± 33 994 ± 333 
TBZ-free 111 ± 46 1168 ± 580 
Putamen 
TBZ-treated 166 ± 38 1613 ± 246 
TBZ-free 167 ± 75 1683 ± 748 
Lateral pallidum 
TBZ-treated 221 ± 58 1000 ± 191 
TBZ-free 282 ± 135 983 ± 330 
Medial pallidum 
TBZ-treated 318 ± 81 1067 ± 333 
TBZ-free 297 ± 104 867 ± 371 
Amygdala 
TBZ-treated 182 ± 56 1518 ± 346 
TBZ-free 178 ± 61 1552 ± 554 
Hippocampus 
TBZ-treated 138 ± 39 1087 ± 279 
TBZ-free 144 ± 34 995 ± 303 
Nigra (compacta) 
TBZ-treated 185 ± 105 1236 ± 329 
TBZ-free 184 ± 55 1148 ± 333 
Frontal cortex 
TBZ-treated 141 ± 37 1370" ± 595 
TBZ-free 137, ± 16 1275 ± 251 
Temporal cortex 
TBZ-treated 136 ± 27 1038 ± 219 
TBZ-free 126 ± 53 965 ± 376 
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The present findings provide direct evidence for the 
effects of tetrabenazine on neurotransmitters in the 
human brain. The results confirm previous studies 
in animals (Lane et al., 1976), demonstrating the 
depletion of monoamines in brain tissue, caused by 
treatment with tetrabenazine. A decrease of 
approximately 40% of DA, NA and SHT. has been 
reported in whole brain of rats, with glutamate, 
aspartate and acetylcholine also decreased, but to a 
lesser extent. The present results show a general 
depletion of monoamines which was more prominent in 
specific areas for particular neurotransmitters. 
The greatest reduction was that of DA in the caudate 
(34% of control value), which may have a role in the 
ameliorative effect of tetrabenazine on chorea. 
There appeared to be no compensatory increase in the 
turnover of DA, as concentrations of HVA were also 
reduced, although not significantly. However, a far 
greater decrease in HVA below control levels has 
been shown in most regions of the brain in HD (see 
section 3.2), indicating a deficit of DA associated 
with the disease process. 
The significant depletion of monoamines in the 
limbic system shows that tetrabenazine was not 
solely affecting areas of the brain associated with 
movement. It is possible that the depletions caused 
by tetrabenazine in the limbic system result in side 
effects, such as depression. certainly deficits of 
monoamines have been implicated in the aetiology of 
. . 
affective disorders (van Praag, 1977). Also, it has 
been found that the effects of tetrabenazine are 
antagonised by tricyclic antidepressants and 
monoamine oxidase inhibitors (Jankovic, 1982), which 
increase synaptic concentrations of monoamine 
neurotransmitters, again providing clinical evidence 
for depletion of monoamines caused by tetrabenazine. 
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There were regional differences in the depletion of 
monoamine caused by tetrabenazine. Regional 
variations were also observed in animal studies, 
which may reflect either differences in turnover, or 
alternatively differing sensitivity of vesicular 
storage to tetrabenazine (Pettibone et al., 1984). 
Along with its effect on the storage of monoamines, 
tetrabenazine has also been shown to have a blocking 
effect on DA receptors (Reches et al., 1983). The 
ability of tetrabenazine to induce acute dystonia 
(Burke et al., 1985) has been described as clinical 
evidence of its blocking properties. Thus, the dual 
action of tetrabenazine on DA systems has been 
proposed to be the basis of its efficacy in the 
treatment of hyperkinetic movement disorders. 
Whether this antagonist action is important 
clinically is unclear, since the ameliorative 
effects of and perhaps some of the side effects can 
be understood in terms of the depletions of 
monoamine transmitters that have been identified 
here. 
.' 
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Chapter 4 
Neurochemical correlates of chorea 
4.1 Introduction 
The aim of this part of the study w ~ s s to attempt to 
define any neurochemical correlates of the chorea in 
HD. 
Chorea is a hyperkinesia characterised by random, 
involuntary jerky fragments of movements and it has 
been postulated that ballism is an extreme form of 
chorea, with a common mechanism (Crossman et al., 
1984: Dewey and Jankovic, 1989). An amelioration of 
choreiform movements in HD can be achieved using 
dopamine blocking/depleting drugs, possibly as a 
result of reduced inhibition of the striatal 
GABAergic efferents. The nigrostriatal 
dopaminergic pathway was initially thought to be 
relatively spared, however our own results (see 
section 3.2) and previous evidence (Reynolds and 
Garrett, 1986) ... suggest that a reduction in dopamine 
turnover occurs in HD. How these changes relate to 
the symptom of chorea in HD is unclear since, 
despite the massive neuronal·losses in the striatum, 
experimental models in the primate have been 
unsuccessful in producing chorea by striatal lesions 
(Crossman et al., 1988). 
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Current ideas implicate GABAergic losses in the 
choreiform movements in HO, especially in pathways 
of the pallidum, subthalamic nucleus (STN) and 
thalamus (see Fig. 4.1). Lesioning the STN in 
primates is known to produce ballism consistently, 
as does injection of a GABA antagonist into the STN. 
The result of both situations is a loss of STN 
activity (as demonstrated by reduced uptake of 2-
deoxyglucose). Injection of the GABA antagonist, 
bicuculline, into the lateral pallidum produced 
chorea, but similar injections into the striatum 
were not found to result in chorea, except when 
diffusion into the lateral pallidum occurred 
(Crossman et al., 1988). Injection of kynurenic 
acid (a glutamate receptor antagonist) into the 
medial pallidum produced chorea presumably due to 
the blockade of the excitatory glutamatergic pathway 
from the STN to the medial pallidum (Robertson et 
al., 1989). Thus the relative balance of the 
different parts of the basal ganglia would appear t o ~ ~
crucial to the understanding of chorea. 
4.2 Methods 
Case histories from the HO series (n = 46) were 
assessed by an experienced neurologist (Or.Kenneth 
Heathfield) to determine the degree of chorea. A 
global impression from the medical and nursing case 
notes, in the 42 cases where there was sufficient 
information, provided approximate gradings: mild, 
moderate and severe. Thus 'mild' described cases in 
which the chorea was limited in site and extent, 
whereas 'severe' were the most greatly affected and 
were profoundly restricted in their mobility. 
Recognising that some lack of precision is 
inevitable in such a retrospective assessment, only 
the two extreme groups were used for comparison 
although data from the intermediate moderate group 
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~ ~ a l s o o shown. Age, sex, post mortem delay and 
duration of disease are shown in Table 4.1. Since 
in almost all of the small groups the distribution 
of the parameters under investigation did not 
approximate to normality, non-parametric Mann 
Whitney u-tests were employed for statistical 
comparison. In each sub-group, conc.entrations of ~ ~ -
aminobutyric acid (GABA), glutamate, dopamine (DA), 
homovanillic acid (HVA) and 5-hydroxytryptamine 
(5HT) were determined from the putamen, caudate and 
medial and lateral pallidum. 
4.3 Results 
The results (Pearson et al., 1990) in Table 4.2 
illustrate the significant losses of GABA in all 
parts of the basal ganglia (see section 3.2). Both 
pallidal regions show significant deficits in GABA 
concentrations, although the medial shows a smaller 
loss than the lateral. Furthermore GABA is found to 
be less decreased in severely choreic as opposed to 
mildly choreic patients. Although also evident in 
the lateral pallidum and striatal regions, the 
effect is only significant in the medial pallidum. 
We found increased concentrations of DA (see section 
3.2) in the putamen in HD , which was found to a 
greater extent in both lateral and medial parts of 
the pallidum, whereas a significant decrease in the 
concentration of HVA was found in all areas of the 
basal ganglia. There was no difference between DA 
(Table 4.3) or HVA (Table 4.4) concentrations in 
mildly and severely choreic in any of the areas 
studied. However, DA in. the moderate group was 
shown to be significantly increased in both the 
lateral pallidum and c a u d ~ t e ; ; only when compared to 
severe group, but not with the mild group. A 
further observation is that concentrations of 
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glutamate (Table 4.5) in the caudate were shown to 
be significantly increased in the severe, as 
compared with the mild group. There were no 
significant changes relating the degree of chorea 
with 5HT concentrations (Table 4.6). 
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Table 4.1 
Details of subjects groviding brain tissue gost mortem: 
chorea 
Values are means. Ranges in parentheses. 
Age Sex Post Duration 
(Years) mortem (Years) 
(Hours) 
Controls 57 24M 3F 31 
(21-82) (3-79) 
Huntington's 
disease 56 . 23M 23F 43 12 
(30-83) (3-153) (3-24) 
Mild 44 5M 4F 57 12 
(30-69) (46-72) (3-20) 
Moderate 58 7M 9F 35 12 
(32-72) (3-153) (5-23) 
Severe 58 6M 10F 42 13 
(43-75) (8-120) (4-24) 
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Table 4.2 
Concentrations of GABA in the basal ganglia: chorea 
Values are means ± s.d. in j.£g/g tissue. 
*p < 0.05 versus severe group, ***p < 0.001 versus controls 
Medial Lateral Putamen Caudate 
pallidum pallidum 
Controls 783 ± 67 744 ± 112 461 ± 62 314 ± 90 
Huntington's 318 ± 105*** 241 ± 93*** 165 ± 52*** 100 ± 40*** 
t-> disease 
t-> 
t-> 
Mild 83 ± 49 247 ± 75* 203 ± 81 148 ± 66 
Moderate 312 ± 108 250 ± 169 169 ± 40 116 ± 45 
Severe 339 ± 90 227 ± 78 169 ± 59 94 ± 24 
---- - - -
Table 4.3 
Concentrations of dopamine in the basal ganglia: chorea 
Values are means ± s.d. in ng/g tissue. 
*p < 0.05 moderate versus severe group 
***p < 0.001 HD versus controls 
Medial Lateral Putamen Caudate 
pallidum pallidum 
Controls 97 ± 76 976 ± 662 4125 ± 1176 2667 ± 694 
~ ~ Huntington's 554 ± 531*** 2918 ± 2171*** 6093 ± 2844*** 2645 ± 2300* 
~ ~ disease l\J 
Mild 334 ± 257 2588 ± 1720 6079 ± 3247 2438 ± 2205 
Moderate 713 ± 552 3886 ± 2603* 6828 ± 3052 3562 ± 2924* 
. Severe 514 ± 617 2154 ± 1643 5300 ± 2729 2032 ± 1801 
- l i b : ; l l ; < ~ ~ ~ ~ ~ =--= -- ---- ~ ~
Table 4.4 
Concentrations of homovanillic acid in the basal ganglia: chorea 
Values are means ± s.d. in ng/g tissue. 
**p < 0.01, ***p < 0.001 HD versus controls 
Medial Lateral Putamen Caudate 
pallidum pallidum 
Controls 3855± 1343 6110 ± 1674 9538 ± 2600 4401 ± 1194 
Huntington's 2937 ± 896** 4440 ± 1450*** 6176 ± 2158*** 2306 ± 1101*** 
disease 
.... 
.... Mild 2968 ± 931 4158 ± 1261 5760 ± 2787 1963 ± 1419 w 
Moderate 3150 ± 1046 5022 ± 1720 6405 ± 1891 2757 ± 1281 
Severe 2616 ± 660 3940 ± 1199 5818 ± 1878 2049 ± 767 
-,--. ~ - ~ ~ ~ % . ~ - - - --= "" ......... ~ ~ ~ ~ ---
Table 4.5 
Concentrations of glutamate in the basal ganglia: chorea 
Values are means ± s.d. in J..£g/g tissue. 
*p < 0.05 mild versus severe group 
**p < 0.05, ***p < 0.001 HD versus controls 
Medial. Lateral Putamen Caudate 
pallidum pallidum 
Controls 749 ± 139 885 ± 179 2160 ± 272 1694 ± 219 
.... Huntington's 1114 ± 541** 1009 ± 218** 1638 ± 397*** 1137 ± 384*** 
.... disease 
,j:l. 
Mild 1001 ± 281 1017 ± 248 1542 ± 489 970 ± 460* 
Moderate 1042 ± 374 962 ± 206 1503 ± 351 1130 ± 446 
Severe 1260 ± 798 1021 ± 205 1706 ± 314 1108 ± 240 
~ . ~ ~ ~ ~ * *... ~ ~ "W ''''i\', -;",_,,,,_ ~ ~ ... ----
.,. 
Table 4.6 
Concentrations of 5-Hydroxytryptamine in the basal ganglia: chorea 
Values are means ± s.d. in ng/g tissue. 
*p < 0.05, ***p < 0.001 HD versus controls 
Medial Lateral Putamen Caudate 
pallidum pallidum 
Controls 245 ± 80.8 224 ± 53.9 320 ± 75.7 219 ± 60.7 
Huntington's 458 ± 179*** 514 ± 219*** 632 ± 216*** 328 ± 221* 
..... disease 
..... 
01 
Mild 501 ± 276 573 ± 231 690 ± 297 290 ± 259 
Moderate 490 ± 168 563 ± 191 678 ± 200 420 ± 285 
Severe 410 ± 111 458 ± 241 593 ± 186 281 ± 131 
__ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ t , . . ~ ~ ~ ? ~ ~ ~ ~ ~ e ' ~ ~ 1 l ! ! ~ " "
4.4 Discussion 
4.4.1 Moderate group 
Data from the moderate group shows a significant 
change in DA levels in two areas compared with the 
severe group. However, although the results have 
been shown, it was felt that valid conclusions could 
not be made due to the lack of precision from 
retrospective assessment of the degree of chorea. 
The two extreme groups could be presumed to be 
strongly defined, whereas there was potentially much 
overlap with the intermediate group. Thus, further 
conclusions will only be drawn from the mild and 
severe results. 
4.4.2 Monoamines in chorea 
The present results (see section 3.2) provide no 
evidence for an increased activity of the dopamine 
system in HD, in fact the sUbstantial losses of HVA 
indicate reduced turnover of this system. The lack 
of any consistent association between the degree of 
chorea and striatal or pallidal DA or HVA suggests 
that this system is unrelated to the production of 
choreiform movements.·· Similarly there appears to be 
a lack of connection between 5HT and choreiform 
" 
movements. 
4.4.3 Amino acids in chorea 
The well-established loss of GABA in HD (see section 
3.2) is obvious here. While pallidal regions show 
significant losses, the medial part shows a smaller 
loss than the lateral, which may result in the 
medial/lateral GABAergic balance being disturbed. 
This is consistent with results from Spokes (1980) 
that demonstrate a loss of glutamate decarboxylase, 
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the synthetic enzyme for GABA, in the lateral but 
not the medial pallidum in HD. Furthermore, our 
study shows GABA to be less decreased in severely 
choreic patients than in those with only mild 
chorea, this being significant only in the medial 
pallidum. Although perhaps counter-intuitive, such 
findings are wholly consistent with--the primate 
models of chorea that implicate a relative 
underactivity of the medial pallidum, demonstrated 
by decreased uptake of 2-deoxyglucose (Crossman et 
al., 1988). In HD the inhibitory GABAergic 
striatal-pallidal pathways are lost, but relatively 
more degeneration occurs to the lateral than to the 
medial pathway, which are functionally separate 
having different peptidergic cotransmitters (Albin 
et al., 1989). Thus the medial pallidum is 
underactive, relative to the lateral part, which 
results in decreased inhibition of the 
venteroanterior (VA) and venterolateral (VL) 
thalamus via its GABAergic projection. The lateral 
pallidum is relatively overactive which results in 
greater inhibition of the STN via its GABAergic 
projection. As a result the excitatory 
glutamatergic pathway from the STN to the medial 
pallidum is also underactive, compounding the effect 
-in the medial pallidum. This combination of effects 
indicates that there is an overactivity of the VA/VL 
. 
thalamus, which mediates the striatal outputs to the 
motor cortex. Presumably, further degeneration of 
the GABAergic innervation of the medial pallidum 
will result in a disinhibition of this structure, 
counteracting, to some extent, the effect described 
above. Thus, as the disease progresses, the initial 
choreiform movements become increasingly more 
akinetic and rigid, as the eventual degeneration of 
this pathway follows the initial loss of lateral 
pallidal GABAergic innervation (Reiner et al., 
1988). 
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4.5 Factors influencing GABA changes 
It is important to consider the many factors which 
could be artefactually affecting the GABA changes, 
although a regionally specific effect argues against 
external influence. The control group contains 
fewer females than the HD group (as does the mild 
compared with severe group), but this cannot account 
for the large changes observed (Reynolds and 
Pearson, 1987a). The minor differences in 
postmortem delay in the HD subgroups would not be 
expected to affect the results, since GABA 
concentrations are reportedly not significantly 
affected by this factor (Perry et al., 1981). GABA 
is similarly unaffected by the cause of death 
(Spokes et al., 1979); moreover bronchopneumonia was 
the major cause of death in both the HD groups. 
Several of the patients studied had received 
neuroleptic drugs, however we have found that such 
treatment has no significant effect on GABA 
concentrations in the HD brain (see section 3.2); 
certainly concentrations of GABA in striatal and 
pallidal regions are reported to be not 
significantly changed from control values in 
neuroleptic-treated schizophrenic patients (Toru et 
al., 1988). Further clinical factors ma¥ be of 
relevance; one such factor is rigidity. within the 
mild chorea subgroup, five of the cases were 
described as displaying rigidity, whereas none of 
the severe group had this symptom. Nevertheless, 
the remainder of the mild subgroup also showed the 
same trend in GABA losses. Another factor is age, 
however, any effect of age would predict a decrease 
of GABA in the older subgroup (the severe subgroup) 
which is contrary to our findings (Spokes et al., 
1979). An associated factor here is age at onset of 
the disease. In particular, two patients in the 
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mild subgroup were younger onset cases (displaying 
symptoms before age 20). However, removal of these 
two cases from the subgroup had no effect on the 
overall results. Nor can this difference be 
ascribed to duration of disease, which exhibited no 
correlation with pallidal GABA concentrations, nor 
any significant difference between the two groups. 
The only other significant finding was the relative 
increase in caudate glutamate concentrations in the 
severe subgroup, compared with the mild. This is 
consistent with a relative loss of corticostriatal 
neurones, perhaps reflecting a temporal effect 
between mild and severe chorea. Again, all the 
above factors discussed in relation to GABA must be 
considered (see section 3.2). A specific glutamate 
change would not be predicted by differences in 
agonal state (Perry et al., 1982), duration of 
disease, sex, age, postmortem delay (Reynolds and 
Pearson, 1987a), drugs, rigidity or age at. onset. 
One factor which may be relevant is the degree of 
dementia (see section 5.3), as in HD, dementia is 
associated with deficits of GABA and glutamate in 
the caudate. Thus, if the mild chorea subgroup were 
relatively more demented this would predict the 
observed change in concentrations of glutamate in 
the caudate. Also evident is a corresponding 
. 
increase in caudate GABA concentrations, although 
this is not significant. However, there is 
insufficient clinical information regarding the, 
degree of dementia of the cases in these subgroups. 
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Chapter 5 
Neurochemical correlates of dementia 
5.1 Introduction 
Huntington's disease (HD) is not just a hyperkinetic 
movement disorder. Clinically, there is a wide 
spectrum of symptoms including psychiatric changes 
and a decline in cognitive function, which may 
precede the first signs of chorea. 
There has been considerable speculation regarding 
the dementia of HD, specifically, comparing it with 
Alzheimer's disease (AD) and Parkinson's disease 
(PD). It has been suggested that HD and PD 
dementias are subcortical and that Alzheimer's 
disease (AD) is cortical in origin (Foster, 1986; 
Cummings and Benson, 1984). "Subcortical dementia" 
was first described in 1974 by Albert et al. using 
progressive supranuclear palsy as an example. 
Clinical symptoms included forgetfulness, slowness 
of thought processes, the inability to manipulate 
acquired knowledge, apathy, depression and altered 
personality. The characteristics of HD dementia, 
reported by McHugh and Folstein (1975) parallelled 
this subcortical dementia model, and were 
. " 
inconsistent with the dementia of AD (where aphasia, 
agnosia, amnesia and intellectual i m ~ a i r m e n t t are 
prevalent). However, an alternative view is .that 
"such classification is an unsubstantiated 
oversimplification and the integration of individual 
subcortical projection systems, with the cortex must 
be understood" (Whitehouse et al., 1986; Chui, 
1989) . 
In HD there is considerable atrophy of the basal 
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ganglia (50% loss) in all areas, induding the 
pallidum, reflecting the neurodegeneration 
occurring. Limbic and cortical areas are also 
atrophied (Lange et al., 1976; de la Monte et al., 
1988), although the degree to which the deficits in 
different regions are involved in the production of 
psychiatric symptoms and dementia is unclear. 
Studies have been made to determine neurochemical 
markers for dementia. One consistent finding is an 
associated loss of cholinergic neurones 
(demonstrated by measuring choline acetyltransferase 
(CAT) activity). Using post mortem cortical tissue 
from patients with AD, there was an inverse 
correlation between cognitive impairments and other 
measures of dementia with CAT activity (Mountjoy et 
al., 1984). A similar equivalent reduction of 
cortical CAT activity was also reported in demented 
PD patients, even without neuropathological signs of 
D (Perry et al., 1983). There was no evidence of 
similar investigations of CAT activity in dementia 
in HD, so our study aimed to determine whether any 
such association with a cholinergic deficit was 
indicated. 
5.2 Methods 
We investigated brain tissue taken post mortem from 
. 
the large series of HD patients and matched 
controls. Dementia was rated on a four point scale 
(absent, mild, moderate and severe) by an 
experienced neurologist (Dr. Kenneth Heathfield) 
using a global assessment of clinical medical and 
nursing records. 
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Table 5.1 
Details of subjects providing brain tissue post mortem: 
dementia 
Values are means ± s.d. *p < 0.05 versus severely 
demented cases. 
Age' Sex Duration 
(years) (years) 
Controls 57 ± 14 24M 3F 
Huntington's disease 56 ± 12 23M 24F 12 ± 6 
Not demented 67 ± 10* 3M 2F 14 ± 4 
Severely demented 54 ± 12 5M 7F 14 ± 4 
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Only the two extreme groups, absent (n=5) or severe 
(n=12) were investigated due to the approximation of 
such a retrospective study (Table 5.1). These were 
almost equivalent to points 1 and 6/7 on the Global 
Deterioration Scale of Reisberg et ale (1982). CAT 
activity was determined in t ~ ~ e e e cortical areas 
(temporal cortex, frontal cortex and hippocampus) 
and in the caudate. Concentrations of ~ ~
aminobutyric acid (GABA), glutamate, 5-
hydroxytryptamine (5HT) and noradrenaline (NA) were 
also measured in striatal and cortical regions of 
the brain tissue. statistical comparisons were made 
using t-test of logarithmically-transformed data. 
5.3 Results and Discussion 
Reduced striatal CAT activity has been well 
established in HD (Spokes, 1980; McGeer and McGeer, 
1976b) and indeed our own results (Reynolds et al., 
1990a) show a significant deficit (60%) in the 
caudate. Also CAT activity was reduced in cortical 
regions with a deficit of 30% in the hippocampus. 
However, there was no association" of the degree of 
dementia with CAT activity deficits and indeed the 
undemented patients had the lowest cortical CAT 
activity, reaching significance in the temporal 
cortex (Table 5.2). One possible e x p l a n ~ ~ i o n n is 
that this reduction could be age-related, as the 
v ~ d e m e n t e d d group had a 3 ( ~ e r . m e a n n age and 
this would predict reduced CAT activity (Rossor et 
al., 1984). The cortical CAT deficits in 
Alzheimer's and Parkinson's dementia are much 
greater than the small reduction seen in HD. 
Furthermore, cortical concentrations of 5HT and NA, 
neurotransmitters involved in AD, were found not to 
be significantly changed in HD dementia (results not 
shown). Therefore it would appear that HD dementia 
does not share a similar profile of cortical losses 
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seen in other dementing diseases; losses which have 
been assumed to be connected with the production of 
symptoms of dementia. 
Amino acid changes in HD were investigated to assess 
any relationship with dementia. It was found that 
cortical and hippocampal GABA concentrations showed 
no effect between undemented and severely demented 
patients, contrasting with deficits reported to 
occur in AD. However, a significant loss of GABA in 
the caudate (but not the putamen) was observed in 
the severely demented group (Table 5.3). This is 
consistent with the hypothesis that HD dementia is 
subcortical in origin and related to neuronal losses 
in the caudate. Glutamate concentrations showed 
similar effects. In HD dementia the hippocampus, 
frontal cortex and putamen showed minor deficits 
(10-17%), whereas the caudate was found to have a 
significant decrease of 42%, compared with 
undemented patients (Table 5.4). 
It is unlikely that these changes are artefactual 
. 
reflections of other differences between the two HD 
subgroups, particularly since the results are so 
regionally specific. There is little difference 
between the duration of disease in each group 
indicating that in general the disease p ~ p c e s s s is 
not more advanced in the demented patients. The 
effect, if any of the lower age of this group would 
be to increase GABA concentrations, notto lower, 
them, as is apparent here. post-mortem delay, 
agonal state and gender are other factors that are 
important to consider as potential sources of 
artefact in the investigation of human autopsy 
tissue: however, they are unlikely to be responsible 
for any SUbstantial differences (see section 3.2) in 
amino acid concentrations in this series. 
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Table 5.2 
Choline acetyl transferase activity in the brain in Huntington's disease: 
dementia 
Values are means ± s.d. in umol/h/g tissue. Nos. of cases in parentheses. 
*p < 0.05, ***p < 0.001 versus controls 
**p < 0.01 versus severely demented cases. 
Hippocampus Temporal Frontal Caudate 
cortex cortex 
Controls 1.04 ± 0.42 0.38 ± 0.06 0.34 ± 0.09 5.51 ± 2.03 
Huntington's disease. 0.72 ± 0.42*** 0.34 ± 0.11 0.30 ± 0.11* 2.21 ± 1 . ~ 3 3
Not demented 0.75 ± 0.37 0.26 ± 0.05** 0.26 ± 0.05 
(4-5) 
'-
Severely demented 0.63 ± 0.30 0.41 ± 0.10 0.31 ± 0.10 
,(10-12) 
* * ~ ~
f-> 
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Table 5.3 
GABA concentrations in the brain in Huntington's disease: dementia 
Values are means ± s.d. in ug/g tissue. Nos. of cases in parentheses. 
*p < 0.05, **p < 0.01, ***p < 0.001 versus controls 
~ p p < 0.001 versus severely demented cases. 
Caudate Putamen Hippocampus Frontal 
cortex 
Controls 314 ± 90 461 ± 62 196 ± 55 196 ± 37 
Huntington's disease 100 ± 40*** 165 ± 52*** 140 ± 43*** 140 ± 37*** 
Not demented 146 ± 26){ 186 ± 49 133 ± 62 131 ± 44 
(4-5) 
Severely demented 81 ± 23 149 ± 14 139 ± 24 138 ± 39 
(10-12 ), 
I-' 
N 
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Table 5.4 
Glutamate concentrations in the brain in Huntington's disease: dementia 
Values are means ± s.d. in ug/g tissue. Nos. of cases in parentheses. 
*p < 0.05, **p < 0.01, ***p < 0.001 versus controls 
1p < 0.05 versus severely demented cases. 
Caudate Putamen Hippocampus Frontal 
cortex 
Controls 1694 ± 219 2160 ± 272 1232 ± 166 1507 ± 272 
Huntington's disease 1127 ± 384*** 1638 ± 397 1082 ± 298** 1366 ± 407* 
Not demented 1628 ± 559+ 1842 ± 527 1228 ± 381 1436 ± 736 
(4-5) 
Severely demented 942 ± 301 1535 ± 287 1104 ± 280 1267 ± 430 
(10-12) 
While this is the first report providing direct 
neurochemical evidence implicating caudate nucleus 
in the dementia of HD, there have been other studies 
indicating caudate nucleus and not the cerebral 
cortex to be the site of the lesion involved in this 
cognitive deficit. Several computerised tomography 
studies have shown cognitive deficits in HD to be 
correlated with various measures of caudate, but not 
cortical atrophy (Bamford et al., 1989; Starkstein 
et al., 1988). Positron emission tomography, used 
to measure regional metabolic activity, has also 
demonstrated that there is no hypometabolism in the 
neocortex in HD, contrary to that in AD and that a 
decrease in the energy metabolism of the caudate is 
related to impaired cognitive function (Berent et 
al., 1988). 
The innervation of the caudate nucleus by the cortex 
is glutamatergic and thus the decrease in caudate 
glutamate that we observe here is consistent with a 
loss of this cortical output pathway. As 
Weinberger et a ~ . · · (1988) have shown, HD does not 
show the expected deficit in cerebral blood flow 
associated with a measurable deterioration of a 
function mediated by intrinsi9 frontal cortical 
systems. Thus the additional neuronal damage of the 
caudate nucleus that is reflected by further amino 
acid losses in dementing HD patients can lead to 
this disruption of cognitive behaviour that is 
essentially cortical in origin. 
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Chapter 6 
Quinolinic acid 
6.1 Metabolism of quinolinic acid 
Quinolinic acid (QA; 2,3 pyridine dicarboxylic acid) 
is an intermediate of the kynurenine pathway (Fig. 
6.1), which results in the formation of nicotinamide 
adenine dinucleotide (NAD) via the metabolism of 
tryptophan, in the periphery. The kynurenine 
pathway is the major route for tryptophan 
metabolism, compared with that producing 5-
hydroxytryptamine (5HT) (During et al., 1989a; Gal 
and Sherman, 1980; Stone and Connick, 1985). 
Although components of the kynurenine pathway have 
been identified in the brain, it has been suggested 
that they may not be metabolised locally, but 
originate from precursors in the periphery, and that 
QA, which cannot cross the blood-brain barrier 
(Foster et al., 1984a) is being synthesized from 
such a precursor (Speciale et al., 1989b). 
QA is synthesized from 3-hydroxyanthranilic acid 
(3HA) (via spontaneous metabolism of ~ - a m i n o - ' '
carboxymuconic-6-semialdehyde (ACMS» and 
metabolized to nicotinic acid m o n o n u c l e o ~ j d e e (NAMN). 
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Figure 6.1 
Tryptophan metabolism 
Tryptophan, __________ ~ - - - - - - - - - - - - ~ ) ) Formylkynurenine 1 1 12 ... 
5-Hydroxytryptophan ?* Kynurenine. ____________ ~ ) ) Kynurenic 
7* acid 
Anthranilic 
acid 
I-HYdroxytryptamine 
5-Hydroxyindoleacetic 
acid 
3 - H y d r o x y k y n u r e n i n e ~ ~ xanthurenic 
I 7* acid 4* 3 - H y d r o x y a n t h r a n i l i c ~ ~ Nicotinic 
l;cid acid 
NAD+ ~ < <__________ ~ _ _ Quinolinic 
6 acid 
1= Tryptophan 2,3-dioxygenase (periphery) 
Indoleamine 2,3-dioxygenase (brain) 
2= Kynurenine formylase 
3= Kynurenine hydroxylase 
4- Kynureninase 
5= 3-Hydroxyanthranilic acid oxygenase 
6= Quinolinic acid phosphoribosyltransferase 
7- Kynurenine transaminase 
8= Anthranilate hydroxylase 
*= vitamin B6 dependent 
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In the rat brain, the synthetic enzyme, 3-
hydroxyanthranilic acid oxygenase (3HAO) and the 
catabolic enzyme, quinolinic acid 
phosphoribosyltransferase (QPRT) have been localized 
to glia. They have a heterogeneous distribution; 
3HAO has been demonstrated immunohistochemically to 
be almost exclusively astrocytic with the caudate, 
septum, nucleus accumbens, neocortex and hippocampus 
showing the highest density of 3HAO cells; whereas 
QPRT was found to be localized in a variety of glial 
cells with the olfactory nerve, medial septum and 
diagonal band of Broca showing the highest density 
of QPRT cells (Kohler et al., 1988). QA has been 
identified in the rat brain with greater 
concentrations in the cortex than in the striatum 
(Wolfensberger et al., 1983). Schwarcz et al. 
(1988) showed that human brain 3HAO activity is 2-3 
times higher than in rat brain, whereas QPRT 
activity is comparable in both •. Their evidence also 
suggested that 3HAO too was glial-based in the human 
brain, with the SUbstantia nigra (s.nigra) having 
the highest 3HAO activity, followed by hypothalamus, 
globus pallidus, medulla, striatum, cerebellum, 
thalamus, cortex and hippocampus. Activity of QPRT 
in the human brain also s h o w e ~ ~ regional variations 
in order of decreasing magnitude: caudate, s.nigra, 
thalamus, hypothalamus, cortex, h i p p o c a m p ~ s , ,
cerebellum and putamen. The cellular localization 
of QPRT in human brain is indefinite,.although glia 
were proposed (Foster et al., 1985). 
The metabolism of tryptophan is subject to many 
controlling factors. The activity of tryptophan 
pyrrolase (a metabolic enzyme of tryptophan) is 
important in relation to the activity of the 
kynurenine pathway and thus the metabolism of QA. 
The activity of'this enzyme can be affected by 
corticosteroids or tryptophan loading. 
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Acute intra-peritoneal (i.p.) injection of 
hydrocortisone increases activity in rat liver, but 
not rat brain, whereas Connick and stone (1988) 
demonstrated that chronic i.p. administration caused 
reductions in QA and 5HT metabolism in the rat 
brain. They suggested that brain tryptophan 
metabolism was reduced as a result o'f the increase 
in liver tryptophan metabolism. systemic tryptophan 
loading has been shown to increase tryptophan 
pyrrolase activity (stone and Connick, 1985) as well 
as increasing concentrations of QA, 5HT and 
tryptophan in the blood, brain and brain 
extracellular fluid (Heyes and Markey, 1988b; Moroni 
et al., 1984a; During et al., 1989a). The effect on 
QA is the greatest, indicating a stronger 
relationship between QA and its precursor. l.p. 
tryptophan administration produced similar effects, 
which were dose-dependent, with QA showing over 200-
fold increase at the highest dose (During et al., 
1989a). 
There is some c ~ n t r a r y y evidence regarding the in 
vivo production of brain extracellular QA after 
exposure to tryptophan, as well as other precursors. 
Speciale et ale (1989b) found_that tissue perfusion 
of tryptophan or kynurenine did not raise 
extracellular QA above the limit of sensitivity of 
their assay, whereas 3HA produced a dose-dependent 
increase in extracellular QA, until steady state, of 
up to several hundred-fold compared to basal levels. 
They suggest that this is the first evidence of a 
functional pathway in vivo from extracellular 3HA to 
QA in the rat brain. The data above regarding the 
effect of systemic tryptophan loading, as compared 
with the in vivo perfusion, imply that a kynurenine 
metabolite is produced in the periphery and is 
metabolized locally to produce QA, c.rossing the 
blood-brain barrier which is impenetrable to QA. 
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Systemic kynurenine also increases rat brain 
concentrations of QA (Speciale et al., 1989b), but 
as kynurenine is freely able to cross the blood-
brain barrier (Gal and Sherman, 1978) this does not 
provide evidence for a functional kynurenine pathway 
in the brain. Of interest a..re. the data from Moroni 
et al. (1985) which shows that rats"fed a 
tryptophan-free diet had doubled QA levels in the 
cortex, compared with controls, whereas 5HT and 5-
hydroxyindoleacetic acid (5HlAA) concentrations were 
decreased. These animals also displayed the 
symptoms of pellagra. This is contrary to the 
consistent relationship between systemic tryptophan 
and brain QA, described earlier. Furthermore, rats 
treated with p-chlorophenylalanine (a drug that 
decreases concentrations of tryptophan and 5HT in 
the brain of rats, by inhibiting the enzyme 
tryptophan hydroxylase) also had reduced 
concentrations of cortical QA (Moroni et al., 
1984a). 
Neuronal damage is a further factor affecting QA . 
metabolism. Neurodegeneration following excitotoxic 
administration has been shown to be associated with 
increased activity of 3HAO and to a lesser degree, 
QPRT. This was demonstrated for a variety of 
neurotoxins including kainic acid ( S p e c i ~ l e e et al., 
1988), ibotenic acid (Schwarcz et al., 1989) and QA 
itself (Foster et al., 1985). Furthermore, Speciale 
et al. (1989b) reported tissue perfusion with 3HA in 
ibotenate-Iesioned tissue caused an 'accelerated 
surge in extracellular QA to the same maximal levels 
as controls'. These findings have been suggested to 
reflect the relative gliosis resulting from the 
neuronal losses, as QA metabolism (as discussed 
above), is thought to be glial-based. However, 
Speciale et al. (1987) provided evidence to suggest 
new synthesis of both 3HAO and QPRT, albeit to a 
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lesser extent. They hypothesized that a small 
neuronal loss may result in increased production of 
QA, which in turn would cause yet more neuronal 
losses, thus forming a feed-forward system. 
other stimuli have also been demonstrated to change 
QA metabolism. Exposure to endotoxin 
(lipopolysaccharide of bacterial origin) or pokeweed 
mitogen (plant antigen) has been demonstrated to 
result in increased QA concentrations in the mouse 
cortex (Heyes et al., 1988) and systemic endotoxin 
also increases concentrations of tryptophan, 5HlAA 
and 3-hydroxykynurenine (3HK) in the mouse cortex 
(Heyes et al., 1989a). They suggested that 
increased systemic tryptophan metabolism following 
infection or endotoxin (resulting from increased 
tryptophan release from skeletal muscle) also 
extended to the brain in mice. This increased 
tryptophan metabolism was also potentiated when 
tryptophan was administered. Tryptophan competes 
with large neutral amino acids for uptake into the 
brain. An increased ratio of tryptophan to large 
neutral amino acids, could cause an increase in 
brain tryptophan metabolism, as more tryptophan is 
taken up into the brain. T h u ~ , , there would be less 
peripheral tryptophan (e.g. reduced serum 
concentrations). A further factor affect;,ing QA is 
probenecid. QA is a substrate of the probenecid-
sensitive organic acid transport system (Connick et 
al., 1988) and probenecid treated rats had twofold 
amount of QA in the cortex, as compared to controls 
(Moroni et al., 1986b). 
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6.2 Neurotoxins 
certain excitatory amino acids,'excitotoxins', can 
cause neurodegeneration by excessive excitation when 
administered to the brain. The potency of these 
compounds appears to be strongly related to their 
~ e u r o e x c i t a t o r y y capacity (Schwarcz et al.,.1984b). 
Characteristic lesions are formed which are 'axon-
sparing'; that is, extrinsic axons and non-neuronal 
cells are spared and intrinsic neurones are lost 
(Olney, 1971). It has been suggested that an excess 
of endogenous neurotoxins may be responsible for the 
neurodegeneration found in diseases such as epilepsy 
and Huntington's disease (HD) (Feldblum et al., 
1979; Coyle and Schwarcz, 1976). Glutamate is one 
such compound, but large amounts are needed in the 
mature rat to produce neurotoxic damage, unless a 
reduction in high-affinity uptake sites occurs 
(Manango and Schwarcz, 1983; Kohler and Schwarcz, 
1981). Of more interest are two exogeneous 
compounds, kainate and ibotenate, which structurally 
resemble glutamate. Injection of these compounds 
into the striatum or hippocampus produced axon-
sparing lesions that provided the e ~ r \ ~ a n i m a l l
models for HD and epilepsy ( C ~ y l e e and Schwarcz, 
1976; Nadler, 1981), although subsequently, QA was 
demonstrated to provide a better animal ~ o d e l l O ~ ~ HD 
(Schwarcz et al., 1983; Beal et al., 1986). 
6.2.1 Selectivity of QA as an animal model for HD 
There are certain similarities between the three HD 
models. Intra-striatal injection resulted in 
lesions that morphologically and neurochemically 
resembled many of the cell losses and changes seen 
in the HD striatum. Thus,. losses of medium spiny 
neurones occurred resulting in reduced markers of 
their neurotransmitters, t-aminobutyric acid (GABA), 
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sUbstance P and acetylcholine. There was sparing of 
large or medium aspiny neurones and the survival of 
the striatal afferents was reflected by unchanged 
or increased levels of dopamine, vasopressin and 5HT 
markers. However, there was a major difference 
between the three models, that involved a selective 
sparing of somatostatin (SS)/ neuropeptide.Y (NPY)/ 
NADPH-d containing neurones, which are not lost in 
the HD striatum; only the QA model spared these 
(Beal et al., 1986). Furthermore there were other 
anomalies regarding the kainate and ibotenate animal 
models of HD. Kainate administration resulted in 
lesions away from the site of injection and produced 
strong convulsive effects; ibotenate was found to 
affect immature rat neurones, whereas HD does not 
usually develop until middle age (Schwarcz et al., 
1983). Thus, a functional excess of the endogenous 
neurotoxin QA may have an aetiological role in HD. 
However, there is also sUbstantial evidence 
disputing the selectivity of the QA model.' A long 
inconclusive debate has continued between Davies/ 
Roberts and B e a ~ ~ et ale regarding the preservation 
of the SS/ NPY/ NADPH-d neurones. Davies and 
Roberts (1987/1988) used immunocytochemical and 
enzyme histochemical methods ~ o o measure numbers of 
these neurones and found no selective sparing, and 
suggested that the increased peptides measured by 
Beal et al., using radioimmunoassay, may reflect 
their presence in striatal afferents., Beal et ale 
(1987/1988b) defended and repeated their results'and 
suggested that the Davies evidence was taken from 
measurements of the absolute core of the lesion, 
where there is total neuronal loss; whereas they 
should have used an outer 'region exhibiting 50% 
loss, where selective increases occur. Furthermore, 
they argued that striatal afferents are also spared 
in kainate lesions, but there is no selective 
sparing of the SS/ NPY/ NADPH-d neurones. 
There is evidence supporting the selective QA lesion 
(Koh et al., 1986; Nemeroff, personal communication 
to Beal, 1987) as well as negating it (Boegman et 
al., 1987; Davies and Roberts, 1988). Both groups 
agree regarding a further selective sparing: the 
cholinergic neurones, especially at the core of the 
lesion (Davies and Roberts, 1988; Boegman et al., 
1987; Beal et al., 1988b). This is concordant with 
preserved groups of cholinergic neurones in HD 
(Ferrante et al., 1987b), but this effect occurs 
with kainate and ibotenate also. If indeed the SS/ 
NPY/ NADPH-d neurones are preserved, there has been 
speculation as to why. Koh et al.(1986) suggested 
that these cells could have a lack of receptors 
through which the neurotoxic effects of QA are 
mediated, the NMDA receptor. Alternatively, Beal et 
al.(1986) suggested that maybe these cells were 
metabolizing QA to NADP or NADPH, as quinones are 
detoxified by NADPH-d (Chesis et al., 1984). The 
relative sparing of the nucleus accumbens in HD 
could also be explained, as the nucleus accumbens 
has 2-3 fold more of these neurones than other 
areas, and thus is protected. A further hypothesis 
is that a particular property related to cells, not 
having spines, is protective {Ferrante et al., 
1987b). The neurotoxic effects of QA are not only 
defined by which neurones are lost, as there is also 
a regional variation. Schwarcz and Kohler (1983) 
demonstrated that an infusion of QA was more 
neurotoxic in the rat striatum, pallidum, 
hippocampus and venteromedial pallidum (equivalent 
to the human basal nucleus). More resistant were 
the cerebellum (especially the purkinje cells), 
s.nigra, amygdala, medial 'septum and hypothalamus. 
It can be observed that, in general, the more 
susceptible regions are those that show neuronal 
degeneration in HD (Ferrante et al., 1987b). 
Another important feature of QA neurotoxicity is 
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that neonate rats are resistant, unlike the adult 
animals (Schwarcz et al., 1984b); this being 
relevant because HD usually begins in middle age. 
6.2.2 Characteristics of QA as a neurotoxin 
A point of consideration is the concentrations of QA 
necessary to produce neurotoxic damage, especially 
with relevance to the hypothesis that increased QA 
may have an aetiological role in HD. In the rat QA 
intra-striatal injections ranging from 12-600 nmole 
were shown to be neurotoxic, although to varying 
degrees (Schwarcz et al., 1983) and from in-vitro 
tissue culture studies, 10 ~ M M QA was neurotoxic 
(During et al., 1989a). Using their intra-cerebral 
microdialysis technique, During estimated levels of 
QA in extracellular fluid of rat striatum to be 
greater than 14 ~ M , , following a systemic tryptophan 
load, and are thus potentially neurotoxic. 
Therefore, tryptophan or any of the other factors 
affecting QA metabolism (see section 6.1) may 
potentiate otherwise normal levels of QA, to produce 
neurotoxic damage. McGeer and Singh (1984) also 
reported that endogenous QA concentrations in the 
rat brain are neurotoxic. Regently, Whetsell and 
Schwarcz (1989) provided evidence that much lower 
concentrations of QA are possible for chronic 
neurotoxic damage to occur (which is more relevant 
to HD as it is an insidious disease). They 
demonstrated that 100 nM QA, when administered 
chronically (more than 7 weeks), produced neurotoxic 
damage to rat cortico-striatal cells in culture. 
Caudate cells, without cortical cells were 
unaffected by the same chronic QA concentrations. 
Thus, they suggested that chronic exposure to only 
slightly hyperphysiological levels of QA in vivo ( > 
1 ~ M ) ) may result in neurotoxic cell losses. A 
further point made was that a combination of cortex 
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and striatum was necessary for neurotoxicity. This 
concurs with studies suggesting an intact cortico-
striatal pathway is a prerequisite for QA 
neurotoxicity in the rat striatum. This may also 
explain why neonates are resistant to QA 
neurotoxicity, as they have not developed these 
afferents to the striatum (Foster et' al., 1983). 
Kim and Choi (1987) also investigated the effects of 
time using cortical cultures: with short exposure 
(20 min), QA was only weakly neurotoxic; whereas 4 
day exposure multiplies its effects by an order of 
magnitude. They hypothesised that nanomolar 
concentrations producing neuronal degeneration in 
vivo, may reflect the lack of uptake of 
extracellular QA, resulting in high local 
concentrations. 
A consequence of the presence of QA is the 
competitive inhibition of monoamine oxidase (MAO)-B 
in human brain synaptosomes, as demonstrated by Naoi 
et al. (1987), with MAO-A not being affected. 3HA 
and xanthurenic acid also inhibited MAO-B, but non-
competitively. Thus, QA may be an endogenous 
modulator of monoamines in the brain. 
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6.2.3 Other neurotoxic compounds (adapted from 
Schwarcz et al., 1984b) 
Exogenous: 
kainate 
ibotenate 
Endogenous: 
glutamate 
homocysteic acid 
( H C ~ ) )
N ' ~ m e t h y l l D-aspartate (NMDA) pyroglutamate (PGA) 
phthalic acid nicotinic acid 
quisqualate tetrahydrofolate 
trans 2-3 PDA aspartate 
cis 2-3 PDA cysteic acid 
AP3 cysteine sulphinate 
AP4 homocysteine 
-sulphinate 
3HK 
picolinic acid 
cysteine 
(PDA = piperidine dicarboxylic acid; AP = 2-amino-
phosphonic acid) 
None of the above compounds have proved to produce 
as good an animal model for HD as QA (Schwarcz et 
al., 1984b; Seal et al., 1986'; Watkins and Olverman, 
1987), except PGA and HCA which have provoked some 
interest. PGA was postulated to be aetiologically 
involved in HD, but it produces minimal 
neurodegeneration even using high concentrations, 
(Rieke et al., 1984). Intrastriatal injection of 
PGA in the rat produced dyskinesias but reduced 
striatal PGA was found in HD, accompanied by a 
peripheral increase (plasma), thus negating any 
hypothetical aetiological role (Uhlhaas and Lange, 
1988). However, the latest study of Rieke et al. 
(1989) provides evidence that chronic intrastriatal 
PGA produces neuronal losses similar to those found 
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in HO. More recently Beal et al.(1990b) suggested 
that HCA could be pathologically involved in HO. 
HCA lesions in the rat striatum produced selective 
cell losses identical to those induced by QA, and 
which could be blocked in similar means. However in 
vivo, HCA has a relatively low potency (2000-4000 
nmol produced 40% losses of GABA): wpereas in vitro 
it was shown to be much more potent and this was 
said to reflect active re-uptake sites in vivo. New 
evidence from Perry and Hansen (1990) demonstrated 
that HCA is probably not abnormally increased in the 
HO striatum: also that patients with homocystinuria 
(with increased HCA) do not have the symptoms of HO. 
Thus evidence does not support the aetiological 
hypothesis of HCA in HO. An earlier study of Perry 
et al. (1987) reported that an unidentified 
neurotoxin caused GABAergic neuronal losses in 
vitro, when cultured with serum from drug-free HO 
patients. 
6.2.4 Behavioural effects of QA 
The animal models of QA were compared with regard to 
their similarity to the symptomology of HO. 
Intrastriatal injection of either kainate and 
ibotenate produced tonic-clonic movements of the 
contra-lateral forelimb in rats (Coyle and Schwarcz, 
1976). Schwarcz and Kohler (1983) demons'trated that 
similar locomotor changes occurred when QA was 
injected unilaterally ( > 150 nmole) lasting 4-6, 
hours. This was accompanied by episodic barrel-like 
rotations and was dose-dependent. Only very large ( 
> 500 nmole) intrahippocampal injections produced 
convulsions, turning, running fits and jumping. 
Sanberg and Fibiger (1989) assessed the behavioural 
abnormalities induced in rats by bilateral 
intrastriatal QA (75, 150, 225, 300 nmol). They 
compared these changes to those reported to occur 
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with kainate and ibotenate: learning difficulties, 
persistent nocturnal locomotor hyperactivity, 
altered feeding and drinking mechanisms and 
potentiated locomotion when aroused. These were 
said to be similar to HD symptoms and although 
chorea was not seen, shorter paw-ground contact with 
longer swing time was postulated to be analagous to 
HD patients movements. QA lesions produced similar 
abnormalities to kainate and ibotenate, but these 
were dose-dependent. A dose of 75 nmol QA produced 
no locomotor impairment, and the 300 dose was fatal, 
as was the 225 dose to one third of its group. The 
150 nmol and 225 nmol doses produced similar effects 
to a 3 nmol dose kainate. It was suggested that 
intermediate doses of QA (150-225 nmol) may be more 
useful to study. Sanberg and Fibiger (1989) also 
reported d y s f u n c t i o ~ i n n metabolism, such as 
weight loss or feeding. QA doses of 150 nmol and 
225 nmol induced an initial weight loss, also seen 
with kainate lesioning. This was likened to the 
cachexia seen in HD, with increased appetite. This 
weight loss has been postulated to reflect increased 
calories used in the dyskinesia, but this hypothesis 
has not been substantiated, and indeed the weight 
loss could reflect a metabolic dysfunction such as 
altered fat metabolism. Further evidence regarding 
behavioral deficits comes from studies involving the 
nucleus basalis. unilateral injection of' (120 nmol) 
QA into this region was shown to produce decreased 
cortical choline acetyltransferase activity together 
with memory impairment (radial maze test) (Beninger 
et al., 1986). 
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6.2.5 QA as an animal model for temporal lobe 
epilepsy 
Seizures have been induced in rats by the 
administration of systemic, intra-ventricular or 
intra-hippocampal excitatory amnio acids (including 
ibotenate, kainate or QA) (Schwarcz and Kohler, 
1983). Initially kainate was thought to provide the 
best model as it selectively damaged the pyramidal 
cells of the hippocampus, which are affected in 
temporal lobe epilepsy. The effects of kainate 
lesions were reduced by prior hippocampal 
d e a f f e r e A ~ ~ J r ~ ~ w h i c h h has a similar action to temporal 
lobotomy used in extreme cases of the disease. 
Ibotenate lesions showed neither of these 
characteristics; furthermore, kainate produced 
neuronal degeneration at sites distant to the 
hippocampus, unlike epilepsy. Thus, a convincing 
animal model was not evident using kainate or 
ibotenate (Schwarcz et al., 1984b). Evidence from 
studies using QA suggest that its excitotoxic 
properties provide a better animal model for 
temporal lobe epilepsy. Intra-hippocampal 
injections of > 500 nmole QA resulted in generalised 
convulsions and 30 nmole QA produced the selective 
losses of pyramidal cells, buf without lesions 
distant from the injection site (Schwarcz and 
Kohler, 1983). 
6.2.6 Neurological disorders possibly' associated, 
with excitotoxins 
other clinical states postulated to involve 
excitotoxic damage include glutaric aciduria-I (GA-
l), stroke, motor neurone disease, hypoglycaemia, 
febrile convulsions and Alzheimer's disease.QA may 
be involved in the recessive, neurodegenerative, 
dyskinetic disorder, GA-I (Heyes, 1987), which bears 
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some resemblance to HD, both clinically and 
neuropathologically (Goodman et al., 1977). 
Pathological changes include atrophy of the putamen, 
caudate and cortex, as in HD, and clinical symptoms 
may include dystonia, chorea, athetosis and speech 
dysarthia. The precursor of QA, ACMS, also forms an 
alternative pathway, to form glutaric and glutaconic 
acids (lysine metabolites). As there is a· 
deficiency of glutaryl-CoA dehydrogenase and 
glutaconyl-CoA decarboxylase, there is increased 
excretion of glutaconic, glutaric and 3-
hydroxyglutaric acids and glutarylglycine. This 
enzymatic deficiency would be expected to result in 
increased metabolism of ACMS to QA, thus it has been 
hypothesized that increased brain QA may be having 
aetiological neurotoxic effects (Heyes, 1987). 
Brain QA has not been determined, however a possible 
animal model can be used, where ACMS decarboxylase 
is blocked by pyrazinamide in rats, thus causing a 
flux through the QA pathway. Furthermore, systemic 
tryptophan-loading, which normally results in 
increased cortical QA, has twice the effect with 
pyrazinamide pretreatment (Heyes, 1987). Further 
support for an aetiological role for QA in GA-I is 
provided by Heyes et ale (1989a). cortical QA and 
3HKconcentrations are increased following 
infection, in the mouse, which was suggested to be 
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consistent with neurological deterioration in GA-I 
occurring at times of infection. A possibly related 
disorder, Rett's syndrome, has also been linked with 
disturbance of glutaric acid metabolism (Chaves-
Carballo, 1987). Evidence suggests that hypoxic-
ischaemic neuronal damage may be mediated via the 
same receptor as QA and prevented by the same 
antagonists (Simon et al., 1984; Germano et al., 
1987). Furthermore, the s ~ m e e pattern of cell .loss 
produced by QA is seen in the hypoxic-ischaemic 
animal model, induced by carotid ligation {Ferriero 
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et al., 1988). Similar mechanisms have been 
suggested to be involved in hypoglycaemia-induced 
neuronal damage (Simon et al., 1986; Wieloch et al., 
1985) and QA has also been implicated in the 
production of febrile convulsions (Legidio et al., 
1988). A possible role for QA in Alzheimer's 
disease (AD) has also been postulated in view of the 
sensitivity of the nucleus basalis to neurotoxic 
damage; these neurones are known to be lost in AD. 
Injection of QA into this area in rats produced 
neuronal losses accompanied by memory deficits 
(Beninger et al., 1986). 
6.3 Neuropharmacological actions of QA 
Evidence suggests that there are two types of 
excitatory amino acid receptors: NMDA (N-methyl-D-
aspartate) and non-NMDA. Kainate and quisqualate 
are thought to act through non-NMDA receptors and QA 
actions have been suggested to be mediated via the 
NMDA receptor (Watkins and Evans, 1981; Ganong and 
Cotman, 1986). 
6.3.1 NMDA receptors 
NMDA receptors are distributed throughout the brain, 
with the CAl region of the hippocampus having the 
greatest density in both rat and man, followed by 
specific layers of the cortex, basal ganglia, septum 
and amygdala (Monaghan and Cotman, 1985). They are 
structurally complex, with many potential sites of 
action and exist in two conformational states: 
resting and activated. Several binding sites have 
been demonstrated to co-localize with NMDA 
receptors, one example being the strychnine-
insensitive high-affinity glycine site. Glycine has 
been shown to increase the frequency of NMDA 
receptor channel opening possibly involving 
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allosteric regulation via a separate site (Foster 
and Kemp, 1989), thus allowing increased binding to 
the site within the channel. Kleckner and 
Dingledine (1988) suggested that glycine and 
glutamate acted as co-agonists as both were vital 
for NMDA receptor response, whilst Mayer et ale 
(1989) demonstrated that glycine inquced faster 
recovery from desensitization. Foster and "Kemp 
(1989) suggested that the action of glycine may be a 
combination of both effects. Furthermore, ~ s e r i n e e
produces similar modulatory effects to glycine (Wood 
et al., 1989). Procter et ale (1989) demonstrated 
impaired coupling between the glycine site with the 
agonist site and a site within the channel, in the 
cortex in AD. They postulated that the 
physiological function of glycine may be relevant in 
this and other neurodegenerative disorders. 
Consequently glycine antagonists, at this site, such 
as HA-966 or kynurenic acid (KA), may provide useful 
tools for the manipulation of NMDA effects in these 
diseases. Another site co-localized with NMDA 
receptors is the phencyclidine (PCP) receptor. PCP 
(as well as KA,' MK801, SKF10047, ketamine,,,J.-
aminoadipate, tetrahydroaminoacridine) act as non-
competitive antagonists within the open channel of 
the NMDA complex (Watkins a n d ~ O l v e r m a n , , 19'51; Kemp 
et al., 1987; Davenport et al., 1988). A sigma-
opiate receptor (now called sigma receptor) was 
thought to be associated with the PCP site and thus 
the NMDA receptor. However recent evidence suggests 
that they are anatomically separate and are defined 
by non-dopaminergic haloperidol, DTG and +3PPP 
binding. They have a different localization to NMDA 
receptors, but agonists f9r sigma sites have effects 
at NMDA sites (Itzhak and stein, 1990; Weissman et 
al., 1988). Divalent cations (e.g. magnesium, 
calcium and zinc) are a further group of non-
competitive antagonists of NMDA receptors. They are 
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thought to act by physically blocking the open 
channel, which may also interact with PCP site 
antagonists (Kemp et al., 1987; Peters et al., 
1987). There are competitive antagonists that act 
at the agonist site of the NMDA receptor, preventing 
receptor activation. These include D-AP5, D-AP7 and 
CGP39653. A further site is a polya,mine site (e.g. 
spermidine). Spermidine has been shown to "enhance 
glutamate at a site distinct from NMDA or glycine 
receptors (Ransom and Stec, 1988). Ethanol has also 
been shown to act as an antagonist and Hoffman et 
al. (1989) suggested that it acts on the co-agonist 
(glycine site) rather than the PCP site. other 
antagonists whose mechanisms are unknown, include 
glutathione and ascorbic acid (Majewska et al., 
1989). 
Young et al. (1988) determined NMDA, PCP and 
quisqualate binding in HD brain and controls. In 
the putamen NMDA receptor binding was reduced by 93% 
as compared to 55-67% losses for the other 
receptors. There were no changes in the cortex. 
The lack of correlation between PCP and NMDA binding 
was unexpected and unexplained. They suggested that 
the loss of NMDA receptors in the HD putamen could 
be due to neurotoxic neurodegeneration, or a primary 
defect in striatal NMDA receptors, or susceptibility 
due to defective energy metabolism. 
6.3.2 QA as an NMDA agonist 
There is much evidence supporting the theory that QA 
acts via NMDA receptors. Iontophoretical or 
peripheral (i.p.) application of QA caused 
excitation of the rat neocortex which could be 
blocked by specific NMDA antagonists (e.g. 2-APH) 
(Stone and Perkins, 1981; Perkins and stone, 1983a, 
1983b). These effects of QA have been demonstrated 
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to be regionally specific: thus the striatum, 
hippocampus and neocortex showed the greatest 
response and cerebellum and spinal cord, the least. 
Furthermore there was a difference between cell-
sensitivity to glutamate and QA, which could be 
predicted as glutamate does not act solely on NMDA 
receptors. However NMDA itself p r o ~ u c e d d a different 
profile to QA. Perkins and stone (1983c) 
hypothesized that there were sub-types of NMDA 
receptors (1 and 2 sites), with NMDAI only acted on 
by NMDA, and NMDA2 activated by both NMDA and QA. A 
consistent finding is the differential release of 
acetylcholine induced by QA and NMDA (Lehman, 1983). 
Garthwaite and Garthwaite (1987) showed that both 
the excitotoxic and neurotoxic properties of QA and 
NMDA were related to their relative affinities for 
NMDA receptors. Studies have shown young rats to be 
more sensitive to QA, having an excitotoxic 
threshold dose of 50 compared to 10000 (mg/kg i.p.) 
in adult rats (Czuczwar and Meldrum, 1982). It has 
been reported that doses of QA that induce 
neurotoxicity may not be convulsant, thus 
differential blockage of selective effects can b ~ ~
achieved (Schwarcz et al., 1984a: Vezzani et al., 
1989) • 
NMDA-mediated neurotoxicity is composed of two 
stages, the first, an initial acute sodium entry, 
accompanied by entry of water resulting in swelling 
and eventual cell lysis. The later stage involves 
calcium influx into the cell which triggers cell 
degeneration. The consequences of this include such 
effects as activation of proteases and 
phospholipases, increased, formation of free 
radicals, swelling of the mitochondria and golgi and 
cytoplasmic damage and aggregation of the nucleus 
(Choi, 1990: Garthwaite, 1990). Swelling is not a 
prerequisite for neurotoxicity; Rothman and Olney 
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(1987) hypothesized that neurotoxicity is related to 
calcium influx through agonist-gated channels 
(especially NMDA), causing mitochondrial 
dysfunction, lipase activation and increased NMDA 
receptor activity. Evidence supporting these 
theories comes from studies made by Kim and Choi 
(1987). Using cortical slices, they showed that QA 
could induce an acute, sodium-dependent excitotoxic 
cell swelling, and a late calcium-dependent 
neurodegenerative stage. However, Vezzani et al. 
(1988) studied the role of calcium on the 
neurotoxicity and convulsant properties of QA, in 
the rat hippocampus. Calcium entry into the cell 
often precedes the onset of seizures and is also 
associated with the activation of NMDA receptors. 
Their results indicated that a decrease in 
extracellular calcium, and thus an inward calcium 
current, was associated with QA-induced seizures. 
Treatment with drugs that block seizures 
(carbamazepine, flunarizine) were shown to prevent 
the extracellular calcium decrease. Contrary to 
this, the neurotoxic effects of QA were unaffected 
by calcium concentrations. Both the neurotoxic and 
excitatory effects were blocked by 2APH, 
demonstrating that NMDA receptors are involved 
although through different mechanisms. Thus they 
postulated that calcium influx may be a causative 
factor in temporal lobe epilepsy induced"by 
excitatory amino acids. 
Schwarcz et al. (1984b) postulated ari extra 
presynaptic role for QA suggesting that it might act 
at a presynaptic receptor causing the release of 
endogenous transmitter (e.g. glutamate), which then 
acts on the post-synaptic,NMDA. This theory is 
consistent with reports that afferent projections 
are necessary for QA neurotoxicity. Connick and 
stone (1989) provides further support for a 
presynaptic site. QA stimulates excitatory amino 
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acid release and purines suppress it, and as co-
injection of a purine agonist 
(phenylisopropyladenosine, PIA) protects against QA 
neurotoxicity, this may explain the mechanism of 
protection. PIA is also a vasodilator and systemic 
administration paradoxically potentiated QA. They 
explained this as having induced hyp.otension, which 
interacted with cells already damaged by QA 
resulting in increased neuronal degeneration. 
6.3.3 Pharmacological antagonism of QA 
Specific NMDA antagonists can attenuate or block the 
effects of QA. 2APH and 5APH were the first 
competitive antagonists demonstrated to prevent QA 
induced seizure and neurotoxicity. However these 
compounds were of limited value as they showed 
limited uptake into the brain and were inactive when 
given orally (Schwarcz and Meldrum, 1985). 
Potentially more promising was the evidence 
suggesting that another endogenous kynurenine 
metabolite, KA, blocked neurotoxicity and seizures 
induced by QA, in striatum and hippocampus of rats 
(Foster et al., 1984b). They showed morphologically 
and neurochemically, that co-injection of KA 
preferentially blocked the effects of QA, when 
compared with effects of other acidic amino acids 
(including NMDA). They suggested that KA and. QA 
share the same functional pattern and maybe linked 
functionally as well as metabolically. Further 
evidence from Beninger et al.(1986) demonstrates the 
protective role of KA, in preventing memory and 
neuronal losses induced by QA in the nucleus 
basalis. They and others (Foster et al., 1984b) 
have postulated that a change in the balance between 
QA and KA may be important in neurodegenerative 
disease. In particular, that KA may be relatively 
decreased in HD (Stone and Connick, 1985). A 
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further effect of KA was shown to be the attenuation 
of infarct size and locomotor deficits in an animal 
model of stroke, after pretreatment (Germano et al., 
1987). 
Systemic administration of the non-competitive 
antagonist MK801 has been shown to prevent QA-
induced neurotoxic damage, and also seizures but at 
a lower threshold dose suggesting only partial 
blockade of the NMDA receptor (Kemp et al., 1 9 8 7 ~ ~
Vezzani et al., 1989). They also reported that 
alpha-1 adrenoreceptors have been suggested to play 
a role in the anti-convulsant action of MK801, and 
QA-induced seizures can be inhibited by their 
activation. MK801 showed easy uptake into the 
brain, but at low doses induced motor impairment and 
it has also been reported to protect against 
ischaemic neurodegeneration in the gerbil 
hippocampus (Foster et al., 1987). Studies have 
also shown systemic ketamine to provide incomplete 
protection against QA, blocking excitation only 
(Lees, 1987), whereas dipicolinic acid (an analog of 
QA) provided complete protection (Boegman et al., 
1986). Systemic pretreatment with GM1 ganglioside 
was shown by Lombardi et ale (1989) to protect 
against QA neurotoxicity, however this is not 
thought to have an action at NMDA receptors and they 
hypothesized that it may be incorporated into cell 
membranes, preventing excitoxic neurodegeneration. 
6.4 Methods of measuring OA metabolism 
6.4.1 Enzymes involved in OA synthesis or metabolism 
QA metabolism can be described either by assessing 
the synthetic and metabolic enzyme activity, or by 
measuring QA concentrations. The presence and 
characterization of 3HAO in rat brain was 
demonstrated by Foster et ale (1986b) using a 
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radioenzymatic assay. This involved the production 
of (14 C) QA from (carboxy_14 C) 3HAO. Further 
localization of brain 3HAO was carried out using 
immunohistochemical techniques using anti-3HAO 
antibodies raised against purified liver 3HAO 
(Kohler et al., 1988a). The radioenzymatic assay 
described above has been applied to .. brain tissue 
from patients with HD (Schwarcz et al., 1988a). 
Results show 3HAO to be significantly increased in 
HD brains, especially in the putamen and caudate, 
but in most other areas also. There was no 
correlation between neuropathology and 3HAO 
activity. It was suggested that this increase was 
merely reflecting astrogliosis, although less 
atrophied areas still showed this increase in 3HAO 
activity. 
QPRT has been purified from rat liver and brain and 
characterized (Okuno and Schwarcz, 1985). Again a 
radioenzymatic assay was used in rat and human brain 
which determined QPRT activity by measuring the 
formation of (3 H) NAMN from (3 H) QA (Foster et 
al., 1988). SiEilar immunohistochemical 
localization, as described for 3HAO above, was 
carried out and here too the radioenzymatic assay of 
QPRT activity was measured irrHD brain tissue 
(Foster et al., 1985). Results demonstrated that 
the activity of QPRT was not significantiy increased 
in caudate or putamen of HD brain, although there 
was a 'trend',towards increased values, but only in 
the caudate. Preliminary data further extended this 
lack of difference to the s.nigra, hypothalamus, 
cerebellum and cortex. Kish et al., (1991) recently 
reported increased cerebellar activity of QPRT (but 
not 3HAO, and not significantly changed in the 
cortex) in brain tissue from patients with 
dominantly inherited olivopontocerebellar atrophy. 
They suggested that this may be a marker for 
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increased catabolism to remove QA from sensitive 
granule cells in this disorder. In brains from 
epileptics, QPRT activity has been found to be 
decreased in frontal and temporal cortex, but not in 
the amygdala or Ammon's horn (Feldblum et al., 
1988). The effect of this was hypothesized to 
create or maintain an epileptic f o c ~ s . .
6.4.2 QA concentrations in the periphery and 
cerebrospinal fluid 
concentrations of QA were first determined in tissue 
and body fluids, using assays that were not 
sensitive to measure brain levels. Early techniques 
for estimating urinary QA involved a microbiological 
method (Henderson and Hirsch, 1949), paper 
chromatography (Jakoby and Bonner, 1951), ion-
exchange followed by colorimetric detection (Heeley 
et al., 1966) or gas-liquid chromatography 
(Toseland, 1 9 6 ~ ) , , thick-layer chromatography 
(Crawford et al., 1 9 7 ~ ) , , high performance liquid 
chromatography (HPLC) and spectrophotometric 
detection (Patterson and Brown, 1980). Human urine 
concentrations of QA/24 hour varied from 25 ~ m o l e s s
(Patterson), 36-78 ~ m o l e s s (Toseland), and following 
a tryptophan load of 5 g, increased to 132-816 
~ m o l e s s (Toseland). Heyes et ale (1985) measured QA 
concentrations in urine from HD patients"and 
controls. Although there was significantly 
decreased QA/24 hours in the HD group as compared 
with controls (31 and 52 ~ m o l e s s respectively), the 
difference d i ~ e a r e d d when the data was corrected 
relative to creatinine and urea excretion. Using a 
radioenzymatic assay, Foster et ale (1986a) measured 
QA in both human urine and plasma (37 pmol/1 ~ l , , 21 
pmol/50 ~ l ) . . Perry et ale (1987) reported no, 
increased QA concentrations in urine, plasma and CSF 
of HD patients, which concurred with data from 
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Schwarcz et al. (1988b) in CSF, also measured by 
radioenzymatic assay. They showed CSF from HD 
patients to have not significantly changed 
concentrations of QA (20 nM) compared with 
schizophrenics (27 nM) and the control range (20-30 
nM). Furthermore, they described 'highly variable' 
QA concentrations in both diseases. .. Recent studies 
were also made involving other neurological 
conditions. QA concentrations showed a threefold 
increase in CSF from patients with AIDS and were 
increased in CSF and plasma in HIV infection (Heyes 
and Markey, 1989b; Heyes et al., 1990a, 1991a). 
There was a positive correlation between CSF QA and 
cognitive dementia and motor dysfunction. After 
treatment with an anti-AIDS drug, AZT (zidovudine), 
and anti-microbial therapy, QA CSF concentrations 
were reduced back to normal in association with 
neurological improvement. Furthermore in an animal 
model of AIDS (Heyes et al., 1990b), CSF KA 
concentrations were increased, but to a lesser 
degree than QA levels. Acute septicemia was also 
reported to result in increased CSF QA, KA and 
kynurenine in animals (Heyes and Lackner, 1990). 
6.4.3 QA concentrations in the brain 
The first identification of QA in the rat and human 
brain was made by Wolfensberger et al.(1983) using 
the ion-exchange method described by Chandler and 
Gholson (1972), followed by HPLC as used by 
Patterson and Brown (1980), prior to derivatization 
and detection using electron impact gas-
chromatography/ mass-spectrometry (GC-MS). 
Concentrations (fmol/mg wet weight) in the human 
brain were 369 (caudate), 567 (frontal cortex), 576 
(cerebellum), which were not found to be 
significantly different from each other. In rat, 
concentrations were 739 (striatum), 1584 (frontal 
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cortex) and 434 (cerebellum), demonstrating a 
difference between species. Later work by Moroni et 
al. (1984a) confirmed the presence of QA in rat 
brain (at similar levels to Wolfensberger) using an 
electron impact GC-MS method; and also in human 
cortex (0.5-0.8 nmol/g wet weight) (Moroni et al., 
1986a, 1986c). The most recent GC-MS method used to 
measure QA involved the use of electron-capture 
negative chemical ionization (CI), which was 
described as being more specific than the usual 
electron impact (EI) methods used previously. 
Furthermore that the use of ( 18 0) QA was a more 
accurate, more suitable internal standard than 2,4 
pyridine dicarboxylic acid used by Wolfensberger and 
Moroni (Heyes and Markey, 1988a, 1988b). In rat 
frontal cortex, Heyes demonstrated a range of 20-180 
fmol/mg QA, with no regional variability throughout 
the rest of the brain. This contrasts with the 
Wolfensberger or Moroni data, which gives a range of 
500-2000 fmol/mg. Heyes ascribed this difference to 
increased specificity and sensitivity. Intra-
striatal microdialysis with GC-MS was the most 
recent method used to monitor extracellular fluid 
(ECF) levels of QA (Speciale et al., 1989b; During 
et al., 1989b). Speciale et al. were only able to 
measure ECF QA levels after loading experiments 
(tryptophan, 3HA, kynurenine) due to the limit of 
sensitivity of their method (20 nM), which was based 
on the radioenzymatic assay of Foster et al.(1986a). 
Heyes and Markey (1988a, 1988b), using their new 
improved CI GC-MS method demonstrated ECF QA levels 
of 5.5 nM, which rose after loading with tryptophan 
and QA. The effects of loading were described 
previously. 
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6.4.4 Clinical measures of QA concentrations in the 
brain 
Moroni et al. (1984b) examined the distribution of 
QA in the rabbit and guinea pig brain; QA was shown 
to be similarly distributed in all the mammals. An 
increase in QA with age was demonstr,ated, this 
reaching almost neurotoxic levels at 30 months. 
This was explained to be partially due to the 
decrease in brain extracellular water, occurring 
during maturation, as QA was expressed /g wet 
weight. A further conclusion reported was that 
newborn rats cortex did not possess the capacity to 
produce QA, further illustrated by the lack of 
effect tryptophan loading has in the brain of 
newborn rats. In the 30 month rats, QA showed a 
particularly large variability, which had previously 
been reported by Wolfensberger et al. (1983). A 
further study by Moroni et al. (1986C) assessed QA 
concentrations in the cortex of patients with AD and 
age-matched controls, to examine the hypothesis that 
increased QA may cause neuronal degeneration in AD. 
Their results demonstrated that QA concentrations in 
three areas of the cortex, showed no difference 
between AD and controls, thus providing evidence 
against the hypothesis. It was suggested that it 
may still be of relevance to measure QA in other 
regions, where there are specific cell deficits in 
AD, such as the hippocampus and nucleus basalis 
(Ball et al., 1985). The lack of change in the 
brain in AD is important, as if QA is increased in 
the brain in HD, these results provide evidence that 
the effect is not merely reflecting tissue atrophy. 
A further finding was that there was no relationship 
between cortical QA and the severity of AD, or with 
age (in contrast with the effect of age on QA 
concentrations in rats). The only studies of brain 
QA that provided positive results, were experimental 
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models of hepatic encephalopathy in the rat (Moroni 
et al., 1986b) and patients with hepatic failure 
(Moroni et al., 1986a). Rats bearing a portocaval 
anastomosis (PA), so that the blood bypasses the 
liver, were demonstrated to have increased QA 
concentrations in the cortex and cerebellum (75% and 
125% respectively, compared with c o n ~ r o l s ) . . 5HT was 
increased only in the brainstem, but 5HIAA was 
increased throughout the brain, reflecting increased 
metabolism of 5HT. Probenecid (a blocker of acid 
transport systems) inhibits QA transport mechanism 
and caused a twofold increase in control cortical 
QA. However in PA animals, probenecid surprisingly 
failed to cause this increase, although it did 
result in even greater 5HT metabolism. An 
aetiological role for tryptophan was suggested by 
Moroni, since tryptophan concentrations are 
increased in plasma and brain in models of hepatic 
encephalopathy (Martin et al., 1983) and tryptophan 
loading causes hepatic coma in dog models of hepatic 
encephalopathy (Ogihara et al., 1966). There were 
similar findings in brain tissue from patients with 
hepatic failure, wi-\:..'" a massive increase in CSF QA 
(sevenfold) and frontal cortex (threefold) as 
compared to controls. Two cortical levels were 
approximately 0.01 mM which is known to be 
neurotoxic in cultures (Whetsell, 1984). Like the 
animal models,' tryptophan administration "aggravated 
the hepatic coma and neurological symptoms (Sourkes, 
1978). Further evidence suggested that 
administration of branched chain amino acids proved 
to be therapeutically useful in hepatic disease, as 
brain tryptophan levels were reduced (Rossi-Fanelli 
et al., 1982). Rats with hypoglycaemia have also 
demonstrated increased concentrations of QA in the 
brain and plasma (Heyes et al., 1990c). Increased 
concentrations of brain and blood QA have also been 
described in Lyme disease and meningitis and in a 
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chronically stimulated immune system (after 
administration of interferon) (Saito et al., 1991). 
6.5 Our method for the determination of brain QA 
concentrations 
The aim of our study was to investigate QA in the 
brain in HO, to provide evidence as to whether an 
increase in brain QA could be an aetiological factor 
in HO. QA concentrations were measured using a 
modification of previous GC-MS methods 
(Wolfensberger et al., 1983; Moroni et al., 1984a, 
1986a). Concentrations were determined in the 
putamen and frontal cortex in tissue taken post-
mortem from neuropathologically confirmed cases of 
HO and matched controls with no history of neuro-
psychiatric disease, supplied by the Cambridge Brain 
Bank. preparation and storage of tissue was as 
described previously (Spokes, 1979). All groups 
were matched for age, sex and post-mortem delay 
(Table 6.1). Statistical comparisons were made 
using Student's t-test on logarithmically-
transformed data and Kendall's rank correlation. 
6.5.1 Modification of previous GC-MS methods: 
The method of Wolfensberger et ale (1983) was used 
initially, but this proved unsuccessful so each 
stage of the extraction and derivatization were 
tested. 
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Table 6.1 
Details of subjects providing brain tissue post 
mortem: guinolinic acid 
Age Sex Postmortem 
(years) (hours) 
Controls 65 ± 10 5M 4F 44 ± 31 
Huntington's 64 ± 9 4M 5F 30 ± 26 
disease 
.. 
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6.5.2 Internal standard 
An internal standard (IS) was used to increase the 
accuracy of the assay. Pyridine 3,4-dicarboxylic 
acid was tried, but this compound did not show the 
same derivatization properties as QA, whereas 
pyridine 2,4-dicarboxylic acid was found to act more 
like QA, and thus was employed. Concentrations of 
QA were calculated from the ratios of peak areas of 
QA and IS (respective retention times 5.6 and 4.8 
min. using GC-MS). 
6.5.3 Homogenization 
Initially a variation on the Wolfensberger et al. 
(1983) method was used: 0.1 M perchloric acid (PCA) 
followed by rehomogenization in 0.1 M f\'\ <3. 4-
disodiumhydrogen phosphate buffer (PB) resulting in 
approximately neutral pH. However QA was shown to 
remain in the pellet after centrifugation, even with 
rehomogenization (only 60% recovery of standards). 
Next 1% acetic acid was added to both the PCA and PB 
to displace QA in the pellet. This proved to be 
better (90-100% recovery), but elution produced a 
precipitate and wet residue which was impossible to 
dry. down. This was s u g g e s t e d ~ t o o be due to the PCA 
perhaps adhering to the column and then eluting in 
an insoluble form. Thus, other forms of" 
homogenization were tested. Moroni et al. (1984a) 
used 0.3 M formic acid and this, followed by 
rehomogenization with 0.1 M PB, was found to be 
optimal. It was shown to produce no precipitate and 
dried down easily. 
6.5.4 Extraction 
The extraction of QA was tested initially using 
large (5-25 ~ g ) ) amounts, and the efficiency was 
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monitored using either a spectrophotometer 
(wavelength = 275 nm: absorbance = 1) or a gas 
chromatograph with flame-ionization detection (GC-
FlO: 3% OV17 2 M column: GCQ support: 115°C: 
nitrogen = 13, hydrogen = 16, air = 10 psi). Pre-
derivatisation purification of samples was necessary 
to remove any contaminants before injection into the 
GC-MS. Various processes were tested in order to 
selectively extract QA or IS, whilst allowing 
further purification stages to be applied. Ether 
and chloroform were found not to extract QA or IS at 
all. Solid phase extraction columns (Bond Elut 1 ml 
or 2.8 ml column volume) were also tried (NH2, C18, 
SAX): only the strong anion exchange (SAX) column 
was of use for the extraction of QA and IS. The 
application of standards to these columns resulted 
in negligible recovery, illustrating attachment to 
the column, whereas the other columns resulted in 
100% recovery on the initial run through. 
Eventually a general washing procedure whilst QA and 
IS adhered to the SAX column, followed by specific 
elution, meant that further purification stages 
(e.g. passing through a C18 column first) were 
unnecessary. 
Priming the column: methanol wash, followed by full 
blank extraction, followed by water wash, was found 
to produce ideal conditions for recoveryPof 
standards. This procedure was shown to remove 
interfering contaminants that produced abnormally 
increased recovery of standards (100-140%) from SAX 
columns. 
6.5 5 Elution 
Wolfensberger et ale (1983) used 0.1 M hydrochloric 
acid to elute the QA and IS from the column, which 
we tried initially (producing 94-100% recovery of 
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standards and samples, in a discrete volume}. 
However, the wet residue and precipitate described 
earlier were impossible to dry down, therefore other 
protocols were tried in order to eliminate these 
problems. Methanol (50-100%) was used but produced 
negligible recoveries, as did acetic acid/ methanol 
combinations. Moroni et al. (1984a,,1986b) reported 
using 5 M formic acid, which proved more successful, 
especially in combination with methanol. varying 
concentrations were tried, but 20% 1 M formic 
acid/80% methanol produced the best results for 
discrete elution in a small volume (1 ml). 
Recoveries varied from 100-140%, which prvided a 
further problem as there appeared to be increased 
concentrations of standards after passing through 
the column. This effect was negated by putting the 
column through a full blank extraction (no tissue, 
no standards) and 100% recoveries were achieved with 
such primed columns. It was found to be necessary 
to "make the eluting solution fresh every day, as 
reduced recoveries (20%) were found to occur with 
old solutions. The columns were washed with water, 
0.1 M formic acid, 25, 50, 80% methanol to remove 
any general contaminants prior to specific elution. 
6.5.6 Transfer of eluate 
The transfer of dried down eluate from plastic 
microtube to reactivial proved a difficult task and 
many different solvents were tested and appraised. 
Wolfensberger et al. (1983) reported using methanol, 
but in our hands there were was a loss of the 
standards or samples (recovery of 50%). 
Derivatization reagent solution was then tried with 
no success (30% recovery). Ammoniacal methanol or 
20% formic acid/80% methanol were both tried 
producing more acceptable recoveries (84-100%). 
Ammoniacal methanol was used routinely as it was 
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found to be easier to dry down after transfer. 
However, there was a further problem with a white 
precipitate after transfer (associated with column 
elution). Eventually, to avoid any transfer losses, 
half of the eluate was dried directly in the 
reactivial, repeating the process with the 
remainder. 
6.5.7 Derivatization 
Wolfensberger et ale (1983) used 100 ul 
pentafluoropropionic anhydride (PFA) and 100 ul 
1,1,1,3,3,3-hexafluoroisopropanol (HFIP) to 
derivatize for 4 hours at 80°C. In our hands, this 
was found to produce inconsistent, incomplete 
derivatization. This was thought to be due to 
variables such as the time of reaction, temperature, 
tubes used, the type of reagent or the volume of 
reagent used. Thus each of these parameters was 
tested until optimal conditions were created for 
derivatisation. Moroni et ale (1984a) used HFIP in 
the presence of trifluoroacetic anhydride (TFAA) at 
60°C for 1 hour', but this too resulted in low 
recoveries and inconsistencies. A time course 
tested derivatisation at 60°C and 110°C with maximal 
responses at 2 hours and 1.5 hours respectively. 
However, the higher temperature produced a greater, 
more consistent response, therefore this"was used 
routinely. At this high temperature problems were 
encountered from leaky reactivials and distorted 
teflon seals and gas chromatography seals (due to 
the high internal pressure), which resulted in the 
solution drying out during derivatization. A 
combination of reactivials and three types of seals 
were eventually optimized. The effect of altering 
the volume of reagent was examined in order to 
reduce the pressure within the reactivial; the 
greater the volume used, the better response (with a 
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maximal effect with 100 ~ l ) . .
6.5.8 Injection medium 
Wolfensberger et al. (1983) used toluene to inject 
into the GC-MS, we tried heptane (50 ~ l ) ) initially. 
There was a problem with 'dirty' samples and water 
(25 ~ l ) ) was used to try to remove the 'dirt' into 
the aqueous layer. Latterly, heptane was used with 
0.1 M ammonia present, as this combination was shown 
to reduce the solvent front and increase the 
response on the GC-MS. Conditions of the GC-MS were 
as follows: 1 ~ l l solution was injected; 15 M x 0.32 
mm chemically-bonded OV1 column at 120°C and a mass 
spectrometer to determine the ions at m/z 272, 300 
and 448. The GC-MS analyses were carried out 
courtesy of Queen Charlotte's Hospital, London by 
John Halket. 
6.5.9 Final method used: 
Using 2,4-pyridine dicarboxylic acid as the IS, 
tissue (200 mg)' was homogenized in 0.5 ml 0.3 M 
formic acid and centrifuged at 12000 g for 3 
minutes. The pellet was resuspended in 0.5 ml PB 
(0.1 M, pH 9.4) and recentrifuged. The combined 
supernatants were centrifuged at 50000 g for 10 min 
and applied to a prewashed SAX column. After 
washing with consecutive 2 ml vols of water, 0.1 M 
formic acid and 25%, 50% and 80% methanol, QA and IS 
were eluted with 1 ml formic acid/methanol (20:80 
v/v). This mixture was dried in a stream of 
nitrogen and derivatized by heating for 90 minutes 
at 110°C with 50 ~ l l HFI and 50 ~ l l TFA. This was 
dried under nitrogen and the derivatives dissolved 
in 50 ~ l l heptane with 25 ~ l l ammonia (0.1 M), prior 
to injection of 1 ~ l l into the GC-MS (VG 7070 with 
Hewlett Packard mass selective detector) • 
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6.5.10 Validation of method 
concentrations of QA were compared with results from 
a calibration curve, obtained by addition of QA (10-
100 ng) to aliquots of a tissue homogenate and taken 
through the above procedure. Ordinary extracted and 
unextracted standard curves were also made. Multi-
ion values were measured (m/z 272, 300 and 448) to 
assess the reproducibility of the method and blank 
extractions were run in each batch of samples. 
Standard curves were also produced for the 
spectrophotometer and GC-FID, whilst working up the 
method. 
6.6 Results 
6.6.1 Validation of extraction method 
Linear standard curves were obtained for both the 
spectrophotometer and GC-FID for increasing 
concentrations of QA. Thus the efficiency of 
extraction and derivatization of large 
concentrations of QA was verified. 
6.6.2 Validation of GC-MS method 
Linear standard curves were produced for"unextracted 
and extracted standards and for standards added to 
tissue. The extracted standards bore a closer 
relationship to the spiked tissue curve, than to the 
unextracted curve, therefore the QA concentration in 
tissue was calculated in reference to the spiked 
tissue calibration curve. Recovery of standards 
added to tissue in the calibration curve provided a 
measure of the prec1s1on of the method, with a 
coefficient of variation of 13%. 
165 
r 
r 
.... 
0'1 
0'1 
Table 6.2 
Quinolinic acid concentrations in the brain in Huntington's disease 
Values are means ± s.d. in ng/g tissue. Range in parentheses. 
Controls 
Huntington's disease 
! 
Putamen Frontal 
94 ± 37 
(24 - 314) 
118 ± 31 
(16 - 371) 
cortex 
48 ± 26 
(22 - 149) 
65 ± 19 
(11 - 149) 
Figure 6.2 
Correlation of quinolinic acid concentrations in the 
striatum and the cortex 
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6.6.3 QA concentrations in the brain in HD 
Our results (Reynolds et al., 1988; Pearson and 
Reynolds, 1989) in Table 6.2 show that there is no 
significant difference in QA concentrations in HD or 
in controls, in either the putamen or the cortex. 
Furthermore there was no significant correlation 
with age, sex, post-mortem delay, nor within the HD 
group with duration of the disease. A significant 
positive correlation (p < 0.01) was shown between QA 
concentrations in the putamen and the cortex, 
indicating a consistency \ N \ + ~ \ r . . . each brain (Fig. 
6.2). However there was a wide variation evident in 
brain QA between individuals. There was no 
significant correlation between QA and 5HT 
concentrations in the putamen. 
6.7 Discussion 
The results indicate that there is no significant 
increase in QA in HD reflected by post-mortem 
concentrations in the brain. Thus this provides no 
support for the hypothesis that increased QA is 
responsible for the neurodegeneration of HD. This 
finding is consistent wth CSF, urine and plasma 
measures of QA in HD (SchwarcE et al., 1988b; Heyes 
et al., 1985; Perry et al., 1987), none of which 
were increased above control values, although 
peripheral values, (see section 6.4) are unlikely to 
reflect brain values. Bruyn and Stoof (1990) 
observed that the 3-fold increase in QA 
concentration in AIDS CSF (Heyes et al., 1989b), 
provides further evidence that increased QA does not 
have an aetiological significance in HD. However 
the possibility of neurotoxic effects due to 
previous transient increases in QA cannot be 
excluded, especially in view of evidence (see 
section 6.3) that chronic exposure to only slightly 
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hyper-physiological levels of QA resulted in 
neurotoxic damage (Whetsell and Schwarcz, 1989). It 
is notable that there is a wide variation in brain 
QA between individuals, an observation also made by 
Wolfensberger et al. (1983). The factor responsible 
for this variation must be understood before any 
definite conclusions can be made, re,garding the role 
of QA in the aetiology of HO. Oespite the-lack of 
change in brain QA in HO, there still remains 
evidence that the metabolism of tryptophan via 
kynurenine is abnormal in HO. The increased 
activity of 3HAO in HO brain (described earlier, 
Schwarcz et al., 1988a) is one example, although 
this has been postulated merely to reflect gliosis 
and not necessarily increased metabolism. stronger 
evidence comes from a study by Connick et al. (1989) 
that measures KA in the brain in HO. Their 
hypothesis was that decreased concentrations of KA 
could have an aetiological effect in HO, due to its 
opposing effects to QA. Therefore normal 
concentrations of QA could have a relatively 
potentiated effect. However their results 
demonstrated increased KA in the motor cortex in HO. 
Thus further study of this system is indicated to 
establish whether there is an overactive metabolism, 
especially as some of the intermediates are also 
neuroactive (Lapin, 1981). 
A recent report has just been published (Heyes et 
al., 1991b) that investigated the regional brain and 
CSF concentrations in HO. Their results are in 
concurrence with those from our study, as they found 
no significant changes in the putamen, cerebellum or 
frontal cortex (BA 10). However, there were slight 
reductions in most regions reaching significance in 
BA 17, 20, 28 as compared to control values •. CSF Q ~ ~
values were also reduced (but not significantly) in 
HO and two early stage patients had similar QA 
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concentrations to the other HD cases. This was 
described as evidence that an early transient 
increase of QA was unlikely, but altered metabolism 
was still a possibility. The great variability of 
QA in the brain and CSF in HD and controls was again 
identified, but there were no significant effects of 
age, sex or post mortem delay. A further study by 
Beal et al. (1990a) reported QA concentrations 
as not significantly changed in the striatum in HD. 
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Chapter 7 
Kynurenines 
7.1 Tryptophan metabolism via the kynurenine pathway 
7.1.1 Periphery 
The metabolism of tryptophan, via the kynurenine 
pathway results in the formation of nicotinamide 
dinucleotide (NAD) and nicotinic acid, as well as 
other associated compounds from metabolism of 
intermediates. Activity and function of this 
kynurenine pathway has been documented in the 
mammalian liver (Fig. 6.1). Initially tryptophan is 
oxidised to N-formylkynurenine involving the enzyme, 
tryptophan pyrrolase (also known as tryptophan 2,3-
dioxygenase). This process has been shown to be 
iron, copper and porphyrin dependent, as well as 
utilising molecular oxygen. The enzyme is inducible 
by tryptophan loading, corticosteroids a n d ~ ~
methyltryptophan (Sourkes et al., 1970), and can be 
inhibited by NADPH, via end product inhibition. N-
formylkynurenine can be metabolised to either 
kynurenine (using the enzyme, kynurenine formylase) 
or anthranilic acid. Kynurenine-hydroxylase 
catalyses the conversion of kynurenine to 3-
hydroxykynurenine (3HK), using NADP and molecular 
oxygen (Battie and Verity, 1981). Alternatively, 
kynurenine can form anthranilic acid using the same 
enzyme (kynureninase) that catalyses the further 
metabolism of 3HK to 3-hydroxyanthranilic acid (3HA) 
(Inada et al., 1984; Takeuchi et al., 1980; Kawai et 
al., 1988). Kynureninase is vitamin B6 dependent, 
as is kynurenine transaminase, the enzyme involved 
in the conversion of kynurenine to kynurenic acid 
(KA), as well as the production of xanthurenic acid 
from 3HK. There is further metabolism of 3HA, via 
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quinolinic acid (QA) , to NAD and nicotinic acid (see 
section 6.1) (stone and connick, 1985; Gal and 
Sherman, 1975). 
7.1.2 Brain 
There has been speculation as to whe,ther the same 
pathway exists (or indeed functions) in cerebral 
tissue. Evidence suggests that most of the 
necessary enzymes are present in the rat brain 
(Okuno et al., 1990; Kohler et al., 1988b; Schwarcz 
et al., 1988a; Battie and Verity, 1981; Kawai et 
al., 1988) and several intermediate compounds have 
been located (Moroni et al., 1988a, 1988b; Joseph et 
al., 1979; Guilarte and Wagner, 1987). Gal and 
Sherman (1978) made a study of kynurenine synthesis 
and metabolism in rat brain. They made 
intraperitoneal (i.p.) injections of radiolabelled 
tryptophan and demonstrated, for the first time, the 
presence in the brain of anthranilic acid, 3HA, 
xanthurenic acid, KA and quinaldic acid. Earlier 
work (Gal, 1974) suggested the presence in rat brain 
of a similar (but not identical) enzyme to 
tryptophan pyrrolase: indoleamine 2,3-dioxygenase. 
This brain enzyme appeared to respond to different 
factors, thus it was affected by tryptophan loading, 
but not cortisol. Also, the brain enzyme is 
reported to be nonspecific for tryptophan, having 
other substrates including 5-hydroxytryptamine 
(5HT), melatonin and 5-hydroxytryptophan (5HTP) 
(Stone and Connick, 1985). The question still 
remains as to whether the kynurenines present in the 
brain are being formed locally, or being transported 
from the periphery through the blood-brain barrier. 
Furthermore, anthranilic acid has been shown to be 
the preferred precursor for the production of 3HA, 
compared with 3HK, in the ~ a t t brain (Baran and 
Schwarcz, 1990). Also, anthranilate hydroxylase 
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(the enzyme catalysing the production of 3HA) has 
been identified in rat brain (Baran and Schwarcz, 
1990). 
Initial evidence suggests that kynurenine and 3HK 
are able to cross this barrier (stone and connick, 
1985), and furthermore, KA has been ,demonstrated to 
be synthesised in the brain (Swartz et al.; 1990b), 
from kynurenine transported across from the 
periphery. They used microdialysis techniques to 
assess whether KA was synthesised in situ in the 
brain, or whether it was transported from the 
periphery. Systemic administration of kynurenine 
(or tryptophan) was demonstrated to produce 
increased concentrations of KA in the rat brain. 
However, only kynurenine produced this effect when 
applied directly into the brain. They suggested 
that kynurenine (and not tryptophan) was the major 
precursor of KA, and was transported through the 
blood-brain barrier from the periphery. The effect 
could be blocked by using a kynurenine 
aminotransferase inhibitor. They also suggested 
that if the QA 'in the brain is not derived from 
local metabolism of kynurenine (but instead 
originates via the anthranilic acid/3HA pathway, as 
described above), then it may'be possible to reduce 
the peripheral kynurenine/QA pathway selectively by 
giving kynureninase inhibitors. Thus systemic QA 
effects could be reduced, and more kynurenine would 
be available for transport into the brain (thus 
increasing cerebral KA concentrations, if required). 
These general effects were consistent with findings 
(Speciale et al., 1990) that also demonstrated that 
administration of aminooxyacetate (the unspecific 
transaminase inhibitor) resulted in marked 
reductions of extracellular KA in rat brain. In 
addition, administration of kynurenine to the 
striatum resulted in increased concentrations of KA. 
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Furthermore, they suggested that intrastriatal 
injections of aminooxyacetate in rat can produce 
neurotoxic degeneration and seizures (similar to 
QA). They hypothesised that this was evidence for 
an indirect link between modulation of KA and 
excitotoxic damage. 
Speciale and Schwarcz (1990; et al., 1989a) studied 
the uptake of kynurenine into rat brain slices (and 
into astrocytes). They described two components of 
uptake: sodium-independent and sodium-dependent. 
The former was suggested to be using the high-
affinity saturable uptake transporter of neutral 
amino acids and was primarily localised to 
astrocytes. The latter non-saturable process was 
localised more in neurones, and regulated by 
extracellular sodium levels. Furthermore, 3HK was 
found to compete with kynurenine for uptake into 
cells (both with and without the presence of 
sodium) • 
More evidence comes from work by Fukui et ale 
(1991). They made an extensive study to determine 
brain uptake and blood-brain transport of 
kynurenines, to try to separate extra-cerebral 
synthesis from local metabolism in the rat brain. 
Their results indicated that kynurenine (and to a 
lesser extent 3HK) is taken up into the Drain via 
the large neutral amino acid carrier system (L-
system), and anthranilic acid via significant 
passive diffusion. However, peripheral 3HA, KA and 
QA were found not to cross the blood-brain barrier 
easily, therefore were suggested not to contribute 
to brain pools. Anthrani.lic acid (unlike 
kynurenine) was suggested to be affected by the 
amount of plasma protein binding. As described 
earlier, anthranilic acid has been shown to be the 
preferred precursor for 3HA in the rat brain. 
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Kynurenine has also been demonstrated to produce 
anthranilic acid in rat brain homogenates (Kawai et 
al., 1988) and they suggested that the activity of 
kynureninase (1.5% of liver activity) is reportedly 
low in rat brain (as is the activity of kynurenine 
hydroxylase). The optimal substrate for 
kynureninase is 3HK as compared with, kynurenine 
(15:1 activity ratio) (Kawai et al., 1988; -Inada et 
al., 1984; Inada et al., 1984; Battie and verity, 
1981). Okuno et ale (1991) described the presence 
of two kynurenine aminotransferases in the human 
brain, with different characteristics to each other, 
and to the similar enzyme identified in rat brain 
astrocytes (Okuno et al., 1990). These two enzymes 
both catalysed the production of KA, but had 
different sensitivities to amino acids, as well as 
different kinetic characteristics. 
Moroni et ale (1988a) demonstrated a circadian 
rhythm for KA in rat brain. Concentrations were 
three times greater at midday than at midnight. 
They also showed that brain KA levels were increased 
with age. A further study (Baran and Schwarcz, 
1990) examined the effects of administering an 
inhibitor of 3HAO (4-CI-3HA); they found rat brain 
concentrations of '3HA were increased. Heyes et ale 
(1989a) demonstrated that systemic tryptophan 
loading resulted in increased concentrations of 3HK, 
QA, 5HT and 5-hydroxyindoleacetic acid (5HlAA). A 
further report from Beal et ale (1991a) described 
results indicating that excitotoxic lesions produce 
increased brain concentrations of KA and increased 
responses to loading with precursor, on the 
formation of KA (Turski et al., 1989). 
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7.2 Neuroactive characteristics of kynurenines 
Many of the kynurenine metabolites exhibit 
neuroactive properties. Lapin (1981) made an 
extensive review of the subject, investigating the 
production of seizures following administration of 
some kynurenines. Intracerebroventricular injection 
of QA, KA , 3HK, and kynurenine produced seizures in 
mice (in order of potency, with QA having the lowest 
threshold value). 3HA, xanthurenic acid, nicotinic 
acid and pico1inic aoid were less effective, with 
anthranilic acid totally ineffective. Peripheral 
injections were generally not effective (except for 
QA), although immature animals were susceptible to 
i.p. administration. This was suggested to 
illustrate the difference in the permeability of the 
blood-brain barrier, which was also immature and 
therefore not a selective barrier. There were also 
qualitative differences in the response to 
individual kynurenines. Thus, kynurenine itself had 
a short latency and produced a charaoteristic unique 
myoclonus and locomotor hyperactivity unlike that 
produced by any of the other kynurenines. These 
myoclonic seizures were blocked using serotonergic 
drugs, which are also known to prevent myoclonus 
clinically (Magnussen et al.,'1977). Also, 
tryptophan has been used to prevent epileptic 
seizures, but the evidence has been contradictory as 
it appears both to inhibit and initiate fits. Lapin 
(1981) described this to be an example of the 
balance between the production of 5HT and the 
kynurenines. The effects of antagonists were 
considered; thus, the convulsant effects of 
kynurenine were selectively antagonised by taurine, 
less selectively by glycine, with GABA and muscimol 
having no effects (although the actions of 
traditional anti-convulsants were varied). The 
actions of administering 3HK, 3HA and KA were not 
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described quantitatively, although the effects of QA 
injections were compared with those of kynurenine 
(see section 6.3). Vecsei and Beal (1990) reported 
intracerebroventricular injections of kynurenine or 
KA in rats. They described ataxia and stereotypic 
behaviour with muscular hypotonia only after the KA 
injection, and slight behavioural ch,anges after 
kynurenine injection. A further study of . 
behavioural actions of KA was described by Schmitt 
et ale (1990). They injected KA into the dorsal 
periaqueductal gray matter of rats, where it was 
observed to have anxiolytic actions. AP7 was 
described as having similar actions. Lapin and 
Rysov (1990) investigated the effects of 
catecholaminergic drugs on QA and kynurenine-induced 
seizures. Kynurenine-induced seizures were 
demonstrated to be increased with anti-dopaminergic 
drugs (reserpine, haloperidol) and prevented with 
dopamine itself. However, QA-induced seizures were 
affected to a lesser degree by the anti-dopaminergic 
drugs, and not at all by dopamine. Also, 
apomorphine, amphetamine, noradrenaline, but not 
serotonin were all anticonvulsant for kynurenine, 
but not QA. Therefore each compound has its own 
particular profile and characteristic mechanisms. A 
further study by Lapin and Rysov (1989) suggested 
that kynurenine-induced seizures involve the GABA 
receptor, the strychnine-insensitive glycine site, 
and the picrotoxin-barbiturate subunit of GABA-
benzodiazepine-chloride channel compl'ex. Guilarte 
et al. (1987) reported that 3HK (1 roM) significantly 
decreased the benzodiazepine receptor binding 
affinity «3H) flunitrazepam) in rat brain and lower 
(Ki = 0.2 ~ M ) ) concentrations of 3HK inhibited the 
effects of GABA stimulation on this binding. 
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7.2.1 Neurotoxicity of kynurenines 
The neurotoxicity of the kynurenines has been little 
studied, although there is one study made by Eastman 
and Guilarte (1989) on the effects on neuronally-
derived cells in culture. cytotoxicity was 
quantitated by determining the release of lactate 
dehydrogenase. Exposure to kynurenine, QA,· KA, 3HK 
and xanthurenic acid was compared to that produced 
by a predictable neurotoxic agent, glutamate. 
Significant toxicity was only seen with 3HK and 
xanthurenic acid (with 100 ~ M M 3HK the threshold 
dose). 3HK neurotoxicity was 1-2 orders of 
magnitude greater than glutamate and the dissimilar 
logarithmic dose response curves were suggested to 
be good evidence that glutamate and 3HK had 
different mechanisms of toxicity. Indeed the well 
established neurotoxic effects of QA were absent and 
thought to be due to the lack of NMDA receptors on 
these neurones. The 3HK toxicity was shown to have 
delayed effects: 8-12 hours exposure produced the 
peak response for chronic experiments, but a shorter 
exposure (2 hours) whilst having no acute effects, 
caused cell lysis 22 hours later. Morphologically, 
the cells retracted their processes, became more 
shrunken, rounded and detached from the culture 
dish. The lack of response to kynurenine was 
explained to be due to the absence of a ring 
hydroxyl group, which would form a quinoid species 
(e.g. quinoneimine). The neuroprotective e f ~ e c t s s of 
antioxidants and taurine were examined (superoxide 
dismutase (SOD), catalase, glutathione, mannitol). 
Glutathione, catalase or (SOD + catalase) together, 
were found to be protective, but mannitol (a 
hydroxyl radical scavenger) and taurine were 
ineffective. Thus, they suggested that hydrogen 
peroxide could change 3HK to a quinone imine by 
oxidation (Tomada et al., 1986). In a further 
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study, Eastman and Guilarte (1990) suggested that 
hydrogen peroxide plays an important role in the 
neurotoxicity of 3HK. 3HK toxicity is delayed after 
initial exposure, which they suggested reflected an 
'ongoing catalase-sensitive toxic process'. 
Catalase attenuates the process, therefore it cannot 
be irreversible. Two possible modes, of action were 
postulated: direct toxicity of hydrogen peroxide, or 
hydrogen peroxide may oxidise 3HK to a toxic 
metabolite. Increased intracellular peroxidase 
activity attenuates 3HK toxicity, thus the former 
mode of action was implicated. Further evidence was 
that horseradish peroxidase pretreatment (that 
increases 3HK metabolism), reduced toxicity. 
Catalase was demonstrated to reduce 3HK toxicity 
post treatment (after removal of extracellular 3HK 
and hydrogen peroxide), suggesting that 
detoxification of intracellular hydrogen peroxide is 
associated with reduced toxicity. Also, 
desferrioxamine, an iron chelator, was shown to 
reduce the toxic effects of 3HK. 
There is extensive literature describing the 
neuroactive actions of KA, particularly in regard to 
its opposing effects to neurotoxins (including QA) 
(see section 6.3). It has been described as a 
'broad spectrum antagonist of excitatory amnino acid 
receptors, antagonising the electrophysiological 
responses to NMDA, kainate and to a lesser extent 
quisqualate receptor agonists'(Swartz et al., 
1990a). At the NMDA receptor complex, KA is thought 
to act both at the agonist site and at the glycine 
allosteric site, where it is several times more 
potent (Danycz et al., 1989). It has been suggested 
that altered endogenous concentrations of KA may 
modulate the effects of neurotoxins in such 
neurological disorders as Huntington's disease (HD), 
stroke, hypoglycaemia or hypoxia. Indeed, co-
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injection of KA was shown to block the neurotoxic 
effects of striatal QA in an animal model of HO, and 
blocked the seizures induced by the administration 
of QA into the rat hippocampus (Foster et al., 
1984b). Further effects were to reduce the neuronal 
degeneration seen in an animal model of ischaemia 
(pre-treatment only) (Germano et al ... , 1987) or to 
protect against biochemical or behavioural 'changes 
as a consequence of QA administration into the 
nucleus basalis (Boegman et al., 1985; Wirsching et 
al., 1989). Jhamandas et ale (1990) compared the in 
vivo and in vitro modulation by kynurenines of QA-
induced damage of the nucleus basalis. 3HA actually 
produced neurotoxic changes similar to QA, but with 
less potency. The mechanism for this was described 
as, unknown, but may be due to 3HA being converted to 
QA in the homogenate, or alternatively 3HA might be 
auto-oxidised to form a free radical species. They 
thought it unlikely that 3HA was acting via the NMOA 
receptor directly. co-injection of other 
metabolites (together with QA) resulted in 
protection (KA > picolinic acid > quinaldic acid > 
anthranilic acid). 
7.3 Previous methods of determining concentrations 
of kynurenines 
Previous methods have enabled the measurement of 3HK 
in urine (Yeh and Brown, 1977), rat plasma 
(Allenmark et al., 1984) and animal brain tissue 
(Heyes, 1988), initially using ion-exchange with 
colorimetric detection and latterly high-performance 
liquid c h r o m a t o ~ p h y y (HPLC) with electrochemical 
detection (ED). Analysis,is often preceded by an 
extraction process to remove any contaminants (e.g. 
uric acid). 
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7.4 Our method for the determination of brain 
concentrations of 3HK 
We qevised a simple HPLC-ED method used for the 
determination of 3HK in human post-mortem brain 
tissue, and involving a straightforward extraction 
of human plasma (which is also applicable to brain 
if necessary). 
7.4.1 Direct method (Pearson and Reynolds, 1991) 
Brain tissue (50-100 mg) was homogenised in 0.5 ml 
of 0.1 M perchloric acid (PCA) containing 100 ~ M M
ascorbic acid and centrifuged at 12000 g. 
Refrigerated stock solutions of 3HK (1 mg/ml in 0.1 
M hydrochloric acid with 100 ~ M M ascorbic acid) were 
diluted daily to 20 ng/ml with PCA. Aliquots of 
standards or sample supernatant were injected 
directly into the HPLC system. 
7.4.2 Extraction method 
This was used for measurment of 3HK in plasma (and 
brain tissue if 3HA determination was required). 
Equal volumes of plasma and PCA were centrifuged at 
12000 g for 3 minutes to produce a supernatant for 
extraction. Alternatively, supernatant from brain 
tissue (prepared as described above for ehe direct 
method) was extracted in the same way as plasma 
supernatant. ThUS, 200 ~ l l supernatant were mixed 
with 50 ~ l l of PCA and 250 ~ l l of 0.1 M phosphate 
buffer (PB) (pH 4.0), resulting in a pH 2.3 
solution. This was then added to a strong cation-
exchange (Icc Bond Elut SCX) column which had been 
pre-washed with 1 ml of methanol, 1 ml of 50% 
methanol-pH 2.3 solution, 4 ml of water and 1ml of 
pH 2.3 solution. Aliquots (0.5 ml) of 50% methanol-
pH 2.3 solution and water washed the column prior to 
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elution with 1 ml of 0.1 M PB (pH 7). All the 
solutions contained 100 ~ M M ascorbic acid. standard 
solutions (0.5 ml of 10 ng/ml at pH 2.3) were 
extracted in the same way as the samples. 
7.4.3 HPLC system 
Aliquots (20 ~ l ) ) of the unextracted standard 
solutions and prepared extracts of standards and 
samples were injected onto the column. Isocratic 
reversed-phase separation was achieved using an ODS-
2 5 uM column (25 cm x 4.6 mm 1.0.) at 40°C, with a 
0.1 M phosphate/acetate buffer at pH 3.2 containing 
2.5 mM octylsulphonate and 0.05 mM EDTA (flowing at 
1.0 ml/minute). Quantification used an 
electrochemical detector (BAS) containing a glassy 
carbon electrode set at 0.60 V (versus Ag/AgCI). 
statistical comparisons were made using the 
Student's t-test of logarithmically-transformed 
data. 
7.4 4 Validation of the method 
Fig. 7.1 illustrates typical chromatograms from a 
directly injected standard and an extracted brain 
samples. In the samples, a single peak was 
demonstrated for 3HK (retention time = 10.4 minutes) 
which was verified by comparison with t h ~ ~ retention 
time of authentic standard peaks, under varying 
chromatographic conditions. Recovery from standards 
added to samples was 97 ± 2% (coefficient of 
variation, n = 5) for unextracted samples and 100 ± 
4% (n = 5) for extracted samples. Also, oxidation 
curves were performed by measuring the peak height 
at varying voltages (0.4-0.9 V). These proved 
similar for the standard, sample and sample with 
added standard, with 0.6 V providing the optimal 
conditions. 
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Figure 7.1 
HPLC chromatogram of 3-hydroxykynurenine and 3-
hydroxyanthranilic acid 
A shows a typical brain sample; B shows a typical 
standard (10ng/ml). Full scale deflection = 1 nA 
I = 31h<. 
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Figure 7.2 
standard curve of 3-hydroxykynurenine and 
3-hydroxyanthanilic acid concentrations 
Hatched circles = 3HA 
Open circles = 3HK 
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Linear standard curves for concentration (0-20 
ngjml) versus response were demonstrated for both 
unextracted and extracted 3HK (Fig. 7.2). The limit 
of detection was approximately 40 fmol 3HK on the 
column. Replicate injections (n = 4) of 20 ~ l l gave 
a 1.0% coefficient of variation. 3HK samples and 
standards were shown to be stable over 18 hours if 
kept at 4°C, but only when ascorbic acid was 
present. The presence of ascorbic acid at all 
stages was found to be a prerequisite for good 
recovery of extracted 3HK, preventing degradation on 
the SCX column. 
A related kynurenine, 3HA, could also be determined 
using this system. However, measurement of 3HA 
without extraction was impossible due to coeluting 
peaks, and although the extraction process was 
applicable to 3HA in the brain, plasma 3HA still 
contained interfering peaks even after extraction. 
Similar validation to the above confirmed the 
identity of the peak in the brain with a retention 
time of 12.2 minutes (see Fig. 7.1). 
Concentrations of 3HK and 3HA were calculated from 
comparisons of sample peak height, corrected for 
dilution. 
7.5 Our study 
In recent years the kynurenine pathway of tryptophan 
metabolism has attracted much interest, especially 
as some of these compounds are neuroactive (see 
section 7.2). Neurotoxin-induced neuronal 
degeneration has been implicated in the aetiology of 
a wide range of neurological conditions (temporal 
lobe epilepsy, glutaric aciduria, HD, febrile 
convulsions, AIDS, ischaemia and hypoxia) (Heyes et 
al., 1989a; Stone and Connick, 1985). In this 
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respect, the involvement of glutamate receptors, 
particularly the NMDA receptor complex, is well 
documented. QA and KA have been shown to have 
opposing actions mediated through this complex 
(Swartz et al., 1990a). Over the last decade the QA 
hypothesis of HD has produced the animal model with 
the most similarities to HD (see section 6.3), 
although there are some discrepancies. It. was 
suggested that increased concentrations of the 
endogenous neurotoxin, QA, may be involved in the 
pathogenesis of HD. However, we have shown (see 
section 6.7) this not to be true, as brain QA in HD 
was unchanged from control values. Another 
kynurenine metabolite, 3HK, has demonstrated 
neurotoxic properties when applied to neuronal cell 
cultures (Eastman and Guilarte, 1989) and 
intracerebroventricular injections of 3HK have been 
shown to induce seizures (Lapin, 1981). Also, in 
vitamin B6 deficient neonatal rats, increased brain 
concentrations of 3HK have been reported (Guilarte 
and Wagner, 1987). As one consequence of vitamin B6 
deficiency is loss of striatal GABAergic neurones 
(Wasynczuk et al., 1983), we hypothesized that 3HK 
may be of interest in HD where there are similar 
cell losses. Furthermore, Heyes et ale (1989a) 
postulated a role for 3HK in. the aetiology of 
febrile convulsions, glutaric aciduria and the 
neuropathology of AIDS. Our study was designed to 
find out whether concentrations of 3HK (or any other 
associated tryptophan metabolites) were changed in 
the brain from patients with HD. Furthermore we 
aimed to identify any factors associated with 
changes in 3HK. Thus, we made a similar study in 
Alzheimer's disease (AD) brain tissue (using matched 
controls), where neuronal degeneration also occurs, 
to assess the effects of tissue atrophy. 
Concentrations of 3HK were determined in the frontal 
and temporal cortex and putamen from the HD g r o ~ p p
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and matched controls, and in the temporal cortex 
from the AD group and controls to match. In order 
to understand more about the metabolic pathway, we 
also determined concentrations of 3HA and tryptophan 
in the brain in HD. Tryptophan concentrations were 
measured using an adaptation of the HPLC-ED method 
(see section 2.3). 
Finally, we made a preliminary study to investigate 
the possibility of a peripheral marker for HD, by 
determining the plasma concentrations of 3HK and 
tryptophan from patients with HD and matched 
controls. 
Brain samples (supplied by the Cambridge and 
Nottingham Brain Tissue Banks) were obtained post-
mortem from patients with neuropathologically-
confirmed HD or AD, and from matched controls with 
no previous history of neuropsychiatric disease. 
Preparation and storage of brain tissue was as 
described previously (Spokes, 1979). 
7.6 Results 
The results from our study in HD (Reynolds and 
Pearson, 1989) (Table 7.1) show 3HK concentrations 
to be significantly increased in the putamen (342% 
of mean control value) and two cortical,.regions 
(169% and 282% of mean control values). 3HA 
concentrations in the frontal cortex in HD were not 
significantly changed from control values. . 
Tryptophan concentrations were slightly increased in 
the HD brain, significantly in the temporal cortex, 
as compared with controls. 
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Table 7.1 
Tryptophan and metabolites in the brain in Huntington's 
disease 
Values are means ± s.d. in ng/g tissue (3HK, 3HA) or ~ g / g g
tissue (tryptophan). *p < 0.05, **p < 0.01, ***p < 0.001 
3HK 
Controls 
Huntington's 
disease 
3HA 
Controls 
Huntington's 
disease 
Tryptophan 
Controls 
Huntington's 
disease 
Temporal 
cortex 
65 ± 56 
(n=20) 
110 ± 47** 
(n=18) 
10 ± 4 
(n=16) 
16 ± 7* 
(n=12) 
Frontal 
cortex 
33 ± 26 
(n=21) 
93 ± 60** 
(n=22) 
12 ± 7 
(n=13) 
19 ± 15 
(n=11) 
Putamen 
19 ± 14 
(n=21) 
65 ± 47*** 
(n=19) 
18 ± 7 
(n=14) 
27 ± 12 
(n=11) 
.... 
()) 
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Table 7.2 
3-Hydroxykynurenine concentrations in the brain in 
Alzheimer's disease 
Values are means ± s.d. in ng/g tissue. 
3HK 
Controls 
Alzheimer's 
disease 
~ ~
Temporal cortex 
65 ± 33 
(n=12) 
82 ± 41 
(n=12) 
.... 
\0 
o 
Table 7.3 
Tryptophan and 3-hydroxykynurenine concentrations in 
plasma in Huntington's disease 
Values are means ± s.d. in ng/ml (3HK) or ~ g / m l l
(tryptophan) < 
3HK 
Controls 
Huntington's disease 
Tryptophan· 
Controls 
Huntington's disease 
7.3 ± 4.1 
(n=7) 
6.7 ± 2.2 
(n=7) 
10.6 ± 1. 2 
(n=7) 
10.2 ± 2.4 
(n=7) 
A significant (p < 0.001) positive correlation was 
evident for cortical and striatal 3HK values in the 
brain in HD and controls. However, no relationships 
were demonstrated between tryptophan and 3HK levels 
and there was only a weak correlation between 3HK 
and 3HA. There were no significant effects of age, 
sex, post-mortem delay or agonal state, or within 
the HD group, age at onset or duration of disease. 
Furthermore, it appears that any group differences 
are not associated with prior medication (e.g. 
tetrabenazine or neuroleptics). In AD cortical 3HK 
was slightly increased (Table 7.2), although this 
was not significantly changed from matched controls 
or HD values. The preliminary study determining 
plasma concentrations of 3HK and tryptophan, showed 
no significant changes from control values (Table 
7.3). 
7.7 Previous studies in the brain in HD 
Previous investigations have been made to determine 
the concentration of kynurenines in the brain in HD. 
Connick et al., (1988; 1989) using a method verified 
by Moroni et ale (1988b), measured KA concentrations 
in the caudate, pallidum, frontal cortex and motor 
cortex from patients dying' with HD and controls. 
They reported a general increase throughout the 
brain in HD, only reaching s i g n i f i c a n c e ~ i n n the motor 
cortex (BA 4). However, only 4 control cases were 
used in the BA 4 comparisons, thus statistical 
analysis is not really possible. The reported' 
increases contradicted their original hypothesis 
that predicted decreased levels of KA causing a 
shift of the QA/KA balance, resulting in 
neurotoxicity. They speculated that increased KA in 
the pallidum may be associated with the production 
of chorea, but correctly 'mentioned that the levels 
used experimentally (Robertson et al., 1988) were 
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much higher than the levels they found. contrasting 
evidence comes from another study by Beal et al. 
(1990a). They measured concentrations of 25 
compounds, mainly components of tryptophan and 
tyrosine metabolism in the putamen in HO. 
Tryptophan, kynurenine, KA, 3HA and 3HK 
concentrations were shown not to be significantly 
changed, whereas 5HT, 5HlAA and 5HTP concentrations 
were significantly increased (by 50%). They also 
reported a significantly increased ratio of 
kynurenine to its metabolites in HO, but a decreased 
tryptophan to its metabolites ratio. They described 
this as evidence for increased tryptophan 
metabolism, but decreased kynurenine metabolism in 
HO. Correlations were evident between tryptophan 
and metabolites (particularly kynurenine) and these 
correlations were generally greater in the brain in 
HO. They suggested that this was evidence for 
increased substrate-driven pathways in HO. Also, 
they reported discrepancies between the absolute 
values of control KA in their study, compared with 
Turski et al. (1988) and Connick (1988; 1989), which 
may explain the contrasting results described in the 
HO brain. CSF concentrations of KA were also 
measured by Beal et al. (1990a) in HO, but these 
were not significantly changed from control values. 
Tryptophan concentrations have been determined in 
many investigations of amino acids in HD. Perry et 
al. (1973) reported no significant changes, as did 
Beal et al. (1990a). Yates et al. (1973) described 
plasma tryptophan levels as not significantly 
changed in HO, however, there was a significant 
reduction in plasma from fasted patients. Also, 
Phillipson and Bird (1977) found total plasma 
tryptophan not to be significantly changed in HO, 
but free plasma tryptophan was reduced (in fasting 
and hypoglycaemic states)'. This was in association 
with increased plasma non-esterified fatty acids 
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(which compete with tryptophan for albumin plasma 
sites, that were reportedly not significantly 
changed). These findings, as well as lowered 
concentrations of plasma neutral amino acids in HD 
(that compete with free tryptophan for transport 
into the brain) were suggested to be consistent with 
increased tryptophan transport into the brain in HD. 
The abnormal growth hormone found in plasma from 
fasting HD patients, further compounds the effects 
(Phillipson and Bird, 1976) (as it affects the 
release of non-esterified fatty acids from 
peripheral deposits). They suggested that in HD 
there is a similar pattern to that seen in 
'metabolic starvation'. 
7.7.1 Other clinical studies of kynurenines 
Tryptophan metabolites (including 5HT and 
kynurenine) were determined throughout the brain in 
schizophrenia, with no significant changes from 
control levels reported by Joseph et al. (1979). 
Administration of systemic endotoxin was reported to 
increase tryptophan, 5HIAA, 3HK and QA in the mouse 
cortex (Heyes et al., 1989a), as well as increasing 
urinary kynurenine and xanthurenic acid (Rapoport 
and Beisel, 1971). A l s o , ~ ~ -interferon (chronically 
adminstered) results in increased brain QA, as well 
as increases of kynurenine and QA conceRtrations in 
plasma (Saito et al., 1991). Increased 
concentrations of KA have also been reported in the 
CSF of HIV-1 patients, septicaemia and retrovirus 
infection (Heyes etal., 1991a; Heyes and Lackner, 
1990; Heyes et al., 1990b) and CSF concentrations of 
kynurenine and QA were also increased in 
septicaemia. Kynurenine was not significantly 
altered in the superficial layers of the spinal 
dorsal horn in normal and arthritic rats (Godefroy 
et al., 1990). The effects of drugs on kynurenine 
193 ' 
metabolism were studied in vivo and in vitro 
(Mostafa et al., 1982); phenothiazines and sUlpiride 
were administered to rats. Phenothiazines were 
shown to increase activity of kynurenine 
hydroxylase, but decreased activity of kynurenine 
transaminase. Sulpiride was without a significant 
effect on either enzyme. However, in vitro, only 
the increased effects with kynurenine hydroxylase 
was seen. Kynurenine transaminase was not 
significantly affected, and again sulpiride had no 
significant effects on either enzyme. 3HA has been 
suspected to have a possible aetiological role in 
bladder cancer which may be associated with 
mitochondrial dysfunction (Teulings et al., 1973; 
Quagliarcello et al., 1964). Manthey et al. (1990) 
suggests that auto-oxidation of 3HA with molecular 
oxygen may form free radical species involved in the 
induction of bladder cancer. 3HK levels have also 
been found to be increased in urine from patients 
with bladder cancer (Abdul-Fadl and Khalafallah, 
1961). Kynurenine has been reported to be increased 
in diseases such as hepatic encephalopathy and 
diabetic coma ,. (Kornhuber et al., 1988). Occasional 
cases of hydroxykynurenuria have been described 
which demonstrate increased urinary excretion of 
kynurenine, 3HK and x a n t h u r ~ n i c c acid. Symptoms 
included chronic stomatitis, ulcerated gums, 
gingivitis and mental retardation that ,did not 
respond to vitamin B complex administration (or 
vitamin B6 alone). An absence of kynureninase was 
hypothesized in these cases (Reddi, 1978). 'Plasma 
tryptophan concentrations have been reported to be 
decreased in depression (Hoes and Loeffen, 1981), as 
has a dysfunction of urinary excretion of 
xanthurenic acid (Hoes and sijben, 1981). Also 
kynurenine has been described as being reduced in 
CSF in epilepsy (Young et al., 1983). Freese et al. 
(1991) reviewed the impact of kynurenines in 
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neurological disorders discussing HD, glutaric 
aciduria, hepatic encephalopathy and porphyria (as 
porphyrin is a co-factor for tryptophan pyrrolase). 
7.8 Discussion 
Our results (described earlier) provide evidence for 
a dysfunction in tryptophan metabol'ism in ,HD. For 
the first time we have shown elevated 3HK 
concentrations in all'the regions measured, 
suggesting a general increase throughout the brain 
in HD. This is consistent with the results of 
Connick et ale (1989) that produced evidence for 
increased tryptophan metabolism (KA) in the motor 
cortex in HD. However, the study by Beal et ale 
(1990a) suggested that the opposite may occur. They 
hypothesized reduced kynurenine turnover in HD but 
found no significant changes in concentrations of 
striatal tryptophan or kynurenines (including 3HK, 
3HA or KA). Thus, our results contradict their 
findings and furthermore, the control values for 
striatal KA reported previously in studies by Turski 
et ale (1988) .and Connick et ale (1989a) are 
quantitatively different. Measuring 25 compounds 
from one sample may increase systematic errors and 
an overall ratio accuracy of, ± 20% was described. 
In the same study HVA concentrations were not 
significantly altered in the brain in HO, which is 
also contrary to our, and other, findings. 
The tryptophan values are consistent with previous 
studies (Perry et al., 1973; Bonilla et al., 1988), 
except for the new finding of an increase in the 
temporal cortex in HD. Brain 3HA concentrations 
have not been reported before in controls or in HD, 
except for the Bealet ale (1990a) study of the 
striatum. 
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The lack of a significant increase of cortical 3HK 
in AD suggests that the effect in HD may not be 
solely related to tissue atrophy, and may reflect a 
genuine dysfunction of tryptophan-kynurenine 
metabolism. Furthermore, the magnitude of the 
increase of 3HK in HD is similar in both the cortex 
and the striatum, which show varying degrees of 
" 
tissue shrinkage. The absence of any effects with 
factors including age, post mortem delay, agonal 
state or drug status is important, as the groups are 
inevitably not controlled. In particular, more 
cases in the HD group died from pneumonia, as 
compared with the control group, and the HD patients 
were mainly taking neuroleptics or tetrabenazine 
before death. However, Beal et ale (1990a) also 
reported that concentrations of kynurenines were not 
significantly affected by age, post mortem delay, 
agonal state or drug status. 
The strong correlation between cortical and striatal 
3HK concentrations (in both controls and in HD) 
provides evidence to validate the methods used. The 
control of brain tryptophan metabolism is not well 
understood, and the lack of any direct correlation 
between 3HK and tryptophan concentrations suggest 
that this is not a simple relationship. Systemic 
tryptophan loading is known to re.sult in increased 
brain concentrations of 3HK (as well as.QA, '5HT and 
5HIAA) (Heyes, 1989) but, (see section 7.1), the 
integrity of the kynurenine pathway in the brain is 
not proven. It is possible (as suggested before) 
that brain 3HK is not a direct result of local 
tryptophan metabolism, but is instead transported 
from the periphery through the blood-brain barrier. 
Here too, the lack of correlation of brain 3HK and 
3HA is perhaps providing evidence for the 
alternative pathway for the formation of 3HA, via 
the metabolism of anthranilic acid (see section 
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7.1). Thus, an increase in the brain concentrations 
may be reflecting elevated peripheral metabolism. 
However, the results from the preliminary study of 
plasma suggest that there is no significant effect 
here." It was speculated that if the plasma showed 
changes, this could have provided an important 
peripheral marker for the disease, that could 
perhaps have formed the basis of an' alternative 
predictor of the disease. Further studies are 
needed to extend the number of patients in the 
series. 
The increase of brain 3HK in HO may be reflecting 
changes in the activity of the enzymes involved, 
both synthetic and metabolic. It has been reported 
that kynurenine hydroxylase and kynureninase usually 
have low activites in rat brain. It may be 
hypothesized that abnormal metabolism or changes in 
vital cofactors could result in the elevated 3HK 
observed in the human brain in HO. Alternatively, 
an abnormal response to an influx of tryptophan 
could produce a consequential increase in 3HK. 
The mechanism of cytotoxic damage induced by 3HK is 
not well characterised. A role for 
excitatory glutamate receptors is not yet proven, 
but a link with hydrogen peroxide and free radicals 
has been postulated (Eastman and G u i l a ~ t e , , 1990). 
Obviously further studies are needed to elucidate 
the mechanisms and effects in the brain, as well as 
a greater understanding of the metabolic factors 
controlling 3HK. 
7.9 vitamin B6 deficiency 
From the diagram of the tryptophan metabolism (Fig 
6.1) via the k y n u r e n i n e s ~ ~ it can be seen that 
vitamin B6 plays a vital role, as some of the 
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enzymes involved have vitamin B6 dependent 
mechanisms. In particular kynureninase and 
kynurenine transaminase are sensitive to vitamin B6 
deficiency, the former more so than the latter, thus 
a build up of particular compounds may occur. Many 
studies have been made to investigate the 
consequences of such a deficiency by measuring 
urinary kynurenine metabolites in various .animals 
(Yeh and Brown, 1977; Korbitz et al., 1963; 
Henderson et al., 1951) and in human beings (Yess et 
al., 1964; Brown et al., 1965) and more recently in 
rat brain (Guilarte and Wagner, 1987). Predictably, 
the results seem to indicate that concentrations of 
xanthurenic acid, 3HK and kynurenine were increased 
in the urine of all species studied, after 
tryptophan loading, but changes of other metabolites 
varied according to the animal. Thus, urinary 
3HA was not significantly changed in the rat, but 
increased in the guinea pig and in humans. QA 
concentrations were not significantly changed in the 
hamster and guinea pig and increased in humans (Yeh 
and Brown, 1977). They suggested that differential 
depression of ' the activity of the two vitamin B6 
dependent enzymes occurred in each species. The 
data of Guilarte and Wagner (1987) showed 
concentrations of 3HK to be,significantly increased 
throughout the brain in vitamin B6 deficient 
neonatal rats. However, the effect was' not observed 
in adult rats, which they suggested was due to the 
residual vitamin B6 in these b r a i n s ~ ~ The increase 
in brain 3HK concentrations was reversible by the 
injection of vitamin B6, and was accompanied by 
increased 5HT and 5HIAA in the frontal cortex, as 
w e n . ~ e u r o l o g i c a l l symptoms including seizures and 
motor excitement. The concentration of 3HK found in 
these neonates would appear to be within the range 
quoted by Eastman (1987)' for neurotoxic action, thus 
this may be aetiologically associated with the 
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neuronal losses described. 
Two further systems have been studied: the 
dopaminergic and GABAergic systems. Firstly, 
progeny of rats which had been fed a diet deficient 
in vitamin B6 had compromised dopaminergic systems, 
at certain stages of development. Thus, 
concentrations of dopamine, homovanillic acid, D2 
receptor binding and activity of DOPA decarboxylase 
(also a vitamin B6 dependent enzyme) were all 
reduced in the striatum (Guilarte et al., 1987). 
Also present were the neurological signs of vitamin 
B6 deficiency: tremor, ataxia and epileptic 
seizures, together with weight loss. The 
neurochemical and neurological changes were 
reversible by the injection of vitamin B6. However, 
the neurological symptoms could be associated with 
other systems such as the GABAergic system, as 
vitamin B6 deficiency also results in the reduction 
of glutamate decarboxylase (another dependent 
enzyme). Thus, there are reduced concentrations of 
GABA in the vitamin B6 deficient rat brain, both in 
neonates and in adults (Bayoumi et al., 1972; 
Bayoumi and Smith, 1972). However, the adult rats 
do not exhibit seizures, contrary to the neonates. 
A postulated loss of striatal GABA neurones has also 
been reported in vitamin B6 deficient rats and their 
progeny (Wasynczuk et al., 1983). The changes 
described above bear some resemblance to those 
observed in HD, and may provide some evidence for 
the possibility of a dysfunction in the utilisation 
of vitamin B6 in HD, during development or in the 
adult. Alternatively, increased 3HK may be the 
common factor responsible for the changes described 
both in vitamin B6 deficiency in neonates and in HD. 
A further area of interest is the investigation of 
hepatic encephalopathy, where there is evidence 
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suggesting abnormal utilisation of vitamin B6 in 
alcoholism (Bowman and Rand, 1984). A dysfunction 
of tryptophan metabolism has been implicated in 
hepatic encephalopathy (Freese et al., 1990) 
together with significantly increased QA in the 
cortex and CSF (Moroni et al., 1986a). Our own 
recent investigation showed cortical 3HK to be 
significantly increased in such patients (data not 
shown: Pearson and Reynolds, 1991). These results 
are consistent with an association of 3HK with 
vitamin B6 deficiency. The evidence that diazepam 
binding inhibitor is increased in CSF from patients 
with hepatic encephalopathy (Rothstein et al., 1989) 
and in the brain in HD (Ball et al., 1988) may be of 
consequence, as 3HK has been shown to decrease 
benzodiazepine receptor binding affinity in rat 
brain (Guilarte et al., 1987). Furthermore, 
Guilarte et ale suggested that the increased brain 
concentrations of 3HK found in neonatal vitamin B6 
deficiency may be associated with seizures. More 
recently (Guilarte, 1991) reported reduced function 
of the NMDA receptor-ion channel in the brain from 
such rats. 
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Chapter 8 
Conclusions 
8.1 General conclusions 
The work described in this thesis has identified 
specific changes in the concentration of 
neurotransmitters in specific regions of the brain 
in Huntington's disease (HO). This knowledge is 
important in the basic understanding of which 
neuronal populations die in HO, which survive, and 
why. Thus we may be able to address the challenge 
of preventing these changes, or in some way 
recompensing losses of neurotransmitters. The model 
of Parkinson's disease (PO) sets a precedent for 
successful, albeit limited, therapy (L-Dopa) 
following the establishment of a particular 
transmitter deficit. However, the paradigm is not 
necessarily appropriate to the study of HO, as in HO 
there is no single transmitter deficit, but instead 
there is a series of changes. The primary neuronal 
losses are ins.eparable, as yet, from the relative 
secondary changes, and simple GABAergic replacement 
therapy does not alleviate. the symptomology. 
Following the same a r g u m e n t , ~ t h e e use of transplants 
of foetal tissue to replace the lost neurones, would 
also appear to be more likely to be effective in PO 
than in HO. Thus, whereas human clinical 
transplants have been attempted and.assessed in PO, 
the analogy is still purely experimental in' animal 
models of HO. Nevertheless, normal growth and 
functioning connections have been described from 
striatal grafts in the animal model of HO (Emson, 
1991). One factor that may be important is that the 
progressive neurotoxic process will still be ongoing 
in the host brain and may also kill the transplanted 
neurones. The timing of the graft may also be a 
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problem as most transplant studies use acute lesions 
to produce animal models of HD (not comparable to 
advanced HD). However, the limited life expectancy 
and lack of adequate treatment in HD may alter the 
validity of its application, as compared to PD. 
The study of the neurochemical or neuropathological 
characteristics of HD is useful, even at a time when 
molecular researchers predict that the gene will 
soon be identified and cloned. All these approaches 
(molecular, neurochemical and neuropathological) are 
relevant and should be studied concurrently, 
especially as the HD gene appears to be more elusive 
than previously anticipated. Moreover, even when 
the gene is identified, there may not necessarily be 
a clear relationship between the gene and its 
expressed product. This can only be adequately 
understood by examining all aspects of the disease 
process. 
By the measurement of parameters such as . 
concentrations of neurotransmitters and their 
metabolites, synthetic or metabolic enzyme 
activities, densities or affinities of receptor or 
uptake sites it is possible to get a profile of a 
neurotransmitter system. This can be compared over 
many regions of the brain, producing an overall 
view. One major consequence of neurochemical 
studies is the identification of subtle changes that 
can be specifically modulated pharmacologically; 
especially now that 'cleaner' drugs can be designed 
to affect sub-types of receptors (e.g. 
quipazine/5HT3, quinpirole/D3). An example of the 
new experimental drug therapies is the use of a 
glycine agonist (as an anti-choreic) to stimulate 
the underactive glutamatergic pathway from the 
subthalamic nucleus to the medial pallidum. . This 
deficit was recently described by Penney and Young 
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(1983) and the studies of Crossman et ale (1988) 
with which our own report of abnormal pallidal {-
aminobutyric acid (GABA) balance associated with 
chorea was consistent. A further associated therapy 
to be tested is the replacement of met-enkephalin, 
that is contained in a pathway lost early in the 
disease (the striato-Iateral pallidum pathway). 
Similarly, substance P therapy is being considered 
in an attempt to modify compounds localised in other 
striatal outputs (Chase, 1991). The strategy of 
modulating single pathways may be more promising 
than the general GABA replacement therapy which does 
not address the regional differences highlighted by 
our study. However, we found the well-established 
striatal deficit to extend to include all regions 
examined, including the cortex, where it provides 
evidence supporting the involvement of the cortex in 
HO. These GABA deficits are consistent with the 
neuropathological and other neurochemical markers of 
GABA neuronal losses. Consequently, there appears 
to be decreased inhibition of the nigrostriatal 
dopaminergic pathway. 
Similarly, our study provides the first 
comprehensive description of decreased 
concentrations of glutamate throughout the brain in 
HO, except in the pallidum and the s.nigra, later 
confirmed by Ellison et ale (1987). Again, this 
provides evidence which is consistent with cortical 
changes in HO. Furthermore, these changes 
contradict the hypothesis that increased endogenous 
glutamate is causing neurotoxic degeneration. Thus 
neuroprotective therapies aimed at decreasing 
glutamatergic function may a g g r ~ v a t e e an already 
compromised system (e.g.· MK801, kynurenic acid, 
glycine antagonists). orugs aimed at increasing 
gl utamate function (e. g. ·glycine agonists) may 
provide an alternative method of alleviating 
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choreiform movements. Furthermore, glutamatergic 
deficits are consistent with the neuropathological 
and other neurochemical studies implicating 
glutamatergic neuronal and receptor losses (e.g. N-
methyl-O-aspartate (NMOA) receptors). 
Our finding of indicators of reduced turnover of the 
dopamine (OA) system in HO in all areas measured 
(except the cortex) are consistent with, and extend 
some of the previous studies (Reynolds and Garrett, 
1986; Kish et al., 1987), but provide no evidence 
for an increased OA system as described by others 
(Melamed et al., 1982; Spokes, 1980). The efficacy 
of dopaminergic blockers or dopamine depletors in 
the alleviation of the chorea in HO has been 
described in terms of stopping the inhibition of the 
dying striato-Iateral pallidal met-enkephalin-
containing GABA projections. Of particular interest 
are reports that dopaminergic agonists (e.g. 
apomorphine) can actually reduce choreiform 
movements. The mechanisms are not completely 
understood, but it has been suggested that 
presynaptic autoreceptors may be involved. The-
increased homovanillic acid (HVA) in the cortex has 
been postulated to reflect striatal degeneration and 
the lack of HVA change associated with neuroleptics 
in HO, provides evidence that an important feedback 
mechanism (perhaps GABAergic) is absent .. in HO. 
Other neuropathological and neurochemical evidence 
supports the idea of an intact nigostriatal pathway 
V'lhich is down-regulated resulting in reduced-activity 
and relatively lacking in inhibition, due to the 
GABA and cholinergic deficits. 
Another novel finding from our investigation is to 
extend the reduced choline acetyl transferase (CAT) 
activity in the striatum 'and hippocampus in HO, to 
include the frontal cortex, again indicating 
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cortical involvement in HD. Relatively less 
inhibition of the nigrostriatal dopaminergic pathway 
may be a consequence of such changes, although 
cholinergic drug therapies do not seem to be 
effective in the reduction of chorea. 
until our study, there were no major investigations 
of the 5-hydroxytryptamine (5HT) system in HO. Our 
results showed both 5HT and 5-hydroxyindoleacetic 
acid (SHlAA) to be substantially increased 
throughout the brain (except the hippocampus). The 
striatal changes were later verified by Kish et al. 
(1987), but they did not examine the cortex. An 
increase in serotonergic terminals reported 
previously (Cross et al., 1986b) appears consistent 
with our findings, and deficits of SHT1 receptors 
may reflect down-regulation in response to increased 
SHT function. A recent hypothesis suggests that 
5HT1A receptors are on glutamatergic neurones 
(personal communication, Bowen, 1991); thus such a 
deficit (SHT1) in HD may be reflecting the cortical 
glutamatergic loss, described earlier (see section 
3.2). Although any increases of concentrations may 
be relative to tissue atrophy, the substantially 
greater increase in 5HlAA as compared to 5HT in the 
temporal cortex suggests that here at least an 
actual increase in turnover may contribute to the 
results. Evidence supporting increased"tryptophan 
function comes from our study of tryptophan 
metabolism, via the kynurenine pathway, which also 
appears to be overactive, resulting in increased 
concentrations of some of the metabolites in HO. We 
have also shown concentrations of tryptophan itself 
to be increased in the temporal cortex in HO, but 
not significantly in the striatum. Furthermore, as 
GABA is reportedly involved in the release of 5HT, 
such increases of 5HT (described above) would be 
predicted in association with theGABA losses in HD. 
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Separating a subset of the major HO group in our 
series, we were able to describe a previously 
unidentified depletion of monoamine transmitters, as 
a consequence of prior treatment with tetrabenazine 
in HO. These results confirmed animal studies 
demonstrating such depletions. The greatest 
reduction was dopamine in the caudate, which may 
provide the basis for the effect of tetrabenazine on 
the alleviation of chorea. However, monoamine 
losses in limbic regions may mediate the production 
of side effects such as depression, drowsiness and 
suicide. Tetrabenazine remains the drug of choice 
in the UK for the amelioration of choreiform 
movements, although it is not available for use in 
USA. 
Of particular interest is our investigation of an 
asymptomatic HO case previously reported in the 
literature by Carrasco and Mukherji (1986). The 
subject had gross striatal atrophy (66% of normal 
control) and neuronal losses of 40% in the caudate 
and 80% in the putamen. As part of our study we 
investigated the neurochemical profile of the brain 
from this case, comparing the changes to controls 
and to our large HO series (Reynolds and Pearson, 
1990a). The most striking feature was the GABA 
deficit observed in the caudate and lateral pallidum 
from the asymptomatic case. In these areas the GABA 
concentrations were midway between the control and 
HO ranges, that showed no overlap. However; in' the 
medial pallidum there was no significant GABA loss 
apparent. These results indicate that degeneration 
of the GABAergic systems of the striatum and lateral 
pallidum can occur (up to a certain threshold), 
before the onset of the clinical symptoms of HO. 
The results also suggest that GABA concentrations in 
the medial pallidum are affected at a later stage. 
206 
Our results are consistent with a reported case by 
Albin et al. (1990b) describing abnormalites of NMDA 
receptors and the loss of substance P fibres in 
presymptomatic HD (with no pathological findings). 
Obviously further studies of these and other 
important presymptomatic cases may enable a greater 
understanding of how the disease progresses 
clinically, pathologically and neurochemically; this 
is in sharp contrast to the majority of 
investigations which can inevitably only examine 
end-stage HD. 
In general the neurochemical changes described in 
the brain in HD are consistent with the 
neuropathological findings, and within the striatum 
the contents of the patches appear relatively 
spared, whereas some of the matrix markers are lost. 
However, a recent report suggests that within the 
patches there are apparent selective islands of 
neuronal loss, whose contents are as yet undefined 
(Young, 1991). Why certain neuronal populations 
degenerate is not known, but a further theory was 
postulated by Emson (1991), regarding the immunity 
of somatostatin/neuropeptide Y/ NADPH-diaphorase 
containing neurones. It was suggested that these 
neurones also contain nitric. oxide synthetase that 
can form free radicals. Thus, any surrounding cells 
were killed off by these neurones produaing free 
radical damage (Emson, 1991). 
On another level, correlations of the symptoms of HD 
were examined in subgroups of the large HD series. 
HD provides a classic situation in which to study 
other diseases, as a model of neuropsychiatric 
disorders (including depression, schizophrenia, 
dementia and dyskinesia). As there is such an 
extensive overlap, any observations made in HD may 
be of potential application to these other 
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disorders. 
In this study, we described the first neurochemical 
correlate of the chorea in HD. Patients with severe 
chorea showed a relatively smaller deficit of GABA 
in the medial pallidum, as compared with those 
having mild chorea. Thus the chorea may relate to 
the residual balance of GABAergic innervation 
between the pallidal regions. This was found to be 
consistent with animal models of chorea (Crossman et 
al., 1988) and current views of the chorea in HD 
(Penney and Young, 1983). A further general 
finding in HD was that whilst pallidal regions 
showed losses of GABA, the medial part shows a 
smaller loss than the lateral part, which is also 
consistent with the above reports, and other 
neurochemical changes (e.g. reduced glutamic acid 
decarboxylase activity described by Spokes, 1980). 
As the disease advances, the initial choreiform 
movements become increasingly akinetic, as the 
eventual degeneration of the striatal-medial 
pallidum pathway follows the initial loss of the 
lateral pallidum GABAergic innervation. 
A further novel correlation comes from our study of 
the dementia in HD, where we were trying to provide 
evidence as to whether the dementia is similar to 
Alzheimer's disease (AD) or to PO and other 
subcortical dementias. Roos (1991) made a report 
suggesting that the plaques and tangles found in HD 
are only consistent with general aging and not with 
the dementia of the disease. AD is associated with 
deficits of cortical CAT activity, that correlates 
with cognitive impairment (Mountjoy et al., 1984). 
Similar deficits have been reported in PO dementia. 
However, in HD we showed the CAT deficit in one 
cortical area and the hippocampus to be unassociated 
with the degree of dementia. Cortical amino acids 
208 
and monoamines have also been reported to be reduced 
in AD (Rossor et al., 1984), but in our study there 
was no correlation with dementia in HD. The only 
neurochemical correlates of the dementia in HD were 
concentrations of GABA and glutamate in the caudate 
which had an inverse association with the severity 
of the dementia. This indication of the involvement 
of the caudate in dementia is consistent with 
previous PET and CAT studies in HD, in which 
dementia and impaired cognitive function are related 
to hypometabolism of the caudate and caudate atrophy 
(and not with meausures of cortical function or 
atrophy) (De la Monte et al., 1988; Bamford et al., 
1989; Starkstein et al., 1988). 
Further studies were intended to be made to try to 
subdivide the HD group to identify neurochemical. 
correlates of other symptoms, including depression, 
aggression and schizophreniform psychosis. However, 
the numbers of these subgroups were too small for 
analysis. Previously described changes in these 
disorders in the normal population were to have been 
examined for their relevance to HD. ThUS, in 
depression deficits of monoamines have been 
implicated (van Praag , 1977), as have cell losses 
in the locus coeruleus and raphe nucleus in 
depression in AD (Zweig et al., 1988; Iversen et 
al., 1983) and low CSF GABA (Lloyd et aI., 1989) and 
enkephalin involvement (Peyser and Folstein, 1990) 
and increased cortico-releasing factor (CRF) in CSF 
(KurIan et al., 1989). Studies looking to identify 
such changes in HD found no association of 
depression with any of the above (except for CSF CRF 
which was linked with the severity of major 
depression). The only other reports were a 
neuropathological investigation that linked HD 
depression with more severe global atrophy of the 
cortex and white matter (De la Monte et al., 1988), 
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and a report relating depression in HD with 
hypometabolism in the prefrontal cortex and thalamus 
(Peyser, 1991). Apathy in HD was found to correlate 
with hypometabolism of the cingulate gyrus (Peyser, 
1991). 
Correlates for aggression are not well 
characterised, although one clinical study has been 
described in HD (Burns et al., 1990). "Mood and 
aggression have been suggested to be mediated by 
serotonergic activity (van Praag et al., 1986) and a 
study of aggression in AD revealed reduced 
concentrations of 5HT in the orbital gyrus of 
aggressive patients (Palmer et al., 1988). 
Neurochemical correlates of schizophrenia include 
lateralised changes of DA concentrations in the 
amygdala, altered 02 receptor binding, limbic GABA 
uptake site deficit, increased cortical 
glutamatergic markers and increased cortical DA 
turnover (Reynolds, 1983, 1989; et al. 1990c; Deakin 
et al., 1989). Whether any of these changes are 
associated with the schizophreniform psychosis found 
in HD remains unproven, as there were insufficient 
patients to study this symptom. 
A likely strategy for the management of HD involves 
the concept of neuroprotection, after further 
characterisation of the excitotoxic model of HD. 
Any potential neurotoxic compounds can be tested in 
animal models and, if a causative agent were to be 
identified, drugs could be developed (or" existing 
ones used) that could prevent the progressive 
neuronal degeneration. It has been postulated 
that the aetiological agent involved in HD results 
from an a ~ r r a n t t metabolic process producing toxic 
concentrations. The tryptophan metabolite, 
quinolinic acid (QA), provides us with the best 
animal model (although there are a few 
discrepancies) for HO. A major aim of this study 
was to investigate and characterise tryptophan 
metabolism, via the kynurenine pathway in HO. It 
was hoped to establish whether metabolism was 
normal, or producing neurotoxic concentrations of 
neuroactive compounds in HO. Working on the initial 
hypothesis for increased concentrations of QA in the 
brain in HO, we set out to provide evidence 
supporting this. Furthermore, activity of its 
synthetic enzyme, 3-hydroxyanthranilic acid 
oxygenase (3HAO), was reported to be significantly 
increased in the brain in HO. However, our results 
were the first to establish that concentrations of 
QA were not significantly changed in both the 
striatum and cortex in HO. This was later confirmed 
by Schwarcz (1988b), who also found no significant 
difference in the CSF, and they too reported the 
large range of values of QA concentrations (in both 
HO and controls) that may limit the use of such 
results • These findings are contrary to the working 
hypothesis and do not support an aetiological role 
for QA in HO. However, a previous transient 
increase can not be excluded and in vitro studies 
suggest that for chronic neurotoxic effects of QA, 
much smaller concentrations are required; thus 
subtle (non-significant) .. changes of QA 
concentrations may be implicated in HO. 
Following these reports, a further study was made by 
C o n n i c k e ~ " ' \ . @ 8 8 ) ) who postulated that although QA 
concentrations were unchanged in HO, a relative 
deficit of kynurenic acid (KA) could be causing 
otherwise normal levels of QA to be neurotoxic. 
However, they found increased concentrations of KA, 
in the motor cortex in HD (but not significant in 
the striatum) , although this change was not 
confirmed by the study of Beal (1990a) •. This 
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evidence for a possible dysfunction of kynurenine 
metabolism in HO, stimulated our hypothesis that 
another neuroactive kynurenine metabolite, 3-
hydroxykynurenine (3HK), could be of interest in HO. 
Our study reported the novel finding of 
significantly increased concentrations of an 
endogenous neurotoxic compound (3HK) throughout the 
regions of the brain in HO. This is of particular 
interest as it is the first description of such an 
increase in HO, and it is tempting to speculate 
whether this compound is of aetiological 
significance in HO. Such an increase may merely be 
reflecting tissue atrophy. However, as no 
significant changes were observed in AO, the effect 
in HO appears to be associated to some degree with 
actual metabolic dysfunction. Furthermore, the 
increased cortical tryptophan concentrations in HO 
also provide evidence supporting an aberrant 
metabolic process. As tryptophan levels did not 
appear to correlate with 3HK, it would seem that 3HK 
metabolism is complex and not mediated by a simple 
controlling mechanism. Results from a very recent 
study by Beal (1990a) in the HO striatum are 
inconsistent with such a change in 3HK 
concentrations. We made a very preliminary study 
using blood from patients with HO to investigate the 
possibility of a peripheral marker for the changes of 
the disease. However, there appeared to be no 
significant difference between HO a ~ d d control values 
(although the numbers of cases were very small) (see 
section 7.8). 
Of note are our new results from a further study 
demonstrating increased concentrations of 3HK in the 
frontal cortex in patients with hepatic 
encephalopathy (Pearson and Reynolds, 1991); a 
dysfunction of tryptophan metabolism and impaired 
utilisation of vitamin B6 have previously been 
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implicated in this disorder. 'Thus, there may be 
some association between the changes found in both 
disorders and further study of 3HK metabolism is 
warranted in order to elucidate and characterise 
such tryptophan metabolism. A further point of 
interest is the i ~ c r e a s e d d diazepam binding inhibitor 
in HD brain and in cerebrospinal fluid from patients 
with hepatic encephalopathy. Whether this has any 
relevance to the decreased benzodiazepine receptor 
binding effect of 3HK remains to be seen. 
These studies have demanded the development and 
adaptation of new methods in order to determine the 
concentrations of neurotransmitters, amino acids and 
other neuroactive compounds, as well as the 
activities of enzymes. Specifically, novel methods 
have been worked up (and published) for the 
measurement of concentrations of QA, and for 3HK, 
and for the amino acids. 
8.1 Further work 
To increase the numbers of cases in order to extend 
the neuroohemical correlates of the symptoms of the 
disease; in particular, to include depression, 
aggression and schizophreniform psychosis. 
To characterise NMDA receptor binding and associated 
sites, in HD to identify any abnormalities. 
To extend the regional distribution of 3HK in the 
brain in controls and in HO, including less 
atrophied areas. This would enable us to understand 
better whether the changes in HD are global. 
Furthermore, extending the peripheral measurement of 
3HK in HD (by increasing the number of cases), will 
provide real evidence as to whether the effects 
observed in the brain have a marker in the periphery 
and whether they are related." 
To examine the in vitro effects of 3HK in cerebellar 
cultures in order to characterise the mode of action 
of the neurotoxic damage. In particular, to 
identify whether the effects are mediated via the 
NMDA, AMPA or other receptors, by the use of 
appropriate antagonists, and comparison of the 
effects with those of known agonists. 
To compare the consequences of intra-striatal 
injection of 3HK in the rat with established animal 
models for HD (such as QA). This would involve the 
comparison of neurochemical and neuropathological 
changes evoked by 3HK with those seen in HD and its 
animal models. 
To study the enzymes involved in the metabolism of 
tryptophan via the kynurenine pathway in the brain, 
both in controls and in HD. The aim is to establish 
any controlling enzymes, co-factors ,or feedback 
mechanisms which could influence the build up of 
3HK, or other neuroactive compounds in the pathway. 
Also, to examine the effects of precursor loading 
(such as tryptophan or kynurenine) to establ"ish 
whether the kynurenine pathway actually functions in 
the human brain. Finally, to identify any specific 
di'fferences occurring in the HD brain as compared to 
control function. ., 
To study benzodiazepine receptor binding in the 
brain in HD, particularly to examine the effects of 
3HK at this site (and in hepatic encephalopathy). 
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